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ABSTRACT 
 
TOTAL SYNTHESIS OF (–)-CALYCIPHYLLINE N 
Artem Shvartsbart 
Amos B. Smith, III 
 
 The dissertation herein describes the first total synthesis of the complex 
Daphniphyllum alkaloid, (–)-calyciphylline N. This alkaloid was chosen as the target in 
our synthetic program due its unprecedented structure, the inherent challenges associated 
with its synthesis, and limited reports of synthetic studies towards members of this family 
of natural products. An initial unsuccessful approach is discussed, followed by a revised, 
ultimately successful approach. Highlights of the synthesis include a substrate controlled, 
intramolecular Diels-Alder reaction to build the bicyclo[2.2.2]octane core and set four 
contiguous stereocenters, a transannular enolate alkylation to secure ring D, a highly 
efficient Stille carbonylation/Nazarov cyclization sequence to construct ring E with 
concomitant activation of a hindered silyl group towards Fleming-Tamao oxidation, and 
an unprecedented, homogeneous hydrogenation of an exceptionally hindered diene ester 
to complete the eastern hemisphere, a structural motif that is common to a variety of the 
Daphniphyllum alkaloids. 
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CHAPTER 1:  
The Daphniphyllum Alkaloids 
1-1: Isolation and Biosynthesis 
 Plants of the Daphniphyllum genus, found in central and southern Japan, China, 
Taiwan, and New Guinea, produce a series of complex alkaloids with over 200 known 
members.1 These natural products have been classified based on six members; 
daphnipylline, secodaphniphylline, yuzurimine, daphnilactone A, daphnilactone B, and 
yuzurine.2 There are also a variety of new additions with unprecedented structures. Given 
the diversity in structure, the Daphniphyllum alkaloids have attracted great interest for 
biosynthetic studies and as challenging targets for total synthesis.3 In the late 1980s, 
Heathcock and co-workers proposed a biosynthetic pathway,4 which culminated in 
several elegant biomimetic total syntheses.5 This pathway begins with the oxidation of 
squalene (1.1) to the squalene dialdehyde species 1.2 (Scheme 1.1). Condensation of a 
primary amine (such as an amino acid) with one of the aldehyde groups would give rise 
to the 1-azadiene 1.3, which can undergo a prototropic shift to the corresponding 2-
azadiene 1.4. Heathcock proposed that a nitrogen nucleophile adds to C(1) of the 
azadiene to produce the nucleophilic enamine 1.5. Intramolecular Michael addition, 
followed by cyclization of the resulting enolate affords 1.7. A series of proton mediated 
addition and elimination processes would ultimately transform 1.7 to the 2-aza-
cyclohexadiene 1.12. An intramolecular aza-Diels-Alder reaction, followed by an aza-
Prins cyclization results in the formation of proto-daphniphylline (1.14), which is 
believed to be a common intermediate in the biosynthesis of all the Daphniphyllum 
alkaloids.  
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Scheme 1.1: Biosynthesis of Proto-Daphniphylline  
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1-2: (–)-Calyciphylline N 
In 2008, Kobayashi and co-workers reported the isolation of (–)-calyciphylline N 
(1.15, Figure 1) from Daphniphyllum calycinum; the structural determination was based 
on extensive NMR analysis, as well as comparison to congeners within the family.6 The 
biological activity of 1.15, however, has yet to be explored. Calyciphylline N possesses a 
unique and intricately complex molecular architecture, consisting of a cagelike, 
hexacyclic ring system. Notable structural features include the dihydropyrrole A ring of 
the western hemisphere and the decahydrocyclopentazulene DEF ring system of the 
eastern hemisphere, surrounding a central bicyclo[2.2.2]octane BC core. Additionally, the 
molecule possesses six contiguous stereocenters with a total of eight stereocenters, three 
of which are bridgehead, quaternary centers. To date, neither (–)-calyciphylline N, nor 
any member of the calyciphylline family of alkaloids has succumbed to total synthesis. 
This fact, as well as the inherent challenge associated with a synthetic effort towards this 
intriguing natural product, rendered this work a worthwhile endeavor.  
 
Figure 1.1: Structure of (–)-Calyciphylline N 
 Biosynthetically, 1.15 can be envisioned to arise from a proto-daphniphylline type 
intermediate 1.16 by the sequence shown in Scheme 1.2.7 Oxidation of the amine in 1.16 
would give 1.17, which could undergo a Grob-type fragmentation by loss of the proton at 
C(7) and cleavage of the C(1)-C(2) bond. Reduction of the resulting imine with 
concomitant cyclization onto the isopropenyl side chain would then give 1.19. A series of 
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oxidations leads to 1.20, which rearranges to 1.21. Functionalization of the side chain, 
followed by formation of a bond between the α carbon of the ester and C(8) would 
provide 1.15. 
 
Scheme 1.2: Proposed Biosynthesis of Calyciphylline N 
1-3: The Carreira Synthesis of (+)-Daphmanidin E 
 In 2011, during the course of our work, Carreira and Weiss reported the total 
synthesis of the closely related congener, (+)-daphmanidin E (1.23, Scheme 1.3).3e 
Daphmanidin E differs from (–)-calyciphylline N by the presence of an acetoxy group at 
C(21) [(–)-calyciphylline N numbering], as well as a conjugated olefin within the F ring. 
Calyciphylline N is a putative biosynthetic precursor of (+)-daphmanidin E,8 through the 
intermediacy of (–)-daphmanidin A (1.24).  
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Scheme 1.3: Biosynthetic Relationship Between (–)-Calyciphylline N and  
(+)-Daphmanidin E 
 
 Carreira’s retrosynthetic analysis of (+)-daphmanidin E is outlined below (Scheme 
1.4). The A ring was envisioned to arise via condensation of a primary amine with the B 
ring ketone, while the bis-unsaturated ester could be constructed by an aldol 
condensation, simplifying the target to tetracycle 1.25. An alkyl-Heck coupling was 
envisaged to access the D ring, with the C(20) methyl group installed by a reagent 
controlled conjugate addition to a nitroalkene. Carreira anticipated that the C(8) 
quaternary center could be constructed by a series of Claisen rearrangements, further 
simplifying the structure to acetonide 1.27, which could then be accessed through 
elaboration of the optically pure, C2 symmetric diester 1.28.  
 
Scheme 1.4: Carreira retrosynthetic analysis of (+)-daphmanidin E 
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 The Carreira synthesis of (+)-daphmanidin E begins with mono-ketalization of 1.28 
(1,3-propanediol), followed by conversion of the remaining ketone to the corresponding 
vinyl triflate to provide 1.29 (Scheme 1.5). Triflate 1.29 underwent a B-alkyl Suzuki 
coupling with the borane derived from TBDPS protected allyl alcohol (1.30) to furnish 
olefin 1.31 in 89% yield. Diastereoselective hydroboration, followed by exhaustive 
reduction of the ester functionalities then delivered triol 1.32, the structure of which was 
confirmed by X-ray crystallography. The 1,3-diol was then selectively protected as the 
acetonide, and the remaining primary alcohol was protected as a benzoate ester, 
providing 1.33 in 95% yield over 2 steps. 
 
Scheme 1.5: Synthesis of Ketone 1.33  
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 7 
center (Scheme 1.7). Selective hydroboration of the monosubstituted olefin delivered 
alcohol 1.38 in 60% yield. After protection of the resulting primary alcohol with Ac2O, 
the TBDPS group was removed with TBAF, and the resulting alcohol was subjected to 
Grieco dehydration to provide ketone 1.39 in good yield over the 3 steps. 
 
Scheme 1.6: Synthesis of Ketone 1.39 
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 8 
discovered that treatment of 1.42 with Me2Zn in the presence of Cu(OTf)2 and chiral 
ligand 1.43 resulted in a reagent controlled conjugate addition to install the C(20) methyl 
group in 90% yield with 5:1 d.r. Reduction of the nitro group in 1.44 with Zn and NH4Cl, 
followed by treatment with Boc2O delivered the Boc protected primary amine 1.45.  
 
 
Scheme 1.7: Synthesis of Amine 1.45 
 Ozonolysis of 1.45, followed by selective reduction of the aldehyde then afforded 
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light emitting diode (LED) led to the cyclized product 1.49 in 93% yield. 
 
Scheme 1.8: Synthesis of Enone 1.49 
 Removal of the acetate protecting group and oxidation of the primary alcohol then 
afforded the corresponding aldehyde, which underwent an aldol condensation upon 
heating with Bn2NH2O2CCF3 to provide α, β, γ, δ-unsaturated aldehyde 1.50 (Scheme 
1.9). Oxidation of the aldehyde and exchange of the benzoate for an acetate group 
delivered methyl ester 1.51. Removal of the N-Boc group was next achieved with 
catalytic TFA, and the resulting primary amine was condensed to the imine by heating 
the ammonium salt in EtOH at 75 °C. Finally, removal of the MOM acetal with Ph2BBr 
delivered (+)-daphmanidin E in 76% yield.  
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Scheme 1.9: Completion of the Total Synthesis of (+)-Daphmanidin E 
 In summary, the total synthesis of (+)-daphmanidin E was completed with a longest 
linear sequence of 38 steps from commercially available materials, with a total count of 
41 steps. It is surprising that Carreira did not continue this work to the monounsaturated 
system, as one additional step would complete the synthesis of (–)-daphmanidin A (1.24).  
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    77%
2) PCC, CH2Cl2
    92%
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O
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    MnO2, MeOH
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    CH2Cl2
    79% (3 steps)
O
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BocHN CO2Me
1) TFA, 
    CH2Cl2
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    EtOH, 75 °C
56%
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(+)-Daphmanidin E (1.23)
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CHAPTER 2: 
An Initial Synthetic Strategy Towards (–)-Calyciphylline N 
2-1: Retrosynthetic Analysis 
From the retrosynthetic perspective (Scheme 2.1), the dihydropyrrole (A) ring in 1.15 
could be constructed by a late stage condensation of a primary amine with the B ring 
carbonyl. We anticipated that the stereochemistry of the EF ring system could in turn be 
set by a chemo- and diastereoselective 1,4-reduction of a bis-unsaturated aldehyde or 
ester, simplifying the target compound to intermediate 2.1. Installation of the nitrogen 
could then be accomplished by a Mitsunobu reaction,1 whereas the C ring secondary 
hydroxyl would be revealed via a Tamao-Kumada oxidation.2 Notably, this strategy 
permits the reactive functionality of the western hemisphere to be masked as a relatively 
unreactive cyclic siloxane. An aldol condensation should permit the formation of the bis-
unsaturated aldehyde, further simplifying the structure to diketone 2.2. The key step of 
the synthesis relies upon an intramolecular epoxide ring opening by a carbanion derived 
from iodo-cyclopentenone 2.3. Side chain elaboration then traces back to the bicyclic 
ester 2.4, which was envisaged to arise from an intramolecular Diels-Alder (IMDA) 
reaction.3 Finally, the requisite triene 2.5 could be realized through the union of 
homoallyic alcohol 2.6 and known silylacrylate 2.7.4  
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Scheme 2.1: Retrosynthetic Analysis 
2-2: Synthesis of Diene 2.6 
The synthesis of diene 2.6 began with commercially available p-tolylacetic acid (2.8, 
Scheme 2.2). Conversion of 2.8 to the mixed anhydride was achieved by treatment with 
pivaloyl chloride and Et3N at –78 °C. Addition of lithiated (S)-4-benzyl-2-oxazolidinone 
[(+)-2.9] in situ at –78 °C furnished imide (+)-2.10 in 86% yield.5 Enolization of (+)-2.10 
with NaHMDS and alkylation with MeI then delivered the methylated derivative (+)-2.11 
in 75% yield with 10:1 d.r.6 The diastereomers from the methylation were readily 
separable by flash chromatography; removal of the chiral auxiliary was then 
accomplished under mild conditions employing 4 equivalents of NaBH4 in a mixture of 
THF/H2O (1:1) at room temperature.7 Distillation of the residue provided the enantio-
merically pure alcohol (–)-2.12 in 91% yield. Birch reduction8 of (–)-2.12 cleanly 
afforded the expected 1,4-cyclohexadiene (–)-2.13 as the only product. Exposure of (–)-
2.13 to potassium tert-butoxide in DMSO/toluene9 resulted in olefin isomerization to give 
an inseparable mixture of 2.6 to (–)-2.13 (3.5:1, respectively). Attempts to increase this 
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ratio via longer reaction times and higher temperatures proved unsuccessful. 
Furthermore, we also noted that these dienes were somewhat unstable, undergoing 
aromatization and other decomposition pathways upon prolonged storage. Therefore, 
these dienes were prepared and used as quickly as possible. 
 
Scheme 2.2: Synthesis of Diene 2.6 
2-3: Synthesis of the Bicyclo[2.2.2]octane core  
Silylacrylate 2.7 was prepared in 72% yield by a cobalt catalyzed, oxidative 
hydrosilylation of ethyl acrylate with phenyl dimethylsilane (2.14, Scheme 2.3).4 
Utilizing a method introduced by Sieburth,10 treatment of 2.7 with 2.2 equivalents of 
TfOH in CH2Cl2 at 0 °C resulted in rapid protodesilylation to afford the corresponding 
silyl triflate with liberation of benzene. Addition of pyridine in situ at –78 °C, followed 
by a solution of the alcohols 2.6 and (–)-2.13 in CH2Cl2 furnished the requisite triene 2.5. 
This compound proved unstable to silica gel chromatography and was therefore carried 
forward without purification. 
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    THF, –78 °C
2) (+)-2.9, n-BuLi, 
    THF, –78 °C
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KOt-Bu
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Scheme 2.3: Synthesis of Triene 2.5 
A number of conditions were investigated to induce the proposed IMDA reaction 
(Scheme 2.4). Thermal cyclization produced a complex mixture of all possible 
diastereomers (as determined by 1H NMR), while the weak Lewis acid ZnCl2 was 
ineffective. On the other hand, the very strong Lewis acid, TiCl4, resulted in 
decomposition of the substrate. Pleasingly, Et2AlCl promoted the cycloaddition to afford 
a mixture of only two diastereomers in 50% yield from 2.6 with 9:1 selectivity. Careful 
analysis of the NOESY spectrum confirmed that the desired diastereomer (–)-2.4 was the 
major product.  
 
Scheme 2.4: Diels-Alder Cyclization of Triene 2.5; NOESY Correlations of the Major 
Diastereomer 
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The high stereoselectivity observed in this reaction may be rationalized by the 
following transition state models. Given the known preference for dienophiles to 
approach the diene π system in an endo fashion,11 the two possible endo transition states 
are presented below (Scheme 2.5). The first transition state depicts an endo approach of 
the dienophile from the top face of the cyclohexadiene, while the second transition state 
depicts an endo approach from the bottom face. By coordinating to the Lewis basic 
oxygen of the ester, Et2AlCl lowers the LUMO of the dienophile, which in turn lowers 
the activation barrier for the cyclization. With the reaction occurring at a much lower 
temperature (25 °C vs. 110 °C), the transition states that are higher in energy and that 
would lead to the undesired diastereomers, cannot be attained. 
 
Scheme 2.5: Diels-Alder Transition State Analysis 
Assuming that the tether adopts a chair conformation in the transition state, an endo 
approach of the dienophile from the top face of the diene π system would place the C(20) 
methyl group axial, resulting in allylic strain with the vinyl hydrogen. This mode of 
cyclization would lead to the undesired product 2.15. Conversely, an endo approach of 
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the dienophile from the bottom face of the diene pi system would place the C(20) methyl 
group in an equatorial position. This mode of approach alleviates the steric interaction 
with the vinyl hydrogen and leads to the desired cycloadduct (–)-2.4. Unfortunately, the 
minor diastereomer could not be isolated in pure form for characterization purposes and 
was thus tentatively assigned as 2.15. 
2-3: Elaboration of the Side Chain Leading to (+)-2.3 
2-3-1: A Reductive Lithiation Strategy 
With bicyclic ester (–)-2.4 in hand, the next challenge we faced was elaboration of the 
side chain. The first strategy we explored relied upon a reductive lithiation of a phenyl 
thioether (Scheme 2.6).12 Synthesis of the required substrate began with LiAlH4 reduction 
of (–)-2.4 and conversion of the resulting alcohol (–)-2.16 to the corresponding iodide    
(–)-2.17 under Appel conditions. Lithiation of thioanisole with n-BuLi in the presence of 
DABCO,13 followed by addition of (–)-2.17 resulted in displacement of the iodide to 
furnish phenyl thioether (–)-2.18. Alkyl phenyl sulfides may be reductively cleaved with 
LiDBB to generate the corresponding alkyllithiums, which can be trapped with various 
electrophiles.12,14 We envisioned that reductive lithiation of (–)-2.18, followed by 
trapping with vinylogous triflate 2.19 would constitute an elegant and simple approach to 
cyclopentenone (–)-2.20. While exposure of (–)-2.18 to LiDBB did successfully generate 
the desired alkyllithium, this carbanion underwent an unexpected cyclization onto the 
siloxane, delivering the trans-fused silacyclopentane (–)-2.21.  
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Scheme 2.6: Synthesis and Reductive Lithiation of Phenylsulfide (–)-2.18 
2-3-2: A Suzuki Coupling Strategy 
Formation of the undesired by-product (–)-2.21 precluded the generation of a strongly 
nucleophilic carbanion at C(11) to complete the side chain elaboration. We therefore 
opted to explore a less nucleophilic intermediate, such as an alkylboron species, that 
could potentially undergo a B-alkyl Suzuki coupling15 with triflate 2.19. Hydroboration 
of the appropriate olefin would provide access to such an intermediate. 
To this end, oxidation of alcohol (–)-2.16 with Dess-Martin periodinane (DMP)16 
provided aldehyde (–)-2.22 in 91% yield (Scheme 2.7). This aldehyde was found to be 
extremely unstable, undergoing extensive decomposition within several days even if 
stored at low temperatures. Subsequent Wittig methylenation under standard conditions 
(MePPh3+Br–, n-BuLi, THF, –78 °C) afforded terminal olefin (–)-2.23 in 80% yield. 
Unfortunately, this particular olefin was found to be extremely resistant to hydroboration. 
A variety of different boranes were examined, including 9-BBN and catecholborane with 
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Wilkinson’s catalyst, which led only to the recovery of starting material. Surprisingly, 
even the relatively small Et2BH and Me2BH were ineffective. Increasing the temperature 
resulted in complex mixtures of products.  
 
Scheme 2.7: Synthesis and Attempted Hydroboration of Olefin (–)-2.23  
 2-3-3: Synthesis of Key Intermediate (+)-2.3 
An extensive survey of the literature revealed an interesting report by Kozikowski, 
who employed novel umpolung chemistry to install cyclopentenones (Scheme 2.8).17 
This approach involves conjugate addition of PPh3 to cyclopentenone (2.24), followed by 
trapping of the resulting enolate with TBSOTf to generate the phosphonium salt 2.25. 
Deprotonation with n-BuLi generated the corresponding ylide, which, when reacted with 
a variety of aldehydes, furnished silyl dienol ethers (2.26). Finally, desilylation with 
TBAF in situ yielded β-susbtituted cyclopentenones (2.27). 
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Scheme 2.8: Kozikowski’s Umpolung Chemistry 
To apply this chemistry in our system, we prepared the homolog of aldehyde (–)-2.22. 
To this end, displacement of the iodide in (–)-2.17 with NaCN in DMSO, followed by 
DIBAL–H reduction of the resulting nitrile, afforded aldehyde (–)-2.28 in 91% yield (2 
steps). Gratifyingly, Kozikowski’s method proved highly efficient, delivering cyclo-
pentenone (–)-2.20 as a crystalline solid (m.p. 77-79 °C) in 91% yield (Scheme 2.9). 
However, we found that 1 M HCl was both more efficient and consistent in the 
desilylation step. Single crystal X-ray analysis established both the relative and absolute 
stereochemistry of (–)-2.20 unambiguously (Scheme 2.9). 
 
Scheme 2.9: Synthesis of Cyclopentenone (–)-2.20 
Treatment of (–)-2.20 with m-CPBA next furnished the desired epoxide (–)-2.29 as a 
single diastereomer in 88% yield. Iodination of the cyclopentenone in (–)-2.29 was then 
attempted under several conditions, including TMSN3/I2, NIS, and I2/pyridine. While the 
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former two conditions led to mixtures of products, Johnson iodination (I2/pyri-
dine/CCl4)18 cleanly afforded the desired iodide (–)-2.3 in 86% yield. To ensure complete 
consumption of starting material and a reasonable reaction time, 6 equivalents of I2 were 
required (Scheme 2.10).  
 
Scheme 2.10: Synthesis of Key Intermediate (–)-2.3 
2-4: Studies Directed Towards the Synthesis of Ring D 
2-4-1: An Epoxide Opening Strategy 
Initial cyclization studies involving lithiation of (–)-2.3 or formation of the Grignard 
reagent by metal halogen exchange with i-PrMgCl led only to complex mixtures of 
products (Scheme 2.11).  
 
Scheme 2.11: Initial Cyclization Studies 
We attributed this problem to be associated with side reactions at the carbonyl group, 
and decided that a protected secondary hydroxyl, in place of the carbonyl, should 
mitigate the formation of by-products. To this end, Luche reduction19 of (–)-2.3, followed 
by protection of the secondary hydroxyl as a TBS ether, furnished 2.30 as a mixture (1:1) 
of diastereomers for further cyclization studies (Scheme 2.12). Although metal halogen 
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exchange of iodide 2.30 with t-BuLi or i-PrMgCl proceeded cleanly, epoxide opening 
was not observed. More forcing conditions (THF, reflux) resulted in the formation of 
unidentifiable by-products. 
We surmised that the use of Lewis acids might activate the epoxide towards the desired 
cyclization. A variety of weak Lewis acids such as ZnCl2 and Ti(iOPr)4 were 
investigated, but the only product observed was that resulting from simple metal halogen 
exchange. Conversion of the vinyllithium species or Grignard reagent derived from 2.30 
to their corresponding cuprates, utilizing various copper sources, also failed to bring 
about the cyclization.  
 After screening multiple weak Lewis acids, we also attempted the use of strong Lewis 
acids such as BF3•OEt2 and TiCl4. In each case however, only products arising from 
skeletal rearrangement were observed. Such rearrangements are common reaction 
pathways for epoxides situated on bridged bicyclic compounds.20 
 Given the failures associated with epoxide opening by a vinyl carbanion, we 
questioned whether radical cyclization conditions might prove more fruitful. Typical 
conditions for generating radicals such as Bu3SnH/AIBN,21 Et3B/O2,22 and SmI223 were 
examined. Unfortunately, these conditions were equally ineffective in bringing about the 
desired cyclization. 
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Scheme 2.12: Attempted Cyclization of Epoxide 2.30 
 The failure of 2.30 to undergo the desired cyclization is likely due to stereoelectronic 
effects. For the epoxide opening to occur, overlap of the σ orbital of the nucleophile with 
the C-O antibonding (σ*) orbital would be necessary in the transition state. The rigidity 
of the bicyclic system prevents the attainment of such overlap (Scheme 2.13).  
 
Scheme 2.13. Hypothesis for the Failure of 2.30 to Undergo Cyclization  
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2-4-2: A Heck Cyclization Cascade Strategy  
Convinced that the transannular epoxide opening was not a viable strategy to access 
the D ring, we opted to revise our original approach. Earlier studies had revealed that the 
siloxane ring in these substrates was subject to nucleophilic opening by phenyllithium. 
We envisioned access to substrate 2.32, bearing a vinyl iodide and a pendant nucleophile 
(carboxylic acid), that could potentially undergo a Heck cyclization cascade24 to furnish 
lactone 2.33 (Scheme 2.14).  
 
Scheme 2.14: Proposed Synthesis of the D Ring via a Heck Cyclization Cascade 
Mechanistically (Scheme 2.15), the proposed cascade reaction involves initial 
oxidative addition of Pd0 into the vinyl iodide bond of 2.32, resulting in the vinyl 
palladium intermediate 2.34. Migratory insertion into the olefin would give an 
alkylpalladium species (2.35) that is incapable of β-hydride elimination, due to the lack 
of syn-β hydrogens. Therefore, the palladium center would be subject to nucleophilic 
attack by the carboxyl group to generate palladacycle 2.36. Finally, reductive elimination 
would deliver lactone 2.33 and regenerate the palladium catalyst.  
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Scheme 2.15: Mechanistic Proposal for the Heck Cyclization Cascade 
 The synthesis of 2.32 first required iodination of enone (–)-2.20. Contrary to (–)-2.29, 
bearing an epoxide in place of the olefin, iodination of (–)-2.20 proceeded in very low 
yields and was accompanied by the formation of substantial amounts of tar, which made 
the workup and purification very difficult. We reasoned it should be possible to access 
iodide 2.37 from aldehyde (–)-2.28 employing a modification of the Kozikowski 
chemistry17 (Scheme 2.8). By utilizing 2-iodocyclopentenone (2.38) and LDA as the base 
(instead of n-BuLi) to avoid metal-halogen exchange, vinyl iodide (–)-2.37 was indeed 
obtained directly from aldehyde (–)-2.28 in 90% yield (Scheme 2.16). Ketalization of the 
carbonyl in (–)-2.37 was found to be quite difficult. Therefore, a Luche reduction19 was 
used to protect this moiety from phenyllithium, which was used in the subsequent step to 
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open the siloxane ring. Exposure of the resulting diol to excess DMP then afforded 
aldehyde  (–)-2.39. Finally, Pinnick oxidation25 provided the requisite intermediate (–)-
2.32 for the Heck cyclization studies. 
 
Scheme 2.16: Synthesis of Heck Cyclization Precursor (–)-2.32 
 A wide variety of conditions were explored to bring about the cascade cyclization 
(Scheme 2.17). These conditions involved the use of various sources of Pd0 or PdII, 
diverse ligands, and several different bases. In many cases, only the product resulting 
from proto-dehalogenation was observed. The other conditions that we surveyed either 
led to the recovery of starting material or decomposition of the substrate. 
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Scheme 2.17: Attempted Synthesis of Lactone 2.33 via a Heck Cyclization Cascade 
 After extensive screening of conditions, we became convinced that the proposed 
Heck cyclization cascade would not be a viable strategy for moving forward. Several 
other approaches were briefly investigated, but proved to be similarly fruitless, and the D 
ring continued to remain elusive.   
 
  
Pd-mediated cascade
Entry Conditions Result
1
2
Pd2(dba)3, P(o-tol)3, Et3N
MeCN, reflux
Unidentifiable by-product
Pd(PPh3)4, P(o-tol)3, Et3N
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Pd2(dba)3, PPh3, Et3N
MeCN, 60 °C
Pd2(dba)3, dppe, Et3N
MeCN, 60 °C
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6 Decomposed
Decomposed7
4 Pd2(dba)3, (2-furyl)3P, NaHCO3
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Complex mixture
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CHAPTER 3 
A Revised Synthetic Approach 
3-1: Regioselective Installation of the C(1) Carbonyl 
 Failure to secure the D ring of (–)-calyciphylline N by the various approaches 
discussed in Chapter 2 convinced us that a significant revision of the synthetic strategy 
was required. We questioned whether or not the epoxide functionality could be opened 
intramolecularly by a pendant hydroxyl group, as this would provide a means to install 
the C(1) carbonyl, potentially a valuable functional handle for further elaboration. 
 To test this hypothesis, reduction of aldehyde (–)-2.28 with NaBH4 in MeOH and 
subsequent epoxidation of (–)-3.1 with m-CPBA afforded epoxy alcohol (–)-3.2 as a 
single diastereomer. Pleasingly, exposure of (–)-3.2 to a catalytic amount of PPTS in 
CH2Cl2 at 0 °C resulted in rapid cyclization. Dess Martin oxidation of the crude mixture 
facilitated purification, providing ketone (+)-3.3 in 67% yield over the two steps.  
 
Scheme 3.1: Installation of the C(1) Carbonyl Group 
 Our ability to access ketone (+)-3.3 now set the stage for the development of a new 
synthetic strategy. 
O Si
O
O Si
O
O
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3-2: A Second Generation Retrosynthetic Analysis 
Our revised retrosynthetic analysis is outlined in Scheme 3.2. Several disconnections 
remain unchanged from the initial synthetic plan (Scheme 2.1), but diverge at 
intermediate 2.2. Thus, the E ring would be constructed at a later stage through a 
cyclopentenone annulation, simplifying the structure to diketone 3.4. The D ring was now 
envisioned to arise via an intramolecular enolate alkylation of iodide 3.5, which in turn 
could be assembled through elaboration of ketone 3.6. Finally, 3.6 could be accessed 
after reductive cleavage of tetrahydropyran (+)-3.3.  
 
Scheme 3.2: Revised Retrosynthetic Analysis 
3-3: Synthesis of Diketone (+)-3.4 
After a brief survey of reaction conditions, we discovered that 4 equivalents of SmI2 
in a solution of THF/MeOH smoothly promoted reductive cleavage1 of the tetrahydro-
pyran ring in (+)-3.3 to provide crystalline hydroxy ketone (+)-3.7 in 82% yield (Scheme 
3.3). Methanol was an essential additive, as rapid protonation of the intermediate enolate 
was necessary to avoid side reactions. Furthermore, quenching of the reaction under 
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different conditions gave widely different results. While a 1 M HCl quench resulted in 
formation of unidentifiable by-products, pouring the reaction mixture into saturated 
NaHCO3 gave consistently high yields of (+)-3.7. Protection of the primary hydroxyl 
then provided TBS ether (+)-3.6 in 97% yield. 
 
Scheme 3.3: Reductive Cleavage of Tetrahydropyran (+)-3.3 
Next, we explored the installation of the C(8) quaternary center. Not surprisingly, 
direct acylation of the sterically hindered carbonyl in (+)-3.6 was found to be quite 
difficult. The lithium enolate, with or without added HMPA, failed to react with Ac2O, 
EtOAc, and 1-acetyl imidazole. The sodium and potassium enolates were found to be 
similarly unreactive. Fortunately, an aldol reaction with acetaldehyde, followed by 
oxidation of the resulting β-hydroxy ketone (DMP), an effective protocol reported in 
1981 by Smith and Levenberg for the construction of 1,3-dicarbonyl compounds,2 led to 
diketone (+)-3.8 in 91% yield over 2 steps (Scheme 3.4). While treatment of (+)-3.8 
under basic conditions with allyl bromide gave complex mixtures of products, a Tsuji-
Trost allylation3 with allyl acetate (3.9), NaH, and catalytic Pd(PPh3)4 (5 mol%) in THF 
furnished the desired product (–)-3.10 as a single diastereomer in 95% yield. 
SmI2 (4 equiv.)
THF/MeOH (20:1)
TBSCl,
imidazole
DMF, 0 °C
97%82%
O Si
O
O
O Si
O
O Si
O
(+)-3.3 (+)-3.7 (+)-3.6
1
OH OTBS
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Scheme 3.4: Installation of the C(8) Quaternary Center 
Interestingly, when deprotection of the TBS ether in (–)-3.10 was attempted with TBAF, 
none of the desired alcohol 3.11 was obtained. Instead, the major product isolated from 
the reaction mixture was identified as acetate (+)-3.12 (Scheme 3.5). Mechanistically, 
this product arises from intramolecular attack of the intermediary alkoxide onto the C(9) 
carbonyl, followed by a retro-Dieckmann reaction. Notably, this result proves that the 
correct stereochemistry at C(8) had been established in the allylation step. 
 
Scheme 3.5: Undesired Retro-Dieckmann Pathway 
Since an alkoxide was identified as the culprit in this undesired side reaction, we 
surmised that deprotection of the TBS ether under acidic conditions would eliminate this 
reaction pathway. Indeed, exposure of (–)-3.10 to catalytic p-TsOH in MeOH provided  
(–)-3.11 in 92% yield (Scheme 3.6). Alcohol (–)-3.11 revealed such a propensity to 
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undergo the undesired retro-Dieckmann pathway that even quenching of the reaction 
mixture with saturated aqueous NaHCO3 resulted in the formation of only the by-product 
(+)-3.12. Therefore a simple aqueous wash to remove p-TsOH was employed in the 
workup. Conversion of the alcohol to the corresponding iodide was then accomplished 
without incident to afford the key cyclization precursor (–)-3.5 in 97% yield. 
 
Scheme 3.6: Synthesis of Iodide (–)-3.5 
We were delighted to find that dropwise addition of LDA to a solution of the 
iodoketone in THF at –20 °C provided tetracycle (+)-3.4 as a crystalline solid (m.p. 123-
125 °C) in 77% yield (Scheme 3.7). Single crystal X-ray analysis confirmed the structure, 
as well as the relative and absolute stereochemical configurations. Interestingly, treatment 
of (–)-3.5 with NaHMDS gave only the elimination product (–)-3.13. 
 
Scheme 3.7: Completion of the D Ring 
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3-4: Construction of Ring E 
With the D ring secured, we next turned our attention to elaboration of the eastern 
hemisphere. For the planned cyclopentenone annulation to construct ring E, we 
envisioned the advancement of (+)-3.4 to a substrate bearing a divinyl carbonyl moiety 
such as 3.14. Nazarov cyclization4 of 3.14 would then permit access to cyclopentenone 
3.15. 
 
Scheme 3.2: General Strategy Towards Construction of Ring E 
3-4-1: A Tandem Rupe Rearrangement/Nazarov Cyclization Strategy 
 One method of accessing divinyl ketones relies upon the acid catalyzed isomerization 
of 1,4-butyne diols (Rupe rearrangement5/dehydration sequence). Under the reaction 
conditions, these intermediates typically undergo the Nazarov cyclization in situ. 
Pursuant to this strategy, we attempted to add the acetylide anion derived from propargyl 
alcohol (or an O–protected propargyl alcohol) to ketone (+)-3.4. Reaction with the fully 
substituted C(1) carbonyl was not considered as a possibility on steric grounds. 
Unfortunately, the C(9) carbonyl was found to be similarly unreactive. Neither the 
lithium acetylide, the Grignard reagent, nor the cerium acetylide was successful in 
providing the desired 1,4-butynediol 3.16, even under forcing conditions (Scheme 3.9). 
Inspection of molecular models suggested that the Dunitz-Bürgi linear trajectory is 
blocked from the bottom face by the concavity of the ring system, and blocked from the 
top face by the presence of the C(21) methyl group. 
O Si
O
O Nazarov 
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O O
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O O
O Si
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Scheme 3.3: Attempted Acetylide Addition to Ketone (+)-3.4 
3-4-2: A Stille Coupling Strategy 
 We next explored the possibility of converting ketone (+)-3.4 to the corresponding 
vinyl tributylstannane, which we anticipated could undergo a Stille coupling6 with 
acryloyl chloride to access 3.14. To this end, enolization of (+)-3.4 with KHMDS in the 
presence of PhN(Tf)2 at –78 °C afforded vinyl triflate (+)-3.19 in 98% yield (Scheme 
3.10). We next attempted to install the vinyl tributylstannane via cross coupling of (+)-
3.19 with (Bu3Sn)2 and catalytic Pd(PPh3)4 (5 mol%). However, the desired stannane 3.20 
was not observed, because (+)-3.19 simply underwent an intramolecular Heck reaction7 
with the pendant allyl group to furnish (+)-3.21 as the major product. 
conditions
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Scheme 3.10: Undesired Heck Cylization of Triflate (+)-3.19 
3-4-3: Synthesis of Ring E Utilizing a Stille Carbonylative Cross Coupling Reaction 
Another method for the construction of divinyl ketones is via the Stille carbonylative 
cross coupling.8 Before exploring this strategy in our system, we were aware that we 
would have to functionalize the pendant allyl group first, in order to eliminate the 
possibility of the Heck cyclization pathway (Scheme 3.10). 
 To this end, hydroboration of (+)-3.4 with 9-BBN,9 followed by oxidation of the 
resulting organoborane (NaOH and H2O2) afforded the expected alcohol (+)-3.22 in 71% 
yield (Scheme 3.11). Protection of the alcohol provided TBS ether (+)-3.23, which was 
converted to vinyl triflate (+)-3.24 in excellent yield (86%) under the previously 
established conditions (KHMDS, PhN(Tf)2, THF, 78 °C). Excess PhN(Tf)2 was extre-
mely difficult to remove from the product, with some remaining even after 
chromatography. Furthermore, the reaction had to be quenched very carefully with pH 7 
buffer at –78 °C to avoid varying amounts of triflate hydrolysis during the workup. 
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Scheme 3.11: Synthesis of Vinyl Triflate (+)-3.24 
With the functionalized vinyl triflate (+)-3.24 in hand, the stage was now set to 
explore the proposed Stille carbonylation. We quickly discovered that while no reaction 
occurred in THF at reflux, heating a DMF solution of (+)-3.24, LiCl, tetravinyltin, and 
catalytic Pd(PPh3)4 (5 mol%) at 90 °C under balloon pressure of CO afforded the 
requisite divinyl ketone (+)-3.25 in 72% yield (Scheme 3.12). Despite a clean reaction 
profile (TLC, crude 1H NMR), silica gel chromatography consistently provided very low 
isolated yields of (+)-3.25 (<30%). Deactivation of the silica gel with Et3N failed to 
improve the yields. However, (+)-3.25 could be purified in good isolated yields by 
employing MPLC. Presumably, the large number of purifications carried out on this 
column had substantially deactivated the silica gel, thus allowing very sensitive 
compounds to be purified efficiently. Despite the harsh conditions typically required for 
Nazarov cyclizations (excess protic or Lewis acids, high temperatures), we were 
delighted to find that exposure of (+)-3.25 to SnCl4 in CH2Cl2 at ambient temperature 
readily led to the cyclization with concomitant removal of the TBS group to furnish 
cyclopentenone (+)-3.26 in 82% yield. While a variety of other Lewis acids (BF3•OEt2, 
1) 9-BBN
    THF, rt
2) NaOH, H2O2
    0 °C → rt
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94%
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FeCl3, etc.) were also effective for promoting this reaction, SnCl4 tended to give the most 
consistent results.  
 
Scheme 3.12: Completion of the E Ring 
3-5: Studies Towards the Construction of Ring F 
3-5-1: Synthesis and Attempted Conjugate Reduction of Unsaturated Ester (+)-3.29 
Having found an efficient strategy for the construction of ring E, we next turned our 
attention towards elaboration of ring F. To this end, oxidation of (+)-3.26 provided 
aldehyde (+)-3.27 in 91% yield (Scheme 3.13). The critical aldol condensation to prepare 
unsaturated aldehyde (+)-3.28 was brought about employing the conditions reported by 
Carreira and Weiss (Bn2NH2O2CCF3, PhH, 50 °C)10 for a similar ring system en route to 
(+)-daphmanidin E (Scheme 1.10).  
 
Scheme 3.13: Aldol Condensation Leading to Aldehyde (+)-3.28 
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Oxidation of (+)-3.28 to the corresponding methyl ester (+)-3.29 was readily achieved 
in 85% yield utilizing Corey’s conditions (AcOH, NaCN, MnO2, MeOH).11 At this point, 
the last major hurdle to overcome towards completion of the EF ring system was 
reduction of the α,β-olefin to set the stereochemistry at C(14) and C(15) (Scheme 3.14). 
We were cognizant of the challenges associated with this task, specifically, that the olefin 
to be reduced was tetrasubstituted and in a sterically hindered environment. Moreover, 
chemoselectivity (1,4- vs. 1,6-reduction), as well as diastereoselectivity (facial selectivity 
of the reduction) were major concerns. However, inspection of molecular models 
suggested the following; that the γ, δ–olefin was more sterically encumbered than the α, 
β–olefin, and that the C(21) methyl group appears to block top facial approach such that 
the reduction should occur with the desired facial selectivity.  
 
Scheme 3.14: Synthesis and Conformational Analysis of (+)-3.29 
 A wide variety of conditions for the reduction of (+)-3.29 were explored (Scheme 
3.15). Stryker’s reagent was ineffective, as was the DIBAL-H/CuI/HMPA protocol. 
Rhodium catalyzed hydrosilylations (Wilkinson’s catalyst or RhCl3 with Et3SiH) resulted 
only in the recovery of starting material, while Li/NH3 reduction gave an intractable 
mixture of products. Attempted heterogeneous hydrogenations (PtO2 or Pd/C) under 
pressures as high as 1000 psi also proved unsuccessful. An interesting result was obtained 
during hydrogenation of (+)-3.29 with Crabtree’s catalyst.12 At 1 atm of H2 pressure, no 
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reaction occurred, while a single new product with the correct mass (M+1 = 429) was 
produced upon hydrogenation at 400 psi. Disappointingly, careful analysis of the 2D 
NMR data including TOCSY, HMBC, and HSQC revealed saturated ester (+)-3.31 to be 
the product, wherein the hydrogenation was accompanied by isomerization of the 
remaining olefin to the undesired C(9)-C(15) position. Upon concluding the incorrect 
regiochemistry of the olefin resulted, we did not perform a NOESY analysis. 
 
Scheme 3.15: Attempted Reduction of the α,β-Olefin in (+)-3.29 
 One possible explanation for the formation of (+)-3.31 involves the initial 
coordination of the iridium catalyst to the ester carbonyl (Scheme 3.16). Migratory 
insertion of the iridium dihydride species would give an allylic iridium intermediate 3.33. 
Reductive elimination through a 1,4-hydride transfer mechanism would then lead to the 
observed product (+)-3.31. 
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Scheme 3.16: Hypothesis for the Formation of Mono-unsaturated Ester (+)-3.31  
 Alternatively, the desired product 3.30 may be formed as an intermediate; subsequent 
reinsertion of the H-Ir–H complex followed by β-hydride elimination would then result in 
isomerization of the remaining olefin.  
3-5-2: Conjugate Reduction of Unsaturated Aldehyde (+)-3.28 
An extensive survey of the literature revealed a variety of conjugate reduction 
conditions that were suitable for unsaturated aldehydes, but not esters. Thus, given the 
difficulties with the 1,4-reduction of unsaturated ester (+)-3.29, we opted to investigate 
the 1,4-reduction of the corresponding aldehyde (+)-3.28. Many conditions for this 
reduction were explored (Scheme 3.17). Heterogeneous hydrogenation was still 
ineffective, as were a variety of CuH methods. Not surprisingly, several conditions 
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resulted in 1,2-reduction of the aldehyde, including rhodium and copper catalyzed 
hydrosilylations.  
 
Scheme 3.17: Attempted Conjugate Reduction of Unsaturated Aldehyde (+)-3.28 
 Finally, a set of conditions [Pd(PPh3)4, ZnCl2, Ph2SiH2]13 was identified that provided 
a mixture of diastereomers (2:1) with the correct mass (Scheme 3.18). The major 
diastereomer could be isolated by silica gel chromatography. Several 2D NMR 
experiments were then performed. Inspection of the TOCSY NMR revealed interrupted 
coupling of the hydrogens at C(13) to C(17), indicating that the highlighted regions were 
isolated spin systems, thus confirming that 1,4- as opposed to 1,6-reduction had occurred, 
and importantly, without concomitant isomerization of the remaining olefin. With the 
correct regiochemistry established, a NOESY spectrum was obtained to determine the 
stereochemistry at C(14) and C(15). The most important nOe correlations were the 
conditions
Entry Conditions Result
1
2
3
4
Et3SiH, (PPh3)3RhCl
Benzene, 60 °C
TMSCl, MeLi, CuI, DIBAL-H
THF, HMPA, –50°C → rt
Ph2SiH2, [Cu], NaOtBu
toluene
H2 (1 atm), Pd/C
EtOAc
5 H2 (100 psi - 1000 psi), Pd/C
EtOAc or MeOH
1,2-reduction
No reaction
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No reaction
No reaction
6 Rh(COD)2BF4, Zn(OTf)2, H2 (400 psi)
MeOH/EtOAc, 70 °C
Complex mixture
O
CHO
O Si
O
CHO
O Si
H
(+)-3.28 3.34
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following: H(21) to H(13α), H(13α) to H(13β), H(13β) to H(14), H(14) to H(15), and 
H(21) to the aldehyde CHO. On the basis of this analysis, the structure of the major 
product could be assigned as 3.34. 
 
Scheme 3.18: Successful 1,4-Reduction of Unsaturated Aldehyde (+)-3.28; TOCSY and NOESY 
Correlations Leading to the Assignment of the Major Diastereomer 
 While the yield and diastereoselectivity for the reduction were certainly not ideal, we 
planned to optimize this reaction at a later stage, towards the very end of the synthesis. 
Moreover, the reaction was not clean and 3.34 could not be isolated in reasonable purity 
for full characterization purposes. Nonetheless, this was a promising result that kept us 
invested in this synthetic route.  
3-5: Elaboration of the Western Hemisphere 
3-5-1: Attempted Tamao-Kumada Oxidation of (+)-3.4 
Having found successful conditions for the conjugate reduction of (+)-3.28, we turned 
our attention towards elaboration of the western hemisphere. We chose to explore the 
Tamao-Kumada oxidation of the siloxane in the less advanced intermediate (+)-3.4; given 
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it was an easily handled solid, and did not contain incompatible functional groups. 
Unfortunately, we quickly discovered that the siloxane ring was completely inert to the 
oxidation (Scheme 3.19). Typical oxidation conditions (various sources of fluoride, 
bicarbonate salts, and H2O2 in various solvents)14 led to recovery of starting material, 
even at high temperatures. On the other hand, strongly basic conditions (CsOH•H2O or 
KH, t-BuOOH)15 resulted in decomposition. 
 
Scheme 3.19: Unsuccessful Tamao-Kumada oxidation of (+)-3.4 
An interesting case arose upon the use of TBAF and H2O2 in the presence of KHCO3 
that afforded a single new product in 91% yield, which was identified as (+)-3.36, 
resulting from desilylation rather than oxidation (Scheme 3.20). This outcome was quite 
unexpected since fluoride mediated desilylations of alkylsilanes typically require elevated 
temperatures, large excesses of fluoride, and extended reaction times. To gain insight into 
this process, two side by side experiments were conducted. In the first, (+)-3.4 was 
O Si
O
O
conditions
O
O
HO
HO
Entry Conditions Result
1
2
3
KF, KHCO3, H2O2
THF/MeOH (1:1), rt → reflux
CsF, CsOH•H2O, t-BuOOH
NMP, rt → 70 °C
CsF, KHCO3, H2O2
THF/MeOH (1:1), 70 °C
No reaction
Decomposed
No reaction
4 TBAT, KHCO3, H2O2
THF, 70 °C
No reaction
5 KH, t-BuOOH
DMF, rt → 70 °C
Decomposed
(+)-3.4 3.35
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treated simply with TBAF in THF. In the second, an earlier substrate, (–)-2.20, lacking a 
carbonyl group at C(1) was subjected to the same conditions. While (+)-3.4 was rapidly 
desilylated, no reaction occurred for (–)-2.20. 
 
Scheme 3.20: Difference in Reactivity Between (+)-3.4 and (–)-2.20; Hypothesis for the 
Formation of (+)-3.36 
The reason for this difference in reactivity may be attributed to the electron 
stabilizing effect of the carbonyl group in (+)-3.4. Fluoride mediated desilylation of (+)-
3.4 would give a homoenolate type intermediate, which after an aqueous quench results 
in the undesired by-product (+)-3.36. Compound (–)-2.20 does not bear a carbonyl group 
capable of stabilizing this anion, and therefore desilylation does not occur. Zakarian and 
coworkers noted a similar observation in a recent total synthesis of maoecrystal V 
(Scheme 3.21).16 Ketone 3.37, bearing a 1,3-relationship between the silyl group and the 
carbonyl in the bicyclo[2.2.2]octane system, was readily desilylated with TBAF at 0 °C 
O Si
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in 1 hour. The same substrate bearing a hydroxyl group (3.38) in place of the carbonyl 
required heating at 80 °C for 12 hours to bring about the desilylation. 
 
Scheme 3.21: Comparison of the Desilylation of (+)-3.4, 3.37, and 3.38 
 
Besides cyclic silyl ethers, any silane bearing an alkoxy, ester, hydrogen, or halogen 
substituent can be oxidized to the corresponding alcohol. Thus, we attempted to 
transform the siloxane moiety of (+)-3.4 into a more reactive silyl group, such as a silyl 
halide or silyl hydride (Scheme 3.22). Tamao reported a number of conditions for 
converting siloxanes into such activated silyl species with concomitant protection of the 
liberated hydroxyl group.17 Unfortunately, subjection of (+)-3.4 to all of the reported 
conditions led either to the recovery of starting material or decomposition. Surprisingly, 
even DIBAL-H or LiAlH4 at high temperature (toluene, reflux) failed to open the 
siloxane. 
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Scheme 3.22: Attempted Activation of the Siloxane in (+)-3.4 
3-5-2: Synthesis of Diol (+)-3.48 
Earlier studies had shown that the siloxane ring could be opened by treatment with 
phenyllithium to furnish the corresponding phenylsilane. Such phenylsilanes (3.41) can 
be converted to highly reactive silyl halides (3.42) employing protic acid or other 
electrophilic conditions (Hg salts, Br2, BF3•OEt2, etc.; Scheme 3.23).18 We reasoned that 
subjection of a phenylsilane derived from (+)-3.4 to one of these conditions might afford 
an activated silane capable of undergoing the oxidation. This two step conversion of an 
arylsilane to a hydroxyl group was pioneered by Fleming, and is thus referred to as the 
Fleming-Tamao oxidation.18 
 
Scheme 3.23: Conversion of Phenylsilanes to Activated Silyl Halides 
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 49 
 The phenyl group was readily introduced by exposure of (+)-3.24 to phenyllithium, 
providing phenylsilane (+)-3.43 in 71% yield (Scheme 3.24). Given that the strongly 
electrophilic conditions of protodesilylation are incompatible with unconjugated olefins, 
it was necessary to elaborate (+)-3.43 further before investigating the oxidation of the 
phenylsilane. Rather than protect the primary hydroxyl of (+)-3.43, we opted to introduce 
the nitrogen at this point, which was accomplished by a Mitsunobu reaction with 
phthalimide to furnish (+)-3.44 in 84% yield. We expected that the phthalimide should 
also serve as a stable protecting group for all of the endgame manipulations. Stille 
carbonylation of (+)-3.44 under the previously established conditions (Scheme 3.12) then 
led to dienone (+)-3.45 in 92% yield. The SnCl4 promoted Nazarov cyclization was 
equally efficient in this system, providing the requisite substrate (+)-3.46 for the 
Fleming-Tamao oxidation studies in 82% yield.  
 
Scheme 3.24: Synthesis of Phenylsilane (+)-3.46 
 Fleming had reported a series of conditions for the one pot conversion of 
phenylsilanes (entries 1-3, Scheme 3.25) to the corresponding alcohols.19 These 
conditions when applied to (+)-3.46 led only to complex mixtures of products. Therefore, 
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we investigated just the electrophilic cleavage of the phenylsilane moiety. At the outset, 
the hindered phenylsilane was resistant to cleavage under typical conditions such as  
BF3•OEt2, BF3•AcOH, and Hg+2 salts. However, we found that exposure of (+)-3.46 to 
HBF4•OEt2 in 1,2-dichloroethane at reflux converted the phenylsilane to the corres-
ponding silyl fluoride (+)-3.47. We were delighted to find that treatment of (+)-3.47 with 
KF and m-CPBA in DMF then resulted in successful Fleming-Tamao oxidation to deliver 
the advanced diol (+)-3.48. At this stage, the yield for the two steps could not be 
determined due the presence of inseparable impurities and/or by-products. As we will 
discuss, the lack of a yield at this point proved immaterial as a different reaction sequence 
that allowed us to move forward was discovered (vide infra). 
 
Scheme 3.25: Successful Fleming-Tamao Oxidation of Phenylsilane (+)-3.46 
Entry Conditions Result
1 Hg(OAc)2, AcOOH
THF, 25 °C → reflux
No reaction at 25 °C,
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 Having found a potential solution for introducing the C ring hydroxyl group and a 
strategy for the elaboration of the eastern hemisphere, we could now begin our final 
endgame studies. 
3-6: References 
1. Molander, G. A.; Hahn, G. J. Org. Chem. 1986, 51, 1135-1138. 
2. Smith, A. B.; Levenberg, P. A. Synthesis 1981, 567-570. 
3. (a) Tsuji, J.; Takahash.H; Morikawa, M. Tetrahedron Lett. 1965, 4387-&. (b) Trost, 
B. M.; Fullerton, T. J. J. Am. Chem. Soc. 1973, 95, 292-294. 
4. Nazarov, I. N.; Zaretskaya, I. I.; Sorkina, T. I. Zh. Obshch. Khim. 1960, 30, 746-754. 
5. Meyer, K. H.; Schuster, K. Ber. 1922, 55B, 819-823. 
6. Milstein, D.; Stille, J. K. J. Am. Chem. Soc. 1978, 100, 3636-3638. 
7. Heck, R. F.; Nolley, J. P. J. Org. Chem. 1972, 37, 2320-&. 
8. Merrifield, J. H.; Godschalx, J. P.; Stille, J. K. Organometallics 1984, 3, 1108-1112. 
9. Brown, H. C.; Knights, E. F.; Scouten, C. G. J. Am. Chem. Soc. 1974, 96, 7765-7770. 
10. Weiss, M. E.; Carreira, E. M. Angew. Chem. Int. Ed. 2011, 50, 11501-11505. 
11. Corey, E. J.; Gilman, N. W.; Ganem, B. E. J. Am. Chem. Soc. 1968, 90, 5616-&. 
12. Crabtree, R. Acc. Chem. Res. 1979, 12, 331-337. 
13. Keinan, E.; Greenspoon, N. J. Am. Chem. Soc. 1986, 108, 7314-7325. 
14. (a) Tamao, K. J. Syn. Org. Chem. Jpn. 1988, 46, 861-878. (b) Tamao, K.; Ishida, N.; 
Tanaka, T.; Kumada, M. Organometallics 1983, 2, 1694-1696. 
15. Smitrovich, J. H.; Woerpel, K. A. J. Org. Chem. 1996, 61, 6044-6046. 
16. Lu, P.; Gu, Z.; Zakarian, A. J. Am. Chem. Soc. 2013, 135, 14552-14555. 
17. Tamao, K.; Yamauchi, T.; Ito, Y. Chem. Lett. 1987, 171-174. 
 52 
18. Fleming, I.; Henning, R.; Plaut, H. J. Chem. Soc. Chem. Commun. 1984, 29-31. 
19. Fleming, I.; Sanderson, P. E. J. Tetrahedron Lett. 1987, 28, 4229-4232. 
 53 
CHAPTER 4 
Total Synthesis of (–)-Calyciphylline N 
4-1: An Improved Route to Diol (+)-3.48 
 Despite having found a successful method for the Fleming-Tamao oxidation of (+)-
3.46, the harsh conditions required to cleave the phenyl group (HBF4•OEt2, 1,2-DCE,  
80 °C) resulted in the formation of inseparable by-products. We therefore developed an 
improved route towards diol (+)-3.48. Considering the mechanism of protodesilylation 
(Scheme 3.23), we anticipated that a more electron donating aryl substituent on the 
silicon, such as 4-methoxyphenyl, should significantly facilitate the protodesilylation 
step. Conceivably, introduction of the 4-methoxyphenyl group could be accomplished by 
siloxane opening with 4-methoxyphenyllithium (4.2), the latter prepared by lithiation of 
4-iodoanisole (4.1) with t-BuLi. Treatment of (+)-3.24 with 4.2 resulted in partial 
cleavage of the triflate; we therefore opted to introduce the aryl group at an earlier stage. 
To this end, exposure of (+)-3.23 to 4.2 at room temperature cleanly afforded arylsilane 
(+)-4.3 in excellent yield (Scheme 4.1). Notably, both of the hindered carbonyl groups 
remained completely inert to nucleophilic addition. 
 
Scheme 4.1: Synthesis of Arylsilane (+)-4.3 
4.2
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 Elaboration of (+)-4.3 was achieved via the same sequence shown in Scheme 3.24. 
Thus, Mitsunobu reaction of (+)-4.3 with phthalimide, followed by treatment of (+)-4.4 
with KHMDS and PhN(Tf)2 delivered vinyl triflate (+)-4.5 in 73% yield (Scheme 4.2). 
The Stille carbonylative coupling of (+)-4.5 proceeded with high efficiency, affording 
divinyl ketone (+)-4.6 in 97% yield. 
 
Scheme 4.2: Synthesis of Divinyl Ketone (+)-4.6 
As described earlier, HBF4•OEt2 was found to be an effective reagent for the 
conversion of phenylsilane (+)-3.46 to fluorosilane (+)-3.47. Given that Nazarov 
cyclizations can also be triggered with protic acid, we reasoned that both of these 
transformations could be achieved in a single flask. At the outset, of course, we could not 
anticipate the facility with which the 4-methoxyphenyl group could be cleaved. We were 
therefore delighted to find that treatment of (+)-4.6 with HBF4•OEt2 in CH2Cl2 at ambient 
temperature cleanly afforded fluorosilane (+)-3.47 in 82% yield. Pleasingly, Fleming-
Tamao oxidation (KF, m-CPBA, DMF) of (+)-3.47 then provided diol (+)-3.48 in 74% 
yield. 
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Scheme 4.3: Improved Synthesis of Diol (+)-3.48 
4-2: Synthesis of Diene Aldehyde (+)-4.12 
 Moving forward, in order to minimize the number of protecting group manipulations, 
we chose to oxidize intially the primary hydroxyl group. To this end, oxidation of (+)-
3.48 with TEMPO and PhI(OAc)21 delivered aldehyde (+)-4.7 in 92% yield (Scheme 
4.4). Installation of a number of different protecting groups onto the secondary hydroxyl 
was explored next. However, protection of the hindered secondary hydroxyl in the 
presence of a relatively unhindered aldehyde was found to be difficult. Any conditions 
involving formation of an alkoxide (e.g., NaH, BnBr) led immediately to decomposition, 
again presumably through retro-aldol pathways. In several instances we did observe 
formation of the desired products, but these products were accompanied by significant 
amounts of decomposition or by-products. 
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Scheme 4.4: Attempted Protection of the Secondary Alcohol of (+)-4.7 
 
Given the difficulties associated with protection of the secondary hydroxyl in the 
presence of the aldehyde, we opted for a strategy involving differentiation of the 
hydroxyl groups prior to elaboration of the eastern hemisphere. Chemoselective 
protection of the primary hydroxyl was readily achieved by treatment of (+)-3.48 with 
TESCl and imidazole in DMF (Scheme 4.5). Under these conditions, the secondary 
hydroxyl was completely unreactive. We anticipated that a MOM acetal would survive 
all the remaining manipulations of the endgame. Furthermore, the last step in the Carreira 
synthesis of (+)-daphmanidin E entailed deprotection of a similar MOM protected 
secondary hydroxyl, suggesting a similar outcome in our system as well. Installation of 
the MOM group onto the hindered secondary hydroxyl of (+)-4.9 proved sluggish, with 
very low conversions observed even after 12 hours at room temperature and a large 
excess of MOMBr. Fortunately, heating (+)-4.9 with MOMBr and i-Pr2NEt in 1,2-
dichoroethane at 80 °C provided (+)-4.10 in 4 hours and 88% yield. Upon treatment with 
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IBX, primary TES ethers can be converted to the corresponding alcohols, which are then 
oxidized to aldehydes under the reaction conditions.2 Exposure of (+)-4.10 to excess IBX 
in DMSO/THF led directly to the desired aldehyde (+)-4.11 in 95% yield. Aldol 
condensation of (+)-4.11 under the previously established conditions (Bn2NH2O2CCF3, 
PhH, 50 °C) then afforded diene aldehyde (+)-4.12 in 69% yield after 2 cycles. While 
carrying out this particular reaction appears operationally simple, a great deal of 
optimization was required to maximize the yield of (+)-4.12. First, careful control of 
temperature was essential as heating the reaction to 60 °C caused an increased amount of 
decomposition. Best conditions involved running the reaction to ~70% conversion and 
recovering the starting material, as prolonged heating also resulted in decomposition. 
Finally, (+)-4.12 appeared to be unstable to silica gel chromatography, as purification by 
this method led to low yields. Purification by preparative TLC was much more effective, 
providing consistently ≥60% yield of (+)-4.12.  
 
Scheme 4.5: Synthesis of Diene Aldehyde (+)-4.12 
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With an effective means of preparing (+)-4.12, we next turned our attention to the 
critical 1,4-reduction (Scheme 4.6). Much to our disappointment, application of the 
successful reduction protocol identified for model substrate (+)-3.28 (Scheme 3.18) 
resulted only in decomposition. 
 
Scheme 4.6: Unsuccessful Conjugate Reduction of Diene Aldehyde (+)-4.12 
4-3: Completion of the Eastern Hemisphere 
The dramatic change in reactivity from substrate (+)-3.28 to (+)-4.12 was both a 
frustrating and discouraging setback, considering the amount of experimentation that was 
necessary to identify these conditions. Undeterred, we decided to advance aldehyde (+)-
4.12 to the corresponding methyl ester (+)-4.14 and investigate the homogeneous 
hydrogenation of this system. A reexamination of the literature revealed several 
reportedly highly active cationic hydrogenation catalysts that had not been explored with 
the model substrate (+)-3.29. As discussed earlier, we had demonstrated that 
hydrogenation of (+)-3.29 with Crabtree’s catalyst at 400 psi of H2 resulted in reduction 
of one olefin with concomitant isomerization of the other.  
Moving forward, oxidation of (+)-4.12 (NaCN, AcOH, MnO2, MeOH) furnished  (+)-
4.14 in 82% yield; a series of hydrogenation catalysts were then screened (Scheme 4.7). 
In most cases, (+)-4.14 was completely inert to reduction. Surprisingly, even 
hydrogenation with the Crabtree catalyst at 700 psi of H2 also led to recovery of starting 
material.  
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In 2008, Pfaltz and coworkers reported that the reactivity of the Crabtree catalyst can 
be enhanced by replacing the PF6 anion with that of tetrakis[bis(trifluoromethyl)-
phenyl]borate (BArF).3 The increase in reactivity is attributed to the extremely weakly 
coordinating nature of the BArF anion, facilitating coordination of functional groups to 
the cationic iridium center and resulting in increased catalytic activity. Hydrogenation of 
(+)-4.14 with [(cod)(py)(PCy3)]IrBArF under 900 psi of H2 afforded a mixture of 
diastereomers (4:1) in 84% yield.  
 
Scheme 4.7: Hydrogenation of (+)-4.14 
Analysis of the LCMS and 13C NMR data indicated that a single double bond had 
been reduced. Moreover, the 1H NMR immediately revealed significant differences in the 
region of interest when compared to the monounsaturated ester (+)-3.31. Consequently, a 
range of 2D NMR experiments were performed to establish the identity of the major 
product (Figure 4.1). In the HMBC spectrum, the hydrogens at C(13) and C(14) could 
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be assigned by virtue of their correlations to the ketone and ester functional groups, 
respectively. TOCSY NMR revealed uninterrupted coupling of the hydrogens from C(13) 
to C(17), indicating an isolated spin system. This analysis confirmed that the reduction 
was chemoselective for the α,β-double bond and, importantly, without isomerization of 
the remaining double bond. With the correct regiochemistry established, a NOESY 
experiment was performed to determine the configurations at the newly generated 
stereocenters, C(14) and C(15). An nOe correlation was observed between the C(21) 
methyl group and H(13α), which in turn showed a strong nOe to H(13β). Continuing with 
this analysis, H(13β) revealed a correlation to H(14), which displayed an nOe to H(15). 
Neither of the hydrogens [H(14) and H(15)] displayed an nOe correlation to the C(21) 
methyl group, indicating that these protons must be β. On the basis of this analysis, the 
structure of the major product could be confidently assigned as the desired diastereomer.    
 
Figure 4.1: 2D NMR Analysis of (–)-4.15 
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4-4: Completion of the Total Synthesis of (–)-Calyciphylline N 
With the eastern hemisphere constructed, all that remained to complete the synthesis 
of (–)-calyciphylline N were two deprotection steps and formation of the dihydropyrrole 
ring. Towards this end, removal of the phthalimide was cleanly achieved by treatment of 
(–)-4.15 with N2H4•H2O in EtOH at room temperature (Scheme 4.8). The condensation 
was brought about by heating the resulting amine with aq. NH4Cl (sat.) in EtOH at 70 °C 
overnight, providing imine (–)-4.16 in 73% yield (2 steps). Finally, Lewis acid (Ph2BBr)4 
mediated removal of the MOM group delivered (–)-calyciphylline N (79%). Totally 
synthetic (–)-calyciphylline N displayed spectral properties in excellent agreement with 
those derived from the natural material [i.e., 1H and 13C NMR (500 and 125 MHz, 
respectively), HRMS parent ion identification, and chiroptic properties].  
 
Scheme 4.8: Completion of the Synthesis 
 In summary, the first total synthesis of a calyciphylline alkaloid, (–)-calyciphylline N, 
has been achieved with a longest linear sequence of 40 steps from commercially available 
materials, quite comparable to the Carreira synthesis of (+)-daphmanidin E in 38 steps 
(longest linear sequence). Highlights of the synthesis include a substrate controlled, 
MOMO
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intramolecular Diels-Alder reaction to form the bicyclic core and to set 4 contiguous 
stereocenters, a highly efficient Stille carbonylation/Nazarov cyclization sequence which 
permits construction of ring E, removes a protecting group, and activates the silyl moiety 
towards Fleming-Tamao oxidation, and an unprecedented, homogeneous hydrogenation 
of an exceptionally hindered diene ester to complete the eastern hemisphere. 
 
 
Figure 4.2: 1H NMR Spectra of (–)-Calyciphylline N (Natural vs. Synthetic) 
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Chemical Shift (δ) 
Natural (–)-Calyciphylline N 
Chemical Shift (δ) 
Synthetic (–)-Calyciphylline N 
Δ δ 
(ppm) 
4.00 (d, J = 5.9 Hz, 1 H) 4.00 (m, 1 H) 0 
3.93 (dd, J = 6.8, 15.6 Hz, 1 H) 3.93, (dd, J = 7.0, 15.4 Hz, 1 H) 0 
3.66 (s, 3 H) 3.59 (s, 3 H) –0.07 
3.54 (m, 1 H) 3.56 - 3.52 (m, 1 H) 0 
3.42 (dd, J = 1.4, 15.6 Hz, 1 H) 3.43 (dd, J = 1.2, 15.5 Hz, 1 H) +0.01 
3.13 (m, 1 H) 3.13 (ddd, J = 5.3, 9.3, 10.7 Hz, 1 H) 0 
2.53 (dd, J = 5.0, 13.6 Hz, 1 H) 2.51 (dd, J = 5.2, 13.5 Hz, 1 H) –0.02 
2.48 (m, 1 H) 2.47 - 2.42 (m, 1 H) 0.03 
2.31 (dd, J = 9.4, 13.6 Hz, 1 H) 2.30 (dd, J = 9.2, 13.6 Hz, 1 H) –0.01 
2.27 (dd, J = 8.6, 14.6 Hz, 1 H) 2.25 (dd, J = 9.1, 15.5 Hz, 1 H) –0.02 
2.12 (m, 2 H) 
2.12 (m, 1 H) 
2.19 - 2.09 (m, 3 H) –0.02 
2.06 (m, 1 H) 
2.01 (m, 1 H) 
2.05 - 2.00 (m, 2 H) - 
1.88 (m, 1 H) 1.89 - 1.85 (m, 1 H) +0.01 
1.81 (m, 1 H) 1.82 (dt, J = 7.3, 12.1 Hz, 1 H) +0.01 
1.56 (m, 1 H) 1.57 - 1.54 (m, 1 H) 0 
1.41 (m, 1 H) 1.42 - 1.38 (m, 1 H) +0.01 
1.27 (m, 1 H) 1.26 (ddd, J = 2.2, 11.1, 13.3 Hz, 1 H) –0.01 
1.20 (m, 1 H) 1.21 (m, 1 H) +0.01 
1.16 (m, 1 H) 1.19 - 1.15 (m, 1 H) +0.01 
1.04 (s, 3 H) 1.04 (s, 3 H) 0 
0.97 (d, J = 6.9 Hz, 3 H) 0.97 (d, J = 7.1 Hz, 3 H) 0 
Table 4.1: 1H NMR Shifts of (–)-Calyciphylline N (Natural vs. Synthetic) 
 
 
Chemical Shift (δ) 
Natural (–)-Calyciphylline N 
Chemical Shift (δ) 
Synthetic (–)-Calyciphylline N 
Δ δ 
(ppm) 
185.7 185.3 –0.4 
176.2 176.2 0 
141.2 141.4 +0.2 
132.2 132.1 –0.1 
67.6 
67.8 
68.0 +0.2-0.4 
57.0 57.0 0 
54.3 54.4 +0.1 
52.6 52.6 0 
51.8 51.9 +0.1 
51.0 51.1 +0.1 
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42.7 42.7 0 
42.2 42.3 +0.1 
39.4 39.5 +0.1 
38.8 38.8 0 
37.0 37.0 0 
34.6 34.6 0 
27.3 27.4 +0.1 
25.2 25.3 +0.1 
23.3 23.4 +0.1 
22.8 22.7 –0.1 
21.4 21.5 +0.1 
16.6 16.7 +0.1 
Table 4.2: 13C NMR Shifts of (–)-Calyciphylline N (Natural vs. Synthetic) 
 
4-4: Future Directions 
From the outset of this work, we also considered other members of the Daphniphyllum 
alkaloids that could be targeted based on our synthetic strategy. We became attracted by 
the possibility of accessing (–)-calyciphyllines C and J from the late stage intermediate, 
diketone (+)-3.22. Retrosynthetically (Scheme 4.9), a late stage hydrogenation of 4.18 
that was successful in the (–)-calyciphylline N synthesis could be employed to set the 
stereochemistry at C(14) and C(15). An aldol condensation would assemble the diene 
ester, simplifying the structure to 4.19. Again drawing inspiration from our work on (–)-
calyciphylline N, a cyclopentenone annulation involving a Stille carbonylation/Nazarov 
cyclization sequence should permit access to ring E, while the azetidine ring could be 
constructed by a Mitsunobu cyclization, revealing lactam 4.20. In turn, 4.20 could be 
assembled from 4.21 via a Beckmann rearrangement. We had shown in our work on the 
(–)-calyciphylline N synthesis that the C(1) and C(9) carbonyl groups were extremely 
resistant to nucleophilic addition. Therefore, chemoselectivity at the C(7) carbonyl group 
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is a distinct possibility in the Beckmann rearrangement step. Finally, 4.21 should be 
readily accessible through elaboration of diketone (+)-3.22. 
 
Scheme 4.9: Retrosynthetic Analysis of (–)-Calyciphyllines C and J 
In the forward direction, protection of (+)-3.22 as the MOM ether, followed by siloxane 
opening with 4-methoxyphenyllithium would provide alcohol 4.22 (Scheme 4.10). 
Benzyl protection of the primary alcohol and Fleming-Tamao oxidation of the arylsilane 
should next afford 4.23. Oxidation of the resulting secondary hydroxyl would deliver the 
key intermediate 4.21. Given that the migratory aptitude of the C(2) quaternary center 
should be greater than that of the C(6) tertiary center, a Beckmann rearrangement of 4.21 
could be expected to provide 4.20 as the major regioisomer. Reduction of the lactam in 
4.20 and removal of the benzyl protecting group would afford the corresponding amino 
alcohol. Formation of the azetidine ring could then be accomplished under Mitsunobu 
conditions to provide 4.24.  
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Scheme 4.10: Proposed Synthesis of Diketone 4.24 
Conversion of 4.24 to vinyl triflate 4.25 could be accomplished under previously 
established conditions (KHMDS, PhN(Tf)2), and in turn our Stille carbonylation/Nazarov 
cyclization strategy [(–)-calyciphylline N, ring E synthesis) could next provide access to 
4.19 (Scheme 4.11). Removal of the MOM acetal under protic or Lewis acidic conditions 
should then deliver 4.27. 
 
Scheme 4.11: Proposed Synthesis of Enone 4.27 
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Oxidation of 4.27 to aldehyde 4.28, followed by an aldol condensation should then lead 
to diene aldehyde 4.29. In turn, 4.29 could then be oxidized to the corresponding methyl 
ester 4.30 (Scheme 4.12). Finally, hydrogenation of the diene ester would afford (–)-
calyciphylline C, saponification of which would then lead to (–)-calyciphylline J. 
 
Scheme 4.12: Proposed Endgame Towards the Total Synthesis of  
(–)-Calyciphyllines C and J 
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CHAPTER 5 
Experimental Information 
5-1: Materials and Methods 
Reactions were conducted in oven- or flame-dried glassware under an atmosphere of 
nitrogen or argon, unless otherwise noted. All solvents were reagent grade. All chemicals 
were purchased from commercial vendors, unless otherwise referenced. Anhydrous 
tetrahydrofuran, diethyl ether, dichloromethane, and toluene were obtained from a Pure 
SolveTM PS-400 solvent purification system. Chloroform was purchased from Fischer 
Scientific (HPLC grade, contains approx. 0.75% ethanol as a preservative). 
Triethylamine, diisopropylamine, and diisopropyl ethylamine were freshly distilled from 
CaH2. Reactions were magnetically stirred unless otherwise stated. Reactions were 
monitored by thin layer chromatography (TLC) with 250 mm Silicycle pre-coated silica 
gel plates or by LCMS [analytical reverse-phased (Sunfire C18; 4.6 mm Å~ 50 mm, 5 
mL) high-performance liquid chromatography with a Waters binary gradient module 
2525 equipped with Waters 2996 PDA and Waters micromass ZQ]. Silica gel flash 
chromatography was performed using ACS grade solvents and silica gel from Silicycle or 
Sorbent Technologies. Preparative TLC was performed using ACS grade solvents and 
500 mm Silicycle pre-coated silica gel plates. Medium pressure liquid chromatography 
purification was performed using an apparatus comprised of a solvent pump (Waters 510 
HPLC pump), injection loop (5 mL), column (20 mm ID x 300 mm, ACE glass) packed 
with silica gel (particle size 18-32 micron, 60 Å pore size), a refractive index detector 
(Waters Associates Differential Refractometer R401), and a chart recorder. Yields refer 
to chromatographically and spectroscopically pure compounds, unless otherwise stated. 
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All melting points were obtained on a Thomas-Hoover apparatus and are uncorrected. 
Infrared spectra were recorded on a Jasco Model FT/IR-480 Plus spectrometer. Proton 
and carbon NMR spectra were recorded on Bruker Avance III 500 MHz spectrometer 
equipped with either an Oxford cryomagnet or a Spectrospin/Bruker cryomagnet 
(500MHZ/52mm) with a 5 mm dual cryo probe. Chemical shifts are reported relative to 
chloroform (δ 7.26) for 1H-NMR and chloroform (δ 77.16) or benzene (δ 128.0) for 13C-
NMR. Optical rotations were measured on a Jasco P-2000 polarimeter. High-resolution 
mass spectra (HRMS) were measured at the University of Pennsylvania on either a 
Waters LC-TOF mass spectrometer (model LCTXE Premier) or a Waters GCT Premier 
spectrometer. Single crystal X-ray structures were determined at the University of 
Pennsylvania. X-ray intensity data were collected on a Rigaku Mercury CCD or Bruker 
APEXII CCD area detector employing graphite-monochromated Mo-Kα radiation 
(λ=0.71073 Å) at a temperature of 143(1) K. 
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5-2: Experimental Procedures Relevant to Chapter 2 
 
Imide (+)-2.10: A 2 L round bottom flask fitted with a mechanical stirrer and 50 mL 
addition funnel was charged with p-tolylacetic acid (12.0 g, 80.6 mmol) and THF (160 
mL). The resulting solution was cooled to –78 °C and Et3N (11.6 mL, 84.0 mmol) was 
added dropwise via addition funnel. Pivaloyl chloride (9.8 mL, 80.6 mmol) was added 
dropwise via addition funnel and the resulting turbid white reaction mixture was stirred at 
–78 °C for 1 hour. In a separate flask, (S)-4-benzyl-2-oxazolidinone (11.9 g, 67.2 mmol) 
was dissolved in THF (140 mL) and cooled to –78 °C. A solution of n-BuLi 
(2.5M/hexanes, 32.3 mL, 80.6 mmol) was added dropwise via addition funnel and the 
resulting deep red solution was stirred at –78 °C for 40 minutes. The solution of lithiated 
oxazolidinone was transferred via cannula to the solution of the mixed anhydride over 1 
hour at –78 °C. The reaction mixture was allowed to warm to room temperature and was 
quenched with saturated aqueous NH4Cl (200 mL). The layers were separated and the 
aqueous layer was extracted with EtOAc (200 mL). The combined organic layers were 
washed with brine (50 mL), dried over MgSO4, and concentrated in vacuo. The resulting 
white solid was triturated with pentane (100 mL x 3) to provide the title compound (17.9 
g, 86%) as a crystalline white solid. [α]  +64.0 (c 0.63 CHCl3). IR (neat) 2918, 2857, 
1779, 1697, 1389, 1358 cm-1. 1H NMR (500 MHz, CDCl3) δ 7.33 - 7.25 (m, 3 H), 7.25 - 
7.21 (m, 2 H), 7.19 - 7.11 (m, 4 H), 4.67 (tdd, J = 3.2, 7.3, 10.7 Hz, 1 H), 4.34 - 4.21 (m, 
2 H), 4.21 - 4.14 (m, 2 H), 3.27 (dd, J = 3.2, 13.5 Hz, 1 H), 2.75 (dd, J = 9.5, 13.5 Hz, 1 
NO
O O
Bn
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H), 2.35 (s, 3 H). 13C NMR (125 MHz , CDCl3) δ 171.6, 153.5, 137.0, 135.3, 130.6, 
129.8, 129.6, 129.5, 129.1, 127.5, 66.3, 55.5, 41.3, 37.9, 21.3. HRMS(ES+) m/z 
332.1255 [(M+Na)+; calcd for C19H19NO3Na: 332.1263]. 
 
Imide (+)-2.11: To a solution of imide (+)-2.10 (17.9 g, 57.9 mmol) in THF (250 mL) at  
–78 °C was added NaHMDS (1 M/THF, 64 mL, 63.7 mmol) dropwise via addition 
funnel. The resulting light orange solution was stirred at this temperature for 1 h. Methyl 
iodide (17.2 mL, 278 mmol) was added dropwise via addition funnel and the reaction 
mixture was allowed to warm to room temperature overnight. The reaction was quenched 
with saturated aqueous NH4Cl (200 mL) and the layers were separated. The aqueous 
layer was extracted with EtOAc (200 mL). The combined organic layers were washed 
with brine (50 mL), dried over MgSO4, and concentrated in vacuo. The residue was 
purified by flash chromatography on silica gel (8:1 hexanes/EtOAc) to afford the title 
compound (14 g, 75%) as a highly viscous, greenish oil. [α]  +141 (c 1.39 CHCl3). IR 
(neat) 2975, 2919, 1779, 1697, 1379, 1360, 1234, 1210, 1189 cm-1. 1H NMR (500 MHz, 
CDCl3) δ 7.39 - 7.33 (m, 2 H), 7.32 - 7.27 (m, 3 H), 7.27 - 7.22 (m, 2 H), 7.15 (app d, J = 
7.9 Hz, 2 H), 5.12 (q, J = 7.0 Hz, 1 H), 4.60 (dddd, J = 2.4, 3.2, 7.6, 9.7 Hz, 1 H), 4.11 
(dd, J = 2.4, 9.1 Hz, 1 H), 4.06 - 3.99 (m, 1 H), 3.36 (dd, J = 3.2, 13.3 Hz, 1 H), 2.83 (dd, 
J = 9.6, 13.4 Hz, 1 H), 2.34 (s, 3 H), 1.56 (d, J = 6.9 Hz, 3 H). 13C NMR (125 MHz, 
CDCl3) δ 174.8, 152.9, 137.4, 136.9, 135.5, 129.5, 129.4, 129.0, 128.1, 127.4, 65.9, 55.8, 
NO
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42.8, 38.0, 21.1, 19.5. HRMS(ES+) m/z 346.1409 [(M+Na)+; calcd for C20H21NO3Na: 
346.1419]. 
 
Alcohol (–)-2.12: To a solution of imide (+)-2.11 in THF/H2O (1:1, 180 mL) was added 
NaBH4 (6.55 g, 173.2 mmol) portion wise at 0 °C. The reaction mixture was warmed to 
room temperature and vigorously stirred overnight. The reaction mixture was diluted with 
EtOAc (100 mL) and the layers were separated. The aqueous layer was extracted with 
EtOAc (50 mL x 2). The combined organic layers were washed with brine (50 mL), dried 
over MgSO4, and concentrated in vacuo. After removal of the solvent, (S)-4-benzyl-2-
oxazolidinone was recovered by filtration and washing with Et2O (200 mL). The 
washings, which contained the product, were concentrated in vacuo and the residue was 
distilled (78 °C/0.1 torr) to provide the title compound (5.94 g, 91%) as a colorless liquid. 
[α]  –19.2 (c 0.82 CHCl3). IR (neat) 3388, 2958, 2918, 2869, 2852, 1643 cm-1. 1H 
NMR (500 MHz, CDCl3) δ 7.21 - 7.09 (m, 4 H), 3.68 (app d, J = 6.9 Hz, 2 H), 2.92 (sxt, 
J = 6.9 Hz, 1 H), 2.35 (s, 3 H), 1.27 (d, J = 7.1 Hz, 3 H). 13C NMR (125 MHz, CDCl3) δ 
140.7, 136.3, 129.4, 127.5, 68.8, 42.1, 21.1, 17.8. HRMS(ES+) m/z 150.1052 [(M)+; 
calcd for C10H14O: 150.1045]. 
 
Alcohol (–)-2.13: Ammonia (1.2 L) was condensed at –78 °C into a 5-L round bottom 
flask fitted with a mechanical stirrer. A solution of alcohol (–)-2.12 (28 g, 187 mmol) in 
absolute EtOH (190 mL) was added via cannula over 15 minutes. Lithium beads (6.47 g, 
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933 mmol) were added in portions until complete consumption of starting material (1H 
NMR analysis). Excess lithium was quenched by further addition of EtOH (ca. 200 mL), 
followed by careful addition of saturated aqueous NH4Cl, and the NH3 was allowed to 
evaporate overnight under a stream of dry N2. The residue was taken up in EtOAc (250 
mL) and washed with water (100 mL). The organic layer was washed with brine, dried 
over MgSO4, and concentrated in vacuo to afford the title compound (27.5 g, 99%) as a 
colorless liquid. [α]  –2.0 (c 0.84 CHCl3). IR (neat) 3355, 3019, 2961, 2923, 2875, 
2819, 1640, 1039 cm-1. 1H NMR (500 MHz, CDCl3) δ 5.55 (br. s., 1 H), 5.41 (br. s., 1 
H), 3.53 - 3.43 (m, 2 H), 2.68 - 2.50 (m, 4 H), 2.32 (sxt, J = 6.9 Hz, 1 H), 1.66 (s, 3 H), 
1.01 (d, J = 7.1 Hz, 3 H). 13C NMR (125 MHz, CDCl3) δ 135.9, 131.4, 120.7, 118.5, 
65.5, 43.2, 31.7, 27.2, 23.0, 15.5. HRMS(ES+) m/z 152.1206 [(M)+; calcd for C10H16O: 
152.1201]. 
 
Alcohol 2.6: DMSO (250 mL) was roughly degassed by bubbling N2 through for 0.5 h. 
Solid KOtBu (83.6 g, 746 mmol) was added and the suspension was cooled to 0 °C. A 
solution of alcohol (–)-2.13 (28.3 g, 187 mmol) in toluene (250 mL) was added dropwise 
via cannula over 20 minutes. The resulting solution was stirred at 0 °C for 1 h, then at 
room temperature for 2 h. After cooling back down to 0 °C, saturated aqueous NH4Cl 
(200 mL) was added and the layers were separated. The aqueous layer was extracted with 
EtOAc (100 mL x 2), and the combined organic layers were washed with brine, dried 
over MgSO4, and concentrated in vacuo. The residue was filtered through a short silica 
plug (4:1 hexanes/EtOAc) to afford an inseparable 3.5:1 mixture of 2.6 to (–)-2.13 (27.5 
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g, 97%). The following data is reported for this mixture. IR (neat) 3346, 2960, 2920, 
2873, 2823, 1654, 1448, 1431, 1029 cm-1. 1H NMR (500 MHz, CDCl3) Diagnostic 
signals for 2.6: δ 5.70 (d, J = 5.4 Hz, 1 H), 5.63 (d, J = 5.2 Hz, 1 H), 1.78 (s, 3 H).  
13C NMR (125 MHz, CDCl3) Major isomer 2.6: δ 136.8, 134.7, 121.0, 119.3, 65.7, 43.2, 
28.9, 24.4, 23.0, 15.3. HRMS(ES+) m/z 152.1205 [(M)+; calcd for C10H16O: 152.1201]. 
 
Ester (–)-2.4: A solution of the silyl acrylate 2.7 (76.7 g, 328 mmol) in CH2Cl2 (820 mL) 
was cooled to 0 °C and TfOH (58 mL, 657 mmol) was added dropwise via addition 
funnel. After stirring for 1 h, the solution was cooled to –78 °C and pyridine (64 mL, 789 
mmol) was added dropwise via addition funnel (pyridinium triflate precipitates). A 
solution of the alcohols 2.6 and (–)-2.13 (40 g, 263 mmol) in CH2Cl2 (375 mL) was 
added dropwise via cannula over 0.5 h. After stirring for an additional 0.5 h, the reaction 
mixture was allowed to warm to room temperature and pentane (200 mL) was added. The 
reaction mixture was filtered through a short pad of celite, which was washed with 
additional pentane (100 mL), and the filtrate was concentrated in vacuo. The residue, 
which still contained some of the pyridinium salt, was redissolved in pentane (300 mL) 
and filtered once more. The filter cake was washed with pentane (100 mL) and the filtrate 
was concentrated in vacuo to provide triene 2.5 (93 g crude weight), which was used 
without purification. 
To a cooled (0 °C) solution of triene 2.5 in toluene (1.5 L) was added Et2AlCl  
(1 M/hexanes, 265 mL) dropwise over 1 h via addition funnel. The resulting solution was 
O Si
CO2Et
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stirred at 0 °C for 2 h, then allowed to stir at room temperature for 36 h. Upon 
completion, the reaction mixture was cooled to 0 °C and a saturated aqueous solution of 
Rochelle’s salt (500 mL) was carefully added. The biphasic mixture was warmed to room 
temperature and vigorously stirred for 3 h. The layers were separated and the aqueous 
layer was extracted with EtOAc (300 mL) The combined organic layers were washed 
with brine, dried over MgSO4, and concentrated in vacuo. The residue was purified by 
flash chromatography on silica gel (10:1 hexanes/EtOAc) to afford the title compound 
(30 g, 50% over 2 steps, 9:1 d.r.; yield based on amount of 2.6) as a light yellow liquid.  
[α]  –50.2 (c 3.1 CHCl3). IR (neat) 3037, 2955, 2908, 2873, 1736, 1637, 1462, 1371, 
1250, 1158 cm-1. 1H NMR (500 MHz, CDCl3) δ 6.28 (d, J = 8.3 Hz, 1 H), 5.94 (d, J = 
8.3 Hz, 1 H), 4.09 (dq, J = 0.8, 7.1 Hz, 2 H), 3.74 - 3.66 (m, 2 H), 2.30 (d, J = 8.3 Hz, 1 
H), 2.16 - 2.07 (m, 1 H), 1.71 - 1.64 (m, 1 H), 1.43 - 1.38 (m, 1 H), 1.24 (t, J = 7.1 Hz, 3 
H), 1.23 - 1.20 (m, 2 H), 1.19 (s, 3 H), 0.89 (dd, J = 2.6, 8.3 Hz, 1 H), 0.86 (d, J = 6.9 Hz, 
3 H), 0.30 (s, 3 H), 0.09 (s, 3 H). 13C NMR (125 MHz, CDCl3) δ 175.4, 139.2, 134.8, 
66.0, 60.2, 52.0, 41.2, 39.7, 37.7, 37.0, 35.6, 23.0, 21.4, 14.5, 12.6, 0.57, –2.63. 
HRMS(ES+) m/z 309.1896 [(M+H)+; calcd for C17H29O3Si: 309.1886]. 
 
Alcohol (–)-2.16: Lithium aluminum hydride (4.8 g, 126 mmol) was suspended in Et2O 
(300 mL) and the suspension was cooled to 0 °C. In a separate flask, ester (–)-2.4 (30 g, 
97.4 mmol) was dissolved in Et2O (300 mL) and transferred to the LiAlH4 suspension via 
cannula over 0.5 h. The reaction mixture was allowed to warm to room temperature and 
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was stirred for 1 h. Upon completion, the reaction mixture was cooled to 0 °C, and H2O 
(4.8 mL) was slowly added dropwise over 0.5 h. Next, an aqueous solution of NaOH 
(15%, 4.8 mL) was added, followed by additional H2O (14.4 mL). The suspension was 
warmed to room temperature and vigorously stirred for 15 minutes. The loose granular 
solid was filtered off and the filter cake was washed with Et2O (150 mL). The filtrate was 
dried over MgSO4 and concentrated in vacuo. The residue was purified by flash 
chromatography on silica gel (4:1 hexanes/EtOAc) to afford the title compound (24.5 g, 
94%) as a colorless oil. [α]  –67.4 (c 0.4 CHCl3). IR (neat) 3434, 3029, 2951, 2872, 
1250, 1102, 1065 cm-1. 1H NMR (500 MHz, CDCl3) δ 6.24 (d, J = 8.5 Hz, 1 H), 5.84 (d, 
J = 8.3 Hz, 1 H), 3.72 - 3.67 (m, 2 H), 3.42 (dd, J = 4.7, 10.8 Hz, 1 H), 3.33 (dd, J = 5.3, 
10.8 Hz, 1 H), 2.08 – 2.01 (m, 1 H), 1.73 - 1.67 (m, 1 H), 1.57 (td, J = 5.0, 7.4 Hz, 1 H), 
1.42 - 1.35 (m, 1 H), 1.20 (s, 3 H), 1.19 - 1.14 (m, 2 H), 0.82 (d, J = 7.1 Hz, 3 H), 0.45 
(dd, J = 2.6, 7.5 Hz, 1 H), 0.25 (s, 3 H), 0.14 (s, 3 H). 13C NMR (125 MHz, CDCl3) δ 
140.5, 135.0, 66.2, 66.1, 48.8, 41.3, 39.6, 36.8, 36.1, 36.0, 23.4, 22.1, 12.5, 1.16, –2.20. 
HRMS(ES+) m/z 267.1784 [(M+H)+; calcd for C15H27O2Si: 267.1780]. 
 
Iodide (–)-2.17: To a cooled (0 °C) solution of alcohol (–)-2.16 (2.40 g, 9.02 mmol) in 
THF (36 mL) was added PPh3 (2.48 g, 9.47 mmol), imidazole (1.22 g, 18.0 mmol), and I2 
(2.73 g, 10.8 mmol) sequentially. The cold bath was removed and the brown solution was 
stirred at room temperature for 10 min. The reaction was quenched with saturated 
aqueous Na2S2O3 (15 mL) and the layers were separated. The aqueous layer was 
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extracted with EtOAc (15 mL x 2). The combined organic layers were washed with brine, 
dried over MgSO4, and concentrated in vacuo. The residue was purified by flash 
chromatography on silica gel (12:1 hexanes/EtOAc) to afford the title compound (2.87 g, 
85%) as a colorless oil. [α]  –32.1 (c 0.22 CHCl3). IR (neat) 3034, 2953, 2916, 2869, 
1636, 1462, 1370, 1250, 1104, 1070, 844 cm-1. 1H NMR (500 MHz, CDCl3) δ 6.20 (d, J 
= 8.3 Hz, 1 H), 5.90 (d, J = 8.3 Hz, 1 H), 3.75 - 3.62 (m, 2 H), 3.16 (dd, J = 4.1, 10.2 Hz, 
1 H), 2.95 (dd, J = 5.3, 10.2 Hz, 1 H), 2.07 (dddd, J = 5.0, 6.7, 11.7, 13.7 Hz, 1 H), 1.71 - 
1.62 (m, 2 H), 1.41 - 1.33 (m, 1 H), 1.23 (s, 3 H), 1.18 - 1.13 (m, 2 H), 0.82 (d, J = 6.9 
Hz, 3 H), 0.42 (dd, J = 2.1, 7.4 Hz, 1 H), 0.26 (s, 6 H). 13C NMR (125 MHz, CDCl3) δ 
138.8, 134.2, 66.2, 47.8, 41.7, 40.0, 39.2, 38.8, 36.5, 22.9, 21.9, 13.7, 12.5, 2.4, –1.8. 
HRMS(ES+) m/z 377.0798 [(M+H)+; calcd for C15H26IOSi: 377.0798]. 
 
Sulfide (–)-2.18: To a solution of DABCO (10.7 mg, 96 µmol) and PhSMe (12 µL, 96 
µmol) in THF (0.7 mL) was added n-BuLi (2.5M/hexanes, 38 µL, 96 µmol) dropwise at 0 
°C. The resulting solution was stirred at 0 °C for 45 minutes and a solution of iodide  
(–)-2.17 (20 mg, 53 µmol) in THF (0.3 mL) was added via cannula. The reaction mixture 
was allowed to warm to room temperature and stir for an additional 1 h. The reaction was 
quenched by the addition of saturated aqueous NH4Cl (2 mL), then diluted with H2O (5 
mL) and Et2O (5 mL). The layers were separated and the aqueous layer was extracted 
with Et2O (5 mL). The combined organic layers were dried over MgSO4 and concentrated 
in vacuo. The residue was purified by medium pressure liquid chromatography (30:1 
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hexanes/EtOAc) to afford the title compound (16 mg, 81%) as a colorless oil. [α]  –25.8 
(c 0.54 CHCl3). IR (neat) 3029, 2951, 2915, 2856, 1650, 1583, 1438, 1249, 1103, 1070 
cm-1. 1H NMR (500 MHz, CDCl3) δ 7.30 - 7.25 (m, 4 H), 7.15 (ddd, J = 2.6, 5.7, 8.5 Hz, 
1 H), 6.17 (d, J = 8.3 Hz, 1 H), 5.79 (d, J = 8.5 Hz, 1 H), 3.71 - 3.64 (m, 2 H), 2.78 (ddd, 
J = 2.6, 6.5, 9.4 Hz, 2 H), 2.01 (dt, J = 6.9, 14.1 Hz, 1 H), 1.72 - 1.67 (m, 1 H), 1.67 - 
1.63 (m, 1 H), 1.52 (dt, J = 4.4, 6.7 Hz, 1 H), 1.39 - 1.29 (m, 2 H), 1.20 (dt, J = 3.8, 12.3 
Hz, 1 H), 1.17 - 1.13 (m, 1 H), 1.12 (s, 3 H), 0.81 (d, J = 6.9 Hz, 3 H), 0.33 (dd, J = 2.8, 
6.9 Hz, 1 H), 0.25 (s, 3 H), 0.09 (s, 3 H). 13C NMR (125 MHz, CDCl3) δ 139.0, 136.8, 
135.1, 129.1, 129.0, 125.9, 66.2, 45.8, 41.3, 39.5, 38.6, 37.8, 35.6, 34.4, 31.7, 23.6, 22.2, 
12.5, 1.6, –1.9. HRMS(ES+) m/z 372.1957 [(M)+; calcd for C22H32OSSi: 372.1943]. 
 
Alcohol (–)-2.21: To a solution of di-tert-butyl biphenyl (500 mg, 1.88 mmol) in THF 
(9.4 mL) was added a large excess of freshly scraped lithium beads. The reaction mixture 
was cooled to 0 °C and vigorously stirred. Within 15 minutes, the characteristic deep 
green color of LiDBB was observed. The reaction mixture was stirred at 0 °C for 4 hours 
to provide a 0.2 M solution of LiDBB. Sulfide (–)-2.18 (20 mg, 53.7 µmol) was dissolved 
in THF (0.2 mL) and the solution of LiDBB was added until the green color persisted. 
The reaction was quenched with saturated aqueous NH4Cl (1 mL) and diluted with Et2O 
(5 mL) and water (5 mL). The layers were separated and the aqueous layer was extracted 
with Et2O (5 mL x 2). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The product was isolated by preparative TLC (4:1 
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hexanes/EtOAc) to afford the title compound (10 mg, 70%) as a colorless oil. [α]  –85.7 
(c 0.35 CHCl3). IR (neat) 3314, 3029, 2935, 2898, 2865, 1636, 1249, 1023 cm-1. 1H 
NMR (500 MHz, CDCl3) δ 6.36 (d, J = 8.3 Hz, 1 H), 5.77 (d, J = 8.3 Hz, 1 H), 3.88 (dd, 
J = 3.6, 10.5 Hz, 1 H), 3.42 (dd, J = 9.0, 10.2 Hz, 1 H), 1.78 - 1.67 (m, 2 H), 1.44 (dt, J = 
4.0, 12.9 Hz, 1 H), 1.40 - 1.31 (m, 2 H), 1.25 (br s, 1 H), 1.17 - 1.10 (m, 2 H), 1.07 (s, 3 
H), 1.04 (d, J = 6.7 Hz, 3 H), 0.71 (ddd, J = 1.4, 9.3, 15.1 Hz, 1 H), 0.67 - 0.58 (m, 1 H), 
0.58 - 0.52 (m, 1 H), 0.20 (s, 3 H), 0.16 (s, 3 H), -0.11 (d, J = 13.3 Hz, 1 H). 13C NMR 
(125 MHz, CDCl3) δ 140.8, 135.6, 66.1, 52.4, 47.1, 43.2, 43.0, 41.6, 37.4, 26.4, 25.7, 
22.0, 13.3, 12.3, –0.3, –1.8. HRMS(ES+) m/z 265.1977 [(M+H)+; calcd for C16H29OSi: 
265.1988]. 
 
Aldehyde (–)-2.22: To a solution of alcohol (–)-2.16 (100 mg, 0.38 mmol) in CH2Cl2 
(2.5 mL) was added Dess-Martin periodinane (191 mg, 0.45 mmol) at room temperature. 
The turbid reaction mixture was stirred for 0.5 hours and quenched with saturated 
aqueous Na2S2O3 (1 mL) and saturated aqueous NaHCO3 (1 mL). The reaction mixture 
was vigorously stirred until the layers became clear (20 minutes). Additional water (4 
mL) was added and the layers were separated. The aqueous layer was extracted with 
CH2Cl2 (5 mL x 2). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash chromatography on silica gel 
(12:1 hexanes/EtOAc) to afford the title compound (90.2 mg, 91%) as a colorless oil.  
[α]  –94.6 (c 0.41 CHCl3). IR (neat) 3035, 2954, 2921, 2871, 2821, 2711, 1719, 1637, 
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1252, 1064 cm-1. 1H NMR (500 MHz, CDCl3) δ 9.07 (d, J = 5.2 Hz, 1 H), 6.34 (d, J = 
8.3 Hz, 1 H), 5.93 (d, J = 8.3 Hz, 1 H), 3.77 - 3.67 (m, 2 H), 2.18 - 2.08 (m, 2 H), 1.74 
(dt, J = 3.6, 10.5 Hz, 1 H), 1.45 - 1.39 (m, 1 H), 1.28 - 1.19 (m, 2 H), 1.21 (s, 3 H), 0.86 
(d, J = 7.1 Hz, 3 H), 0.79 (dd, J = 2.8, 7.1 Hz, 1 H), 0.28 (s, 3 H), 0.03 (s, 3 H). 13C NMR 
(125 MHz, CDCl3) δ 203.7, 141.1, 133.7, 66.0, 59.7, 40.8, 39.8, 36.6, 35.0, 31.8, 23.4, 
21.7, 12.6, –0.1, –2.6. HRMS(ES+) m/z 264.1540 [(M)+; calcd for C15H24O2Si: 
264.1546]. 
 
Olefin (–)-2.23: Methyl triphenylphosphonium bromide (81 mg, 0.23 mmol) was 
suspended in THF (1 mL) and cooled to 0 °C. A solution of NaHMDS (1 M/THF, 0.22 
mL, 0.23 mmol) was added dropwise, and the resulting light orange solution was stirred 
at room temperature for 1 hour. The solution of the phosphorous ylide was cooled to 0 °C 
and a solution of aldehyde (–)-2.22 (50 mg, 0.19 mmol) in THF (0.3 mL) was added by 
syringe. The reaction mixture was warmed to room temperature and quenched with 
saturated aqueous NH4Cl (1 mL). The reaction mixture was diluted with EtOAc (5 mL) 
and H2O (5 mL). The layers were separated and the aqueous layer was extracted with 
EtOAc (5 mL). The combined organic layers were dried over MgSO4 and concentrated in 
vacuo. The residue was purified by flash chromatography on silica gel (30:1 
hexanes/EtOAc) to afford the title compound (39.6 mg, 80%) as a colorless oil. [α]  –
70.7 (c 0.42 CHCl3). IR (neat) 3073, 3033, 2953, 2923, 2868, 2854, 1638, 1251, 1096, 
1066 cm-1. 1H NMR (500 MHz, CDCl3) δ 6.24 (d, J = 8.3 Hz, 1 H), 5.81 (d, J = 8.5 Hz, 1 
O Si
€ 
D
20
 82 
H), 5.23 (td, J = 9.9, 16.8 Hz, 1 H), 4.83 (dd, J = 2.0, 8.7 Hz, 1 H), 4.80 (s, 1 H), 3.75 - 
3.63 (m, 2 H), 2.09 - 1.99 (m, 1 H), 1.92 (dd, J = 7.9, 9.3 Hz, 1 H), 1.70 (dt, J = 3.8, 13.3 
Hz, 1 H), 1.35 (dt, J = 4.2, 12.1 Hz, 1 H), 1.29 - 1.25 (m, 1 H), 1.20 - 1.13 (m, 1 H), 1.05 
(s, 3 H), 0.83 (d, J = 7.1 Hz, 3 H), 0.41 (dd, J = 2.8, 6.9 Hz, 1 H), 0.28 (s, 3 H), 0.06 (s, 3 
H). 13C NMR (125 MHz, CDCl3) δ 143.7, 139.9, 134.6, 113.2, 66.1, 52.7, 41.0, 39.8, 
38.9, 37.1, 35.3, 23.7, 21.9, 12.5, 1.0, –2.2. HRMS(ES+) m/z 262.1758 [(M)+; calcd for 
C16H26O2Si: 262.1753]. 
 
Aldehyde (–)-2.28: To a solution of iodide (–)-2.17 (2.87 g, 7.63 mmol) in DMSO (17 
mL) was added NaCN (561 mg, 11.4 mmol) and the reaction mixture was heated to 60 
°C for 3 h. After cooling to room temperature, the solution was diluted with Et2O and 
water (20 mL each). The layers were separated and the aqueous layer was extracted with 
EtOAc (20 mL x 2). The combined organic layers were washed with brine, dried over 
MgSO4, and concentrated in vacuo. The residue was filtered through a silica plug (9:1 
hexanes/EtOAc) and the product was used without further purification. 
 The resulting nitrile (1.99 g, 7.23 mmol) was dissolved in CH2Cl2 (25 mL), cooled to 
–78 °C, and DIBAL-H (1.5 M/toluene, 10.6 mL, 15.9 mmol) was added dropwise over 
15 min. Excess DIBAL-H was quenched by the slow addition of EtOAc (5 mL) at –78 °C 
and the solution was allowed to warm to room temperature. Saturated aqueous Rochelle’s 
salt (20 mL) was added and vigorous stirring was continued for 1.5 h. The layers were 
separated and the aqueous layer was extracted with CH2Cl2 (20 mL x 2). The combined 
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organic layers were washed with brine, dried over MgSO4, and concentrated in vacuo. 
The residue was purified by flash chromatography on silica gel (13:1 hexanes/EtOAc) to 
afford the title compound (1.89 g, 91% over 2 steps) as a colorless oil. [α]  –42.5 (c 
0.78 CHCl3). IR (neat) 3029, 2953, 2911, 2873, 2723, 1724, 1463, 1371, 1251, 1102, 
1069, 834 cm-1. 1H NMR (500 MHz, CDCl3) δ 9.71 (t, J = 2.4 Hz, 1 H), 6.23 (d, J = 8.5 
Hz, 1 H), 5.77 (d, J = 8.3 Hz, 1 H), 3.68 (app d, J = 8.1 Hz, 2 H), 2.41 - 2.34 (m, 1 H), 
2.05 - 1.92 (m, 3 H), 1.71 (ddd, J = 3.6, 9.9, 12.9 Hz, 1 H), 1.42 (ddd, J = 4.7, 10.1, 12.2 
Hz, 1 H), 1.26 (dt, J = 3.8, 12.2 Hz, 1 H), 1.20 - 1.12 (m, 1 H), 1.10 (s, 3 H), 0.82 (d, J = 
6.9 Hz, 3 H), 0.34 (dd, J = 2.9, 6.8 Hz, 1 H), 0.30 (s, 3 H), 0.11 (s, 3 H). 13C NMR (125 
MHz, CDCl3) δ 202.9, 140.3, 134.2, 66.2, 50.6, 41.4, 41.2, 39.8, 39.5, 37.6, 35.3, 23.8, 
22.0, 12.4, 1.49, –2.14. HRMS(ES+) m/z 279.1774 [(M+H)+; calcd for C16H27O2Si: 
279.1780].  
 
Enone (–)-2.20: Triphenylphosphine (1.59 g, 6.08 mmol) was dissolved in THF (20 mL) 
and TBSOTf (1.4 mL, 6.08 mmol) was added, followed by dropwise addition of 2-
cyclopenten-1-one (0.5 mL, 6.08 mmol) at room temperature. After 45 min, TLC 
indicated complete consumption of the enone, and the solution was cooled to –78 °C. A 
solution of n-BuLi (2.37M/hexanes, 2.56 mL, 6.08 mmol) was added dropwise and the 
reaction mixture turned black. After stirring for an additional 0.5 h, a solution of the 
aldehyde (–)-2.28 (846 mg, 3.04 mmol) in THF (4 mL) was added by syringe. The 
resulting solution was allowed to warm to room temperature and quenched with 1 M HCl 
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(10 mL). The layers were separated and the aqueous layer was extracted with EtOAc (15 
mL x 2). The combined organic layers were dried over MgSO4, filtered, and concentrated 
in vacuo. The residue was purified by flash chromatography on silica gel (4:1 
hexanes/EtOAc) to afford the title compound (954 mg, 91%) as a white solid. Crystals 
suitable for X-ray analysis were obtained by slow evaporation from ethyl acetate. Melting 
point 77-79 °C. [α]  –26.5 (c 0.8 CHCl3). IR (neat) 3028, 2951, 2870, 1709, 1616, 
1250, 1103 cm-1. 1H NMR (500 MHz, CDCl3) δ 6.19 (d, J = 8.3 Hz, 1 H), 5.91 - 5.86 (m, 
1 H), 5.81 (d, J = 8.3 Hz, 1 H), 3.69 (app d, J = 7.9 Hz, 2 H), 2.54 (dd, J = 3.0, 4.8 Hz, 2 
H), 2.41 - 2.34 (m, 2 H), 2.22 (dtd, J = 5.4, 16.1, 23.2 Hz, 2 H), 2.03 (qt, J = 7.3, 14.1 Hz, 
1 H), 1.70 (ddd, J = 3.2, 9.9, 12.5 Hz, 1 H), 1.64 - 1.54 (m, 2 H), 1.46 (dt, J = 4.1, 6.9 Hz, 
1 H), 1.40 - 1.32 (m, 1 H), 1.30 - 1.19 (m, 2 H), 1.16 (s, 3 H), 0.82 (d, J = 6.9 Hz, 3 H), 
0.37 (dd, J = 2.8, 6.9 Hz, 1 H), 0.25 (s, 3 H), 0.14 (s, 3 H). 13C NMR (125 MHz, CDCl3) 
δ 210.1, 183.3, 139.0, 135.1, 129.3, 66.3, 46.4, 41.4, 39.5, 38.6, 37.8, 35.8, 35.4, 32.2, 
31.8, 31.5, 23.6, 22.2, 12.5, 1.82, –1.89. HRMS(ES+) m/z 345.2259 [(M+H)+; calcd for 
C21H33O2Si: 345.2250]. 
 
Epoxide (–)-2.29: Enone (–)-2.20 (500 mg, 1.45 mmol) was dissolved in CH2Cl2 (7.5 
mL) and NaHCO3 (243 mg, 2.90 mmol) was added. The solution was cooled to 0 °C and 
m-CPBA (70%, 551 mg, 2.18 mmol) was added in one portion. The reaction mixture was 
stirred at 0 °C for 0.5 h and for an additional 1 h at room temperature. The suspension 
was diluted with CH2Cl2 (20 mL), saturated aqueous Na2S2O3 (15 mL), and saturated 
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aqueous NaHCO3 (15 mL each), and the biphasic mixture was vigorously stirred for 45 
minutes. The layers were separated and the aqueous layer was extracted with CH2Cl2 (20 
mL). The combined organic layers were dried over MgSO4 and concentrated in vacuo. 
The residue was purified by flash chromatography on silica gel (2:1 → 1:1 
hexanes/EtOAc) to afford the title compound (448 mg, 86%) as a colorless oil. [α]  –4.3 
(c 0.9 CHCl3). IR (neat) 2957, 2866, 1707, 1676, 1615, 1251 cm-1. 1H NMR (500 MHz, 
CDCl3) δ 5.94 (s, 1 H), 3.70 (dd, J = 4.6, 11.5 Hz, 1 H), 3.60 (t, J = 11.5 Hz, 1 H), 2.98 
(d, J = 5.0 Hz, 1 H), 2.91 (dd, J = 1.2, 5.0 Hz, 1 H), 2.58 (dd, J = 3.0, 4.4 Hz, 2 H), 2.47 - 
2.35 (m, 3 H), 2.33 - 2.21 (m, 1 H), 1.92 - 1.84 (m, 1 H), 1.80 (ddd, J = 4.7, 6.9, 11.4 Hz, 
1 H), 1.65 - 1.49 (m, 3 H), 1.45 - 1.33 (m, 3 H), 1.14 (s, 3 H), 1.01 (dt, J = 3.9, 11.9 Hz, 1 
H), 0.87 (d, J = 6.9 Hz, 2 H), 0.65 (dd, J = 2.6, 5.9 Hz, 1 H), 0.24 (s, 3 H), 0.19 (s, 3 H). 
13C NMR (125 MHz, CDCl3) δ 209.8, 182.2, 129.6, 66.3, 60.0, 56.5, 45.0, 41.2, 40.1, 
35.9, 35.7, 35.4, 32.7, 32.5, 32.2, 31.8, 23.8, 19.2, 12.2, 2.21, -1.00. HRMS(ES+) m/z 
361.2199 [(M+H)+; calcd for C21H33O3Si: 361.2199]. 
 
Enone (+)-2.3: To a solution of enone (–)-2.29 (447 mg, 1.24 mmol) in pyridine (2.5 
mL) and CCl4 (2.5 mL) was added I2 (1.88 g, 7.44 mmol) in one portion at room 
temperature. The dark brown solution was stirred for 8 h and quenched with saturated 
aqueous Na2S2O3 (5 mL). The layers were separated and the aqueous layer was extracted 
with CH2Cl2 (5 mL x 2). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash chromatography on silica gel 
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(2:1 hexanes/EtOAc) to afford the title compound (519 mg, 86%) as a colorless oil. [α]  
+1.3 (c 0.3 CHCl3). IR (neat) 2957, 2919, 2866, 1707, 1640, 1598 cm-1. 1H NMR (500 
MHz, CDCl3) δ 3.71 (dd, J = 4.6, 11.7 Hz, 1 H), 3.61 (t, J = 11.7 Hz, 1 H), 2.98 (d, J = 
5.0 Hz, 1 H), 2.92 (d, J = 5.0 Hz, 1 H), 2.81 - 2.69 (m, 2 H), 2.62 - 2.51 (m, 3 H), 2.39 
(dt, J = 4.1, 12.7 Hz, 1 H), 1.83 (ddd, J = 4.7, 6.9, 11.4 Hz, 1 H), 1.76 (tt, J = 4.1, 13.0 
Hz, 1 H), 1.61 (dt, J = 3.1, 11.8 Hz, 1 H), 1.55 (tt, J = 3.0, 11.9 Hz, 1 H), 1.46 (dt, J = 
4.2, 7.2 Hz, 1 H), 1.43 - 1.37 (m, 1 H), 1.35 (ddd, J = 5.0, 7.7, 12.9 Hz, 1 H), 1.18 (s, 3 
H), 1.03 (dt, J = 3.8, 11.8 Hz, 1 H), 0.88 (d, J = 6.9 Hz, 3 H), 0.74 (dd, J = 2.5, 6.6 Hz, 1 
H), 0.26 (s, 3 H), 0.25 (s, 3 H). 13C NMR (125 MHz, C6D6) δ 201.2, 180.3, 103.6, 66.2, 
58.7, 55.8, 45.3, 41.2, 40.1, 35.8, 35.7, 34.8, 32.9, 32.6, 31.8, 31.3, 23.5, 19.4, 12.0, 2.47, 
–1.06. HRMS(ES+) m/z 487.1151 [(M+H)+; calcd for C21H32IO3Si: 487.1166]. 
 
Vinyl Iodide 2.30: To a solution of enone (+)-2.3 (430 mg, 0.884 mmol) in MeOH (5 
mL) was added CeCl3•7H2O (822 mg, 2.21 mmol) and the resulting suspension was 
cooled to 0 °C. Sodium borohydride (83.5 mg, 2.21 mmol) was carefully added and the 
reaction mixture was allowed to warm to room temperature. Water (5 mL) was added, 
followed by EtOAc (5 mL), and the layers were separated. The aqueous layer was 
extracted with EtOAc (5 mL x 2). The combined organic layers were dried over MgSO4 
and concentrated in vacuo. The residue was purified by flash chromatography on silica 
gel (2:1 hexanes/EtOAc) to afford the corresponding allylic alcohol (353 mg, 82%) as a 
colorless oil. 
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 To a solution of the allylic alcohol (10.4 mg, 0.0213 mmol) in CH2Cl2 (0.2 mL) were 
added DMAP (one small crystal) and Et3N (15 µL, 0.106 mmol) sequentially. TBSCl (4.8 
mg, 0.0319 mmol) was added and the reaction mixture was stirred at room temperature 
for 12 h. The reaction mixture was diluted with CH2Cl2 (5 mL) and water (5 mL) was 
added. The layers were separated and the aqueous layer was extracted with CH2Cl2 (5 
mL). The combined organic layers were dried over MgSO4 and concentrated in vacuo. 
The residue was purified by flash chromatography on silica gel (15:1 hexanes/EtOAc) to 
afford the title compound (11.9 mg, 93%, 1:1 d.r.) as a colorless oil. IR (neat) 2956, 
2929, 2857, 1639, 1461, 1250, 1113 cm-1. 1H NMR (500 MHz, CDCl3) Diagnostic 
signals: δ 4.76 - 4.69 (m, 1 H), 3.72 - 3.66 (m, 1 H), 3.63 - 3.56 (m, 1 H), 2.98 (d, J = 5.0 
Hz, 1 H), 2.90 (d, J = 5.2 Hz, 1 H), 0.93 (s, 9 H), 0.16 (s, 3 H), 0.13 (s, 3 H). 13C NMR 
(125 MHz, CDCl3) δ 150.1, 150.1, 100.2, 100.1, 82.7, 66.3, 59.3, 59.2, 56.7, 45.2, 45.1, 
41.2, 40.1, 35.7, 35.7, 35.6, 33.4, 33.2, 33.0, 32.9, 32.7, 32.0, 32.0, 26.1, 23.8, 23.7, 19.3, 
18.5, 12.2, 2.3, 2.3, –1.0, –4.2, –4.3. HRMS(ES+) m/z 625.2005 [(M+Na)+; calcd for 
C27H47IO3Si2Na: 625.2006]. 
 
Iodide (–)-2.37: Triphenylphosphine (179 mg, 0.683 mmol) was dissolved in THF (1.7 
mL) and TBSOTf (0.16 mL, 0.683 mmol) was added, followed by dropwise addition of 
2-iodo-2-cyclopentenone (142 mg, 0.683 mmol) in THF (0.5 mL) at room temperature. 
After 45 min, TLC indicated complete consumption of the enone, and the solution was 
cooled to –78 °C. In a separate flask, n-BuLi (1.89 M/hexanes, 0.36 mL, 0.683 mmol) 
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was added to a solution of i-Pr2NH (95 µL, 0.683 mmol) in THF (1 mL) at –78 °C. After 
stirring for 0.5 h at this temperature, the resulting solution of LDA was transferred to the 
solution of the Wittig salt dropwise via cannula, producing a deep black solution of the 
ylide. After stirring for an additional 0.5 h, a solution of the aldehyde (–)-2.28 (95 mg, 
0.341 mmol) in THF (0.5 mL) was added by syringe. The reaction mixture was allowed 
to warm to room temperature and 1 M HCl (4 mL) was added. The reaction mixture was 
vigorously stirred for 1 h and the layers were separated. The aqueous layer was extracted 
with EtOAc (5 mL x 2) and the combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash chromatography on silica gel 
(5:1 hexanes/EtOAc) to afford the title compound (145 mg, 90%) as a colorless oil. [α]  
–6.5 (c 0.31 CHCl3). IR (neat) 3028, 2950, 2918, 2854, 1709, 1641, 1598 cm-1. 1H NMR 
(500 MHz, CDCl3) δ 6.21 (d, J = 8.5 Hz, 1 H), 5.82 (d, J = 8.3 Hz, 1 H), 3.71 (app d, J = 
7.9 Hz, 2 H), 2.73 - 2.68 (m, 2 H), 2.59 - 2.54 (m, 2 H), 2.37 (dt, J = 5.1, 12.7 Hz, 2 H), 
2.07 (sxt, J = 7.3 Hz, 1 H), 1.72 (ddd, J = 3.2, 9.7, 12.7 Hz, 1 H), 1.53 (ddd, J = 4.2, 6.7, 
13.9 Hz, 1 H), 1.49 - 1.43 (m, 1 H), 1.39 (ddd, J = 4.4, 10.5, 11.9 Hz, 1 H), 1.28 - 1.18 
(m, 2 H), 1.22 (s, 3 H), 1.15 (ddd, J = 3.0, 4.2, 12.3 Hz, 1 H), 0.83 (d, J = 6.9 Hz, 3 H), 
0.47 (dd, J = 2.9, 7.0 Hz, 1 H), 0.27 (s, 3 H), 0.20 (s, 3 H). 13C NMR (125 MHz, CDCl3) 
δ 203.6, 183.5, 139.2, 135.0, 102.3, 66.3, 46.4, 41.4, 39.5, 38.5, 37.8, 35.9, 33.9, 33.1, 
32.5, 31.6, 23.5, 22.2, 12.4, 2.0, –2.0. HRMS(ES+) m/z 471.1206 [(M+H)+; calcd for 
C21H32IO2Si: 471.1216]. 
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Aldehyde (+)-2.39: To a solution of enone (–)-2.37 (518 mg, 1.10 mmol) in MeOH (6 
mL) was added CeCl3•7H2O (491 mg, 1.32 mmol) and the resulting suspension was 
cooled to 0 °C. Sodium borohydride (104 mg, 2.75 mmol) was carefully added and the 
reaction mixture was allowed to warm to room temperature. Water (5 mL) was added and 
the mixture was diluted with EtOAc (10 mL). The turbid mixture was transferred to a 
separatory funnel and 1 M HCl (5 mL) was added. The resulting clear layers were 
separated and the aqueous layer was extracted with EtOAc (10 mL x 2). The combined 
organic layers were dried over MgSO4 and concentrated in vacuo. The product was used 
directly in the next step without purification. 
 To a solution of the allylic alcohol (518 mg, 1.10 mmol) in THF (8 mL) was added 
PhLi (2 M/Bu2O, 0.83 mL, 1.65 mmol) dropwise at room temperature. After stirring for 
15 minutes, the reaction was quenched by the addition of saturated aqueous NH4Cl (10 
mL). The layers were separated and the aqueous layer was extracted with EtOAc (10 mL 
x 2). The combined organic layers were dried over MgSO4 and concentrated in vacuo. 
The residue was purified by flash chromatography on silica gel (3:1 hexanes/EtOAc) to 
afford the corresponding diol (453 mg, 75% over 2 steps) as a colorless oil. 
 To a solution of the diol (253 mg, 0.460 mmol) in CH2Cl2 (2 mL) and MeCN (1 mL) 
was added NMO (118 mg, 1.01 mmol), followed by TPAP (8 mg, 0.023 mmol) at room 
temperature. The reaction mixture was stirred for 2 h and the solvent was removed in 
vacuo. The residue was dissolved in CH2Cl2 and filtered through a short pad of silica gel. 
Evaporation of the solvent afforded the title compound as a colorless oil, which was used 
directly in the next step without purification. [α]  +21.0 (c 0.39 CHCl3). IR (neat) 2949, 
2932, 2860, 2726, 1711, 1642, 1596, 1427, 1250, 1110 cm-1. 1H NMR (500 MHz, 
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CDCl3) δ 9.77 (d, J = 3.4 Hz, 1 H), 7.63 - 7.55 (m, 2 H), 7.40 - 7.32 (m, 3 H), 6.30 (d, J = 
8.5 Hz, 1 H), 5.97 (d, J = 8.5 Hz, 1 H), 2.54 - 2.47 (m, 3 H), 2.46 - 2.43 (m, 1 H), 2.43 - 
2.35 (m, 2 H), 1.97 (dt, J = 5.2, 13.0 Hz, 1 H), 1.70 - 1.62 (m, 2 H), 1.39 - 1.30 (m, 1 H), 
1.30 - 1.25 (m, 1 H), 1.27 (s, 3 H), 1.24 - 1.20 (m, 1 H), 1.17 - 1.11 (m, 2 H), 1.10 - 1.05 
(m, 1 H), 1.08 (d, J = 6.7 Hz, 3 H), 1.05 - 0.98 (m, 2 H), 0.89 (dd, J = 2.7, 5.6 Hz, 1 H), 
0.52 (s, 3 H). 13C NMR (125 MHz, CDCl3) δ 205.6, 203.7, 183.6, 139.7, 137.7, 135.0, 
134.1, 129.3, 128.1, 101.9, 51.8, 47.6, 43.1, 38.3, 37.6, 35.9, 34.6, 33.4, 33.0, 32.3, 31.9, 
24.2, 10.8, –0.4, –1.9. HRMS(ES+) m/z 569.1326 [(M+Na)+; calcd for C27H35IO2SiNa: 
569.1349]. 
 
Acid (+)-2.32: To a solution of aldehyde (+)-2.3 (252 mg, 0.460 mmol) and 2-methyl-2-
butene (0.48 mL, 4.60 mmol) in t-BuOH (4 mL) and H2O (1 mL) was added a solution of 
NaClO2 (207 mg, 2.30 mmol) and Na2H2PO4 (273 mg, 2.30) in H2O (1 mL) at room 
temperature. The reaction mixture was stirred for 1 h and quenched with pH 7 buffer (5 
mL). The reaction mixture was diluted with CH2Cl2 (10 mL) and the layers were 
separated. The aqueous layer was extracted with CH2Cl2 (10 mL x 2). The combined 
organic layers were dried over MgSO4 and concentrated in vacuo. The residue was 
purified by flash chromatography on silica gel (2:1 hexanes/EtOAc) to afford the title 
compound (207 mg, 80% over 2 steps) as an amorphous solid. [α]  +15.6 (c 0.21 
CHCl3). IR (neat) 3213, 2950, 2860, 1705, 1646, 1595, 1427, 1322, 1250, 1109 cm-1. 1H 
NMR (500 MHz, CDCl3) δ 7.57 (dd, J = 3.0, 6.3 Hz, 2 H), 7.38 - 7.32 (m, 3 H), 6.51 (d, 
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J = 8.5 Hz, 1 H), 5.87 (d, J = 8.7 Hz, 1 H), 2.68 (q, J = 6.9 Hz, 1 H), 2.51 - 2.44 (m, 2 H), 
2.40 (ddd, J = 4.8, 10.3, 12.9 Hz, 2 H), 1.96 (dt, J = 5.1, 12.9 Hz, 1 H), 1.66 - 1.57 (m, 2 
H), 1.34 - 1.28 (m, 1 H), 1.27 - 1.25 (m, 1 H), 1.24 (s, 3 H), 1.20 - 1.14 (m, 2 H), 1.13 (d, 
J = 6.9 Hz, 3 H), 1.07 - 0.98 (m, 2 H), 0.87 (dd, J = 1.8, 5.7 Hz, 1 H), 0.51 (s, 3 H), 0.49 
(s, 3 H). 13C NMR (125 MHz, CDCl3) δ 203.9, 183.9, 180.1, 139.7, 136.0, 135.7, 134.1, 
129.2, 128.1, 101.8, 47.9, 44.8, 43.2, 37.7, 37.3, 35.6, 34.5, 33.4, 33.0, 32.3, 31.2, 24.2, 
13.6, –0.6, –1.9. HRMS(ES+) m/z 561.1326 [(M–H)+; calcd for C27H34IO3Si: 561.1322]. 
 
5-3: Experimental Procedures Relevant to Chapter 3 
 
Alcohol (–)-3.1: Aldehyde (–)-2.28 (9.0 g, 32.3 mmol) was dissolved in EtOH (150 mL) 
and NaBH4 (1.46 g, 38.8 mmol) was added portion wise at room temperature. Upon 
completion, water was added carefully to quench excess hydride, the solution was 
concentrated to ca. 40 mL, and the aqueous layer was extracted with EtOAc (30 mL x 3). 
The combined organic layers were dried over MgSO4, filtered, and concentrated in 
vacuo. The residue was purified by flash choromotography on silica gel (4:1 
hexanes/EtOAc) to afford the title compound (9.0 g, 99%) as a colorless oil. [α]  –55.6 
(c 0.46 CHCl3). IR (neat) 3408, 3029, 2950, 2872, 1645, 1250, 1104, 1067 cm-1. 1H 
NMR (500 MHz, CDCl3) δ 6.19 (d, J = 8.3 Hz, 1 H), 5.79 (d, J = 8.3 Hz, 1 H), 3.69 (d, J 
= 7.9 Hz, 2 H), 3.61 - 3.45 (m, 2 H), 2.01 (qd, J = 7.3, 14.8 Hz, 1 H), 1.74 - 1.64 (m, 2 
H), 1.48 (dt, J = 4.5, 7.0 Hz, 1 H), 1.40 - 1.33 (m, 1 H), 1.22 (dt, J = 4.0, 12.0, 1 H), 1.18 
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- 1.11 (m, 3 H), 1.16 (s, 3 H), 0.81 (d, J = 6.9 Hz, 3 H), 0.35 (dd, J = 2.9, 6.6 Hz, 1 H), 
0.25 (s, 3 H), 0.18 (s, 3 H). 13C NMR (125 MHz, CDCl3) δ 139.2, 135.1, 66.4, 61.1, 43.1, 
41.4, 39.6, 38.9, 38.2, 37.7, 35.6, 23.7, 22.3, 12.5, 1.54, –1.86. HRMS(ES+) m/z 
281.1944 [(M+H)+; calcd for C16H29O2Si: 281.1937]. 
 
Epoxide (–)-3.2: To a cooled (0 °C) solution of alkene (–)-3.1 (9.0 g, 32.1 mmol) in 
CH2Cl2 (200 mL) was added NaHCO3 (5.4 g, 64.2 mmol), followed by m-CPBA (8.6 g, 
38.6 mmol). The reaction mixture was allowed to warm to room temperature and stir for 
1 h. Saturated aqueous Na2S2O3 (20 mL) and saturated aqueous NaHCO3 (20 mL) were 
added, and the mixture was vigorously stirred for an additional 0.5 h. After diluting with 
water (30 mL), the layers were separated and the aqueous layer was extracted with 
CH2Cl2 (30 mL x 2). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash chromatography on silica gel 
(2:1 hexanes/EtOAc) to afford the title compound (6.36 g, 70%) as a colorless oil. [α]  –
7.4 (c 1.78 CHCl3). IR (neat) 3440, 2959, 2919, 2869, 1254, 1120, 1085, 1055 cm-1. 1H 
NMR (500 MHz, CDCl3) δ 3.72 - 3.63 (m, 2 H), 3.63 - 3.50 (m, 2 H), 2.97 (d, J = 4.8 
Hz, 1 H), 2.89 (dd, J = 1.0, 5.0 Hz, 1 H), 1.94 (tdd, J = 3.9, 7.8, 17.2 Hz, 1 H), 1.81 - 1.73 
(m, 1 H), 1.60 - 1.44 (m, 3 H), 1.41 - 1.30 (m, 3 H), 1.11 (s, 3 H), 1.01 (dt, J = 4.4, 12.5 
Hz, 1 H), 0.86 (d, J = 6.9 Hz, 3 H), 0.63 (dd, J = 2.5, 6.4 Hz, 1 H), 0.23 (s, 3 H), 0.21 (s, 
3 H). 13C NMR (125 MHz, CDCl3) δ 66.3, 61.2, 59.0, 56.6, 41.2, 40.9, 40.0, 37.7, 35.8, 
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35.2, 32.3, 23.8, 19.2, 12.2, 1.60, –1.08. HRMS(ES+) m/z 297.1899 [(M+H)+; calcd for 
C16H29O3Si: 297.1886]. 
 
Ketone (+)-3.3: Epoxide (–)-3.2 (6.36 g, 21.4 mmol) was dissolved in CH2Cl2 (150 mL) 
and cooled to 0 °C. PPTS (268 mg, 1.07 mmol) was added and the resulting solution was 
stirred at 0 °C for 1 h. After warming to room temperature, the solution was washed with 
water (30 mL), and the aqueous layer was extracted with CH2Cl2 (20 mL x 2). The 
combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. 
The product was used without purification. 
 The resulting alcohol was dissolved in CH2Cl2 (150 mL) and cooled to 0 °C. NaHCO3 
(3.59 g, 42.8 mmol) was added, followed by Dess-Martin periodinane (10.8 g, 25.7 
mmol). The reaction mixture was stirred at room temperature for 1 h, then quenched with 
saturated aqueous Na2S2O3 (30 mL). After stirring for 15 min, the layers were separated 
and the aqueous layer was extracted with CH2Cl2 (20 mL x 2). The combined organic 
layers were dried over MgSO4 and concentrated in vacuo. The residue was purified by 
flash chromatography on silica gel (4:1 hexanes/EtOAc) to afford the title compound (4.2 
g, 67% over 2 steps) as a colorless oil. [α]  +98.0 (c 2.52 CHCl3). IR (neat) 2950, 2863, 
1720, 1473, 1253, 1137, 1103 cm-1. 1H NMR (500 MHz, CDCl3) δ 3.71 - 3.61 (m, 3 H), 
3.55 (dt, J = 3.6, 12.8 Hz, 1 H), 3.50 (d, J = 1.8 Hz, 1 H), 2.33 - 2.21 (m, 2 H), 1.98 - 1.91 
(m, 1 H), 1.68 - 1.51 (m, 4 H), 1.15 (s, 3 H), 0.89 (td, J = 3.2, 13.7 Hz, 1 H), 0.77 (d, J = 
6.9 Hz, 3 H), 0.72 (dd, J = 1.8, 4.6 Hz, 1 H), 0.34 (s, 3 H), 0.11 (s, 3 H). 13C NMR (125 
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MHz, CDCl3) δ 211.0, 80.5, 65.8, 58.1, 48.7, 36.0, 35.1, 34.1, 31.7, 30.9, 29.5, 22.4, 
17.5, 12.0, –0.60, –2.05. HRMS(ES+) m/z 295.1728 [(M+H)+; calcd for C16H27O3Si: 
295.1729]. 
 
Alcohol (+)-3.7: The following reaction was run in two batches, which were combined 
for purification.  
Batch 1 (1.56 g (+)-3.3, 5.31 mmol): A 1-L flask was charged with Sm0 powder (3.18 g, 
21.2 mmol) and the flask was flushed with nitrogen for 5 min. The flask was wrapped 
with aluminum foil and THF (212 mL) was added. The suspension was stirred vigorously 
while freshly distilled CH2I2 (1.7 mL, 21.2 mmol) was added dropwise in the dark. The 
suspension changed gradually to a teal, then deep blue solution within 0.5 h. The solution 
was stirred for an additional 4 h before a solution of the ketone (1.56 g, 5.31 mmol) in 
THF (6 mL) and MeOH (3 mL) was added dropwise at room temperature via cannula. 
The reaction mixture was rapidly poured into a vigorously stirring solution of saturated 
aqueous NaHCO3 (30 mL) and the resulting suspension was filtered through a pad of 
celite. The layers were separated and the aqueous layer was extracted with EtOAc (20 
mL x 2). The combined organic layers were dried over MgSO4 and concentrated in vacuo 
to afford the first batch of (+)-3.7. 
 Batch 2 (517 mg (+)-3.3, 1.76 mmol): To a rapidly stirring suspension of Sm0 powder 
(1.05 g, 7.03 mmol) in THF (70 mL) was added freshly distilled CH2I2 (0.56 mL, 7.03 
mmol) in the dark. The suspension gradually turned to a deep blue solution within 0.5 h 
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and vigorous stirring was continued for an additional 4 h. A solution of ketone (+)-3.3 
(517 mg, 1.76 mmol) in THF (2 mL) and MeOH (1 mL) was added dropwise via cannula. 
An identical workup as above provided another batch of (+)-3.7. The combined batches 
were purified by flash chromatography on silica gel (1:1 hexanes/EtOAc) to afford the 
title compound (2.32 g, 82%) as a white solid. Melting point 103-105 °C. [α]  +62.9 (c 
0.94 CHCl3). IR (neat) 3436, 2953, 2876, 1709, 1251 cm-1. 1H NMR (500 MHz, CDCl3) 
δ 3.71 - 3.59 (m, 3 H), 3.58 - 3.51 (m, 1 H), 2.36 (dd, J = 2.5, 18.3 Hz, 1 H), 2.25 (tt, J = 
6.7, 11.9 Hz, 1 H), 2.04 (d, J = 18.2 Hz, 1 H), 2.01 (ddd, J = 3.2, 10.5, 13.9 Hz, 1 H), 
1.88 (dtd, J = 4.6, 7.5, 11.9 Hz, 1 H), 1.73 (dddd, J = 2.0, 7.1, 10.1, 13.1 Hz, 1 H), 1.67 - 
1.56 (m, 2 H), 1.55 - 1.49 (m, 1 H), 1.35 (br s, 1 H), 1.23 (ddd, J = 6.7, 13.9, 20.4 Hz, 1 
H), 1.00 (s, 3 H), 0.72 (d, J = 6.7 Hz, 3 H), 0.65 (dd, J = 2.0, 5.9 Hz, 1 H), 0.35 (s, 3 H), 
0.21 (s, 3 H). 13C NMR (125 MHz, CDCl3) δ 213.7, 65.5, 61.0, 48.5, 46.6, 38.3, 36.8, 
36.4, 36.3, 34.8, 25.2, 18.4, 12.2, 0.6, –1.3. HRMS(ES+) m/z 297.1890 [(M+H)+; calcd 
for C16H29O3Si: 297.1886]. 
 
Ketone (+)-3.6: A solution of alcohol (+)-3.7 (2.86 g, 9.66 mmol) and imidazole (1.97 g, 
29.0 mmol) in DMF (39 mL) was cooled to 0 °C. TBSCl (1.74 g, 11.6 mmol) was added 
and the reaction mixture was allowed to warm to room temperature. After 2 h, the 
reaction mixture was diluted with EtOAc (30 mL) and quenched by the addition of water 
(30 mL). The layers were separated and the aqueous layer was extracted with EtOAc (30 
mL x 2). The combined organic layers were dried over MgSO4 and concentrated in 
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vacuo. The residue was purified by flash chromatography on silica gel (10:1 
hexanes/EtOAc) to afford the title compound (3.84 g, 97%) as a colorless oil. [α]  +22.3 
(c 0.63 CHCl3). IR (neat) 2953, 2935, 2879, 2859, 1713, 1466, 1252, 1099, 1070, 834 
cm-1. 1H NMR (500 MHz, CDCl3) δ 3.67 - 3.56 (m, 3H), 3.54 - 3.45 (m, 1 H), 2.34 (dd, J 
= 2.6, 18.4 Hz, 1 H), 2.27 - 2.17 (m, 1 H), 2.02 - 1.96 (m, 1 H), 2.01 (dd, J = 1.4, 18.6 
Hz, 1 H), 1.84 - 1.75 (m, 1 H), 1.75 - 1.66 (m, 1 H), 1.65 - 1.51 (m, 3 H), 1.13 (tdd, J = 
5.9, 7.9, 13.7 Hz, 1 H), 0.96 (s, 3 H), 0.87 (s, 9 H), 0.71 (d, J = 6.7 Hz, 3 H), 0.60 (dd, J = 
2.2, 6.1 Hz, 1 H), 0.32 (s, 3 H), 0.20 (s, 3 H), 0.03 (s, 3 H), 0.02 (s, 3 H). 13C NMR (125 
MHz, CDCl3) δ 213.8, 65.5, 61.1, 48.4, 46.6, 37.8, 37.0, 36.4, 36.2, 34.9, 34.8, 26.1, 
25.3, 18.5, 18.4, 12.2, 0.51, –1.41, –5.06, –5.12. HRMS(ES+) m/z 411.2753 [(M+H)+; 
calcd for C22H43O3Si2: 411.2751]. 
 
Diketone (+)-3.8: To a cooled (–78 °C) solution of diisopropylamine (0.85 mL, 6.14 
mmol) in THF (25 mL) was added n-BuLi (2.5M/hexanes, 2.45 mL, 6.14 mmol) 
dropwise. After stirring for 0.5 h, a solution of ketone (+)-3.6 (1.26 g, 3.07 mmol) in THF 
(9 mL) was added dropwise via cannula. The resulting solution was stirred for 0.5 h at  
–78 °C before MeCHO (5M/THF, 1.35 mL, 6.73 mmol) was added dropwise by syringe. 
The reaction was quenched at –78 °C with saturated aqueous NH4Cl (10 mL). Upon 
warming to room temperature, water (10 mL) was added and the layers were separated. 
The aqueous layer was extracted with EtOAc (20 mL x 2). The combined organic layers 
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were dried over MgSO4 and concentrated in vacuo. The product was used without 
purification. 
 The resulting β-hydroxy ketone was dissolved in CH2Cl2 (20 mL) and cooled to 0 °C. 
Sodium bicarbonate (564 mg, 6.72 mmol) was added, followed by Dess-Martin 
periodinane (1.84 g, 4.36 mmol). The reaction mixture was stirred at 0 °C for 15 min, 
then at room temperature for 0.5 h. Upon completion, saturated aqueous Na2S2O3 (10 
mL) was added and the biphasic mixture was stirred vigorously for 15 min. The layers 
were separated and the aqueous layer was extracted with CH2Cl2 (15 mL x 2). The 
combined organic layers were dried over MgSO4 and concentrated in vacuo. The residue 
was purified by flash chromatography on silica gel (12:1 hexanes/EtOAc) to afford the 
title compound (1.37 g, 91% over 2 steps) as a colorless oil. [α]  +57.8 (c 0.8 CHCl3). 
IR (neat) 2954, 2926, 2879, 2857, 1722, 1698, 1253, 1099 cm-1. 1H NMR (500 MHz, 
CDCl3) δ 3.70 - 3.57 (m, 3 H), 3.53 (d, J = 1.2 Hz, 1 H), 3.49 (ddd, J = 5.7, 8.3, 10.3 Hz, 
1 H), 2.28 (s, 3 H), 2.25 - 2.11 (m, 2 H), 1.96 (ddd, J = 2.4, 11.1, 14.1 Hz, 1 H), 1.92 - 
1.79 (m, 2 H), 1.52 (ddd, J = 4.0, 5.9, 8.5 Hz, 1 H), 1.38 (ddt, J = 1.8, 7.7, 11.1 Hz, 1 H), 
1.13 (tdd, J = 5.5, 8.5, 10.9 Hz, 1 H), 1.04 (s, 3 H), 0.88 (s, 9 H), 0.69 (d, J = 6.7 Hz, 3 
H), 0.58 (dd, J = 2.2, 5.9 Hz, 1 H), 0.33 (s, 3 H), 0.20 (s, 3 H), 0.03 (s, 3 H), 0.02 (s, 3 H). 
13C NMR (125 MHz, CDCl3) δ 208.7, 205.0, 66.5, 65.4, 60.7, 48.6, 39.7, 38.7, 36.8, 
36.0, 35.0, 33.6, 31.0, 26.0, 23.5, 18.4, 18.1, 12.0, 0.43, –1.30, –5.08, –5.13. 
HRMS(ES+) m/z 453.2858 [(M+H)+; calcd for C24H45O4Si2: 453.2856]. 
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Diketone (–)-3.10: To a cooled (0 °C) solution of diketone (+)-3.8 (1.37 g, 3.03 mmol) 
and Pd(PPh3)4 (174 mg, 0.151 mmol) in THF (16 mL) was added sodium hydride (60 
wt% in mineral oil, 145 mg, 3.63 mmol), followed by dropwise addition of allyl acetate 
(0.39 mL, 3.63 mmol). The reaction mixture was warmed to room temperature and stirred 
for 0.5 h. The reaction was quenched by addition of saturated aqueous NH4Cl (10 mL). 
The layers were separated and the aqueous layer was extracted with EtOAc (15 mL x 2). 
The combined organic layers were dried over MgSO4 and concentrated in vacuo. The 
residue was purified by flash chromatography on silica gel (15:1 hexanes/EtOAc) to 
afford the title compound (1.41 g, 95%) as a colorless oil. [α]  –1.8 (c 0.94 CHCl3). IR 
(neat) 2955, 2927, 2881, 2857, 1699, 1469, 1253, 1097 cm-1. 1H NMR (500 MHz, 
CDCl3) δ 5.72 (tdd, J = 7.1, 9.9, 17.0 Hz, 1 H), 5.04 (td, J = 0.9, 10.0 Hz, 1 H), 4.94 (dd, 
J = 1.7, 16.9 Hz, 1 H), 3.70 - 3.56 (m, 2 H), 3.49 (t, J = 6.1 Hz, 2 H), 2.85 - 2.76 (m, 1 
H), 2.31 (tdd, J = 6.9, 11.7, 13.5 Hz, 1 H), 2.24 (s, 3 H), 2.14 (dd, J = 7.0, 13.6 Hz, 1 H), 
2.05 - 1.88 (m, 2 H), 1.73 - 1.57 (m, 3 H), 1.33 (ddd, J = 6.2, 11.9, 14.0 Hz, 1 H), 1.07 (s, 
3 H), 1.06 - 0.99 (m, 1 H), 0.87 (s, 9 H), 0.75 (d, J = 6.7 Hz, 3 H), 0.73 (dd, J = 2.0, 8.5, 1 
H), 0.35 (s, 3 H), 0.24 (s, 3 H), 0.01 (s, 6 H). 13C NMR (125 MHz, CDCl3) δ 210.8, 
208.9, 133.3, 118.6, 66.9, 65.0, 62.6, 49.1, 43.4, 40.5, 38.6, 38.3, 35.5, 35.3, 33.9, 33.2, 
26.2, 21.0, 18.6, 18.0, 12.6, 0.91, –1.71, –5.09, –5.16. HRMS(ES+) m/z 493.3172 
[(M+H)+; calcd for C27H49O4Si2: 493.3169]. 
O Si
O
O
OTBS
€ 
D
20
 99 
 
Acetate (+)-3.12: To a solution of TBS ether (–)-3.10 (12 mg, 0.0243 mmol) in THF (0.3 
mL) was added TBAF (1 M/THF, 36 µL, 0.0364 mmol) at room temperature. The 
reaction mixture was stirred for 12 h and quenched by the addition of saturated aqueous 
Na2S2O3 (1 mL). The layers were separated and the aqueous layer was extracted with 
EtOAc (2 mL x 2). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash chromatography on silica gel 
(8:1 hexanes/EtOAc) to afford the title compound (4 mg, 44%) as a colorless oil. [α]  
+20.7 (c 0.27 CHCl3). IR (neat) 2956, 2922, 2877, 2858, 1740, 1707, 1641, 1469, 1367, 
1235, 1072 cm-1. 1H NMR (500 MHz, CDCl3) δ 5.91 (tdd, J = 6.8, 10.1, 16.9 Hz, 1 H), 
5.05 - 4.99 (m, 2 H), 4.11 (ddd, J = 5.9, 7.4, 11.0 Hz, 1 H), 3.89 (td, J = 7.3, 11.0 Hz, 1 
H), 3.67 (dd, J = 4.8, 11.7 Hz, 1 H), 3.64 - 3.57 (m, 1 H), 2.43 - 2.34 (m, 1 H), 2.30 - 2.16 
(m, 3 H), 2.03 (s, 3 H), 2.01 - 1.92 (m, 2 H), 1.82 (ddd, J = 2.2, 11.3, 13.7 Hz, 1 H), 1.74 
- 1.65 (m, 1 H), 1.45 - 1.37 (m, 2 H), 1.26 (dt, J = 7.1, 13.7 Hz, 1 H), 0.99 (s, 3 H), 0.69 
(d, J = 6.7 Hz, 3 H), 0.61 (dd, J = 2.1, 6.0 Hz, 1 H), 0.34 (s, 3 H), 0.18 (s, 3 H). 13C NMR 
(125 MHz, CDCl3) δ 214.2, 171.0, 137.3, 116.0, 65.4, 63.3, 52.1, 48.4, 40.8, 38.4, 36.5, 
34.8, 32.7, 32.0, 30.6, 23.5, 21.1, 18.1, 12.2, 0.6, –1.3. HRMS(ES+) m/z 401.2125 
[(M+Na)+; calcd for C21H34O4SiNa: 401.2124]. 
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Alcohol (–)-3.11: To a cooled (0 °C) solution of silyl ether (–)-3.10 (3.57 g, 7.25 mmol) 
in MeOH (30 mL) was added p-toluenesulfonic acid (275 mg, 1.45 mmol). The reaction 
mixture was stirred at 0 °C for 0.5 h, then allowed to warm to room temperature. Ethyl 
acetate (20 mL) was added and the solution was washed with water (20 mL). The 
aqueous layer was extracted with EtOAc (20 mL x 2) and the combined organic layers 
were dried over MgSO4 and concentrated in vacuo. The residue was purified by flash 
chromatography on silica gel (2:1 hexanes/EtOAc) to afford the title compound (2.52 g, 
92%) as a white solid. Melting point 89-91 °C. [α]  –4.5 (c 0.7 CHCl3). IR (neat) 3442, 
2956, 2924, 2882, 1697, 1354, 1253, 1053 cm-1. 1H NMR (500 MHz, CDCl3) δ 5.73 
(tdd, J = 7.1, 10.0, 17.0 Hz, 1 H), 5.04 (td, J = 0.7, 10.1 Hz, 1 H), 4.95 (dd, J = 1.5, 16.9 
Hz, 1 H), 3.73 - 3.43 (m, 4 H), 2.80 (dd, J = 7.3, 13.7 Hz, 1 H), 2.32 (ddd, J = 4.9, 6.6, 
11.3 Hz, 1 H), 2.25 (s, 3 H), 2.15 (dd, J = 6.7, 13.5 Hz, 1 H), 2.05 - 1.88 (m, 2 H), 1.75 - 
1.63 (m, 2 H), 1.56 (ddd, J = 4.1, 5.5, 9.3 Hz, 1 H), 1.38 - 1.26 (m, 2 H), 1.11 - 1.05 (m, 1 
H), 1.08 (s, 3 H), 0.78 (dd, J = 2.0, 9.0, 1 H), 0.76 (d, J = 6.5, 3 H), 0.36 (s, 3 H), 0.25 (s, 
3 H). 13C NMR (125 MHz, CDCl3) δ 210.6, 209.0, 133.3, 118.6, 66.9, 64.9, 62.8, 49.1, 
43.3, 41.1, 38.6, 38.1, 35.7, 35.3, 33.8, 33.0, 20.7, 17.9, 12.6, 0.98, –1.72. HRMS(ES+) 
m/z 379.2308 [(M+H)+; calcd for C21H35O4Si: 379.2305]. 
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Iodide (–)-3.5: To a cooled (0 °C) solution of alcohol (–)-3.11 (2.52 g, 6.66 mmol) in 
THF (25 mL) was added PPh3 (2.09 g, 8.00 mmol), imidazole (993 mg, 14.6 mmol), and 
I2 (2.02 g, 8.00 mmol) sequentially. The cold bath was removed and the brown solution 
was stirred at room temperature for 10 min. The reaction was quenched with saturated 
aqueous Na2S2O3 (15 mL) and the layers were separated. The aqueous layer was 
extracted with EtOAc (15 mL x 2). The combined organic layers were dried over MgSO4 
and concentrated in vacuo. The residue was purified by flash chromatography on silica 
gel (10:1 hexanes/EtOAc) to afford the title compound (3.17 g, 97%) as a colorless oil. 
[α]  –1.6 (c 0.7 CHCl3). IR (neat) 2956, 2924, 2882, 2860, 1698, 1353, 1253, 1169, 
1101 cm-1. 1H NMR (500 MHz, CDCl3) δ 5.72 (tdd, J = 7.1, 10.0, 17.0 Hz, 1 H), 5.05 
(td, J = 0.9, 10.0 Hz, 1 H), 4.96 (dd, J = 1.7, 16.9 Hz, 1 H), 3.70 - 3.58 (m, 2 H), 3.17 - 
3.06 (m, 2 H), 2.78 (dd, J = 7.5, 13.7 Hz, 1 H), 2.31 (ddd, J = 4.8, 6.6, 11.4 Hz, 1 H), 
2.24 (s, 3 H), 2.21 - 2.15 (m, 1 H), 2.06 - 1.88 (m, 3 H), 1.68 (dddd, J = 2.2, 6.1, 11.5, 
13.9 Hz, 1 H), 1.53 (ddd, J = 4.6, 5.7, 8.9 Hz, 1 H), 1.43 - 1.32 (m, 2 H), 1.14 (s, 3 H), 
0.76 (d, J = 6.7 Hz, 3 H), 0.70 (dd, J = 2.2, 8.7 Hz, 1 H), 0.43 (s, 3 H), 0.27 (s, 3 H). 13C 
NMR (125 MHz, CDCl3) δ 210.3, 208.7, 133.0, 118.8, 67.0, 64.9, 49.1, 46.6, 43.2, 39.1, 
38.4, 35.3, 35.0, 33.8, 33.1, 21.0, 18.0, 12.6, 6.79, 1.33, –1.11. HRMS(ES+) m/z 
489.1317 [(M+H)+; calcd for C21H34IO3Si: 489.1322]. 
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Diketone (+)-3.4: The following reaction was run in three batches, which were combined 
for purification. 
Batch 1 (937 mg (–)-3.5, 1.92 mmol): To a cooled (–20 °C) solution of diisopropylamine 
(0.93 mL, 6.72 mmol) in THF (13.5 mL) was added n-BuLi  
(2.5 M/hexanes, 2.69 mL, 6.72 mmol) dropwise and the resulting solution was stirred at 
this temperature for 40 minutes. In a separate flask, iodide (–)-3.5 (937 mg, 1.92 mmol) 
was dissolved in THF (13 mL) and cooled to –20 °C. The solution of LDA was added 
dropwise via cannula to the solution of (–)-3.5 over 45 minutes while maintaining the 
temperature at –20 °C. The reaction mixture was allowed to warm to room temperature 
and quenched with saturated aqueous NH4Cl (10 mL). The layers were separated and the 
aqueous layer was extracted with EtOAc (10 mL x 2). The combined organic layers were 
dried over MgSO4 and concentrated in vacuo to provide the first batch of crude (+)-3.4. 
Batch 2 (980 mg (–)-3.5, 2.01 mmol): The exact procedure as above with the same 
quantities of all reagents and solvents provided a second batch of crude (+)-3.4. 
Batch 3 (1.03 g (–)-3.5, 2.11 mmol): Diisopropylamine (1.03 mL, 7.38 mmol) was 
dissolved in THF (14 mL) and cooled to –20 °C. A solution of n-BuLi (2.5 M/hexanes, 
2.95 mL, 7.38 mmol) was added dropwise and the resulting solution was stirred at –20 °C 
for 40 minutes. In a separate flask, iodide (–)-3.5 was dissolved in THF (14 mL) and 
cooled to –20 °C. The solution of LDA was transferred dropwise via cannula to the 
solution of (–)-3.5 over 1 h while maintaining the temperature at –20 °C. The reaction 
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mixture was allowed to warm to room temperature and quenched with saturated aqueous 
NH4Cl (30 mL). The layers were separated and the aqueous layer was extracted with 
EtOAc (20 mL x 2). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The three crude batches were combined, adsorbed on silica, and 
purified by flash chromatography on silica gel (10:1 hexanes/EtOAc) to afford the title 
compound (1.68 g, 77%) as a white solid. X-ray quality crystals were obtained by slow 
evaporation from EtOAc. Melting point 123-125 °C. [α]  +154 (c 0.91 CHCl3). IR 
(neat) 2956, 2926, 2884, 2862, 1702, 1687, 1253, 1097, 1066 cm-1. 1H NMR (500 MHz, 
CDCl3) δ 5.66 (dddd, J = 5.5, 8.3, 10.1, 16.8 Hz, 1 H), 4.96 (d, J = 10.1 Hz, 1 H), 4.90 (d, 
J = 17.0 Hz, 1 H), 3.77 - 3.62 (m, 2 H), 2.99 (dd, J = 5.5, 14.1 Hz, 1 H), 2.83 - 2.74 (m, 1 
H), 2.51 - 2.37 (m, 2 H), 2.25 (dd, J = 8.2, 14.0 Hz, 1 H), 2.12 - 2.02 (m, 1 H), 1.98 - 1.90 
(m, 1 H), 1.90 - 1.69 (m, 4 H), 1.53 - 1.42 (m, 2 H), 1.37 (td, J = 5.0, 13.5 Hz, 1 H), 1.18 
(dd, J = 2.6, 5.9 Hz, 1 H), 0.88 (s, 3 H), 0.66 (d, J = 6.7 Hz, 3 H), 0.38 (s, 3 H), 0.13 (s, 3 
H). 13C NMR (125 MHz, CDCl3) δ 211.2, 208.6, 135.6, 117.1, 70.8, 65.6, 49.3, 43.7, 
43.5, 40.3, 36.0, 34.8, 33.5, 33.0, 30.0, 21.2, 18.8, 16.6, 12.1, 0.40, –1.73. HRMS(ES+) 
m/z 383.2021 [(M+Na)+; calcd for C21H32O3SiNa: 383.2018]. 
 
Diene (–)-3.13: To a cooled (–78 °C) solution of iodide (–)-3.5 (10.4 mg, 0.0213 mmol) 
in THF (0.5 mL) was added NaHMDS (1 M/THF, 27 µL, 0.0277 mmol) dropwise. The 
reaction mixture was allowed to warm to room temperature and saturated aqueous NH4Cl 
(0.5 mL) was added. Water (5 mL) and EtOAc (5 mL) were added and the layers were 
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separated. The aqueous layer was extracted with EtOAc (5 mL) and the combined 
organic layers were dried over MgSO4 and concentrated in vacuo. The residue was 
purified by flash chromatography on silica gel (10:1 hexanes/EtOAc) to afford the title 
compound (7.7 mg, 95%) as a colorless oil.  [α]  –23.2 (c 1.60 CHCl3). IR (neat) 3076, 
2956, 2924, 2880, 2857, 1699, 1636, 1471, 1420, 1383, 1353, 1253, 1105, 1065, 1000 
cm-1. 1H NMR (500 MHz, CDCl3) δ 5.82 (tdd, J = 7.3, 9.7, 16.8 Hz, 1 H), 5.37 (td, J = 
9.6, 16.6 Hz, 1 H), 5.04 (dd, J = 0.8, 10.1 Hz, 1 H), 4.99 (dd, J = 1.7, 3.7 Hz, 1 H), 4.97 - 
4.91 (m, 2 H), 3.67 - 3.56 (m, 2 H), 2.71 (dd, J = 7.7, 13.9 Hz, 1 H), 2.31 (ddd, J = 5.0, 
6.5, 11.1 Hz, 1 H), 2.25 (dd, J = 6.5, 13.9 Hz, 1 H), 2.19 (s, 3 H), 2.08 (t, J = 9.4 Hz, 1 
H), 2.03 - 1.95 (m, 2 H), 1.72 - 1.64 (m, 1 H), 1.30 (ddd, J = 7.3, 13.5, 15.5 Hz, 1 H), 
1.06 (s, 3 H), 0.97 (dd, J = 2.1, 9.6 Hz, 1 H), 0.78 (d, J = 6.7 Hz, 3 H), 0.31 (s, 3 H), 0.08 
(s, 3 H). 13C NMR (125 MHz, CDCl3) δ 210.4, 208.2, 139.3, 133.5, 118.5, 118.1, 67.1, 
65.0, 51.2, 48.1, 41.9, 38.0, 35.4, 33.4, 32.4, 30.0, 21.4, 18.2, 12.7, 1.0, –1.9. 
HRMS(ES+) m/z 361.2199 [(M+H)+; calcd for C21H33O3Si: 361.2199]. 
 
Triflate (+)-3.19: To a solution of ketone (+)-3.4 (5 mg, 0.0138 mmol) and PhN(Tf)2 (20 
mg, 0.0552 mmol) in THF (0.3 mL) at –78 °C was added KHMDS (0.5 M/toluene, 36 
µL, 0.0180 mmol) dropwise. After stirring for 0.5 h at this temperature, the reaction 
mixture was quenched by the rapid addition of pH 7 buffer (2 mL) at –78 °C and 
resulting mixture was allowed to warm temperature. Water (5 mL) and EtOAc (5 mL) 
were added, and the layers were separated. The aqueous layer was extracted with EtOAc 
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(5 mL), and the combined organic layers were dried over MgSO4 and concentrated in 
vacuo. The residue was purified by flash chromatography on silica gel (15:1 
hexanes/EtOAc) to afford the title compound (6.7 mg, 98%) as a colorless oil. [α]  
+89.7 (c 0.75 CHCl3). IR (neat) 2955, 2884, 2855, 1712, 1668, 1639, 1403, 1248, 1210, 
1140 cm-1. 1H NMR (500 MHz, CDCl3) δ 6.07 (dd, J = 3.8, 10.3 Hz, 1 H), 5.83 (dddd, J 
= 5.4, 7.9, 10.1, 16.9 Hz, 1 H), 5.03 (dd, J = 1.2, 10.3 Hz, 1 H), 4.99 (dd, J = 1.4, 16.8 
Hz, 1 H), 3.75 - 3.63 (m, 2 H), 2.72 (dd, J = 5.4, 15.5 Hz, 1 H), 2.49 (dd, J = 7.8, 15.4 
Hz, 1 H), 2.42 (ddd, J = 5.3, 6.5, 11.4 Hz, 1 H), 2.24 - 2.16 (m, 1 H), 2.10 - 2.00 (m, 3 
H), 1.97 - 1.89 (m, 1 H), 1.84 (dddd, J = 2.6, 8.7, 11.3, 14.5 Hz, 1 H), 1.74 (ddd, J = 2.8, 
4.6, 6.9 Hz, 1 H), 1.44 (ddd, J = 7.3, 10.7, 13.7 Hz, 1 H), 1.20 - 1.16 (m, 1 H), 1.15 (s, 3 
H), 1.02 (dd, J = 2.4, 6.5 Hz, 1 H), 0.67 (d, J = 6.9 Hz, 3 H), 0.36 (s, 3 H), 0.11 (s, 3 H). 
13C NMR (125 MHz, CDCl3) δ 208.8, 151.2, 134.9, 123.9, 117.9, 65.5, 62.3, 48.5, 44.1, 
40.1, 36.4, 35.0, 33.5, 32.5, 27.7, 21.2, 18.5, 18.1, 12.2, 0.3, –2.0. HRMS(ES+) m/z 
493.1685 [(M+H)+; calcd for C22H32F3O5SSi: 493.1680]. 
 
Diene (+)-3.21: A solution of triflate (+)-3.19 (4 mg, 0.008 mmol), (Bu3Sn)2 (6 µL, 0.012 
mmol), Pd(PPh3)4 (1 mg, 0.81 µmol) and thoroughly flame dried LiCl (1.7 mg, 0.041 
mmol) in THF (0.2 mL) was heated to reflux for 3 h. The reaction mixture was cooled to 
room temperature and the solvent was removed in vacuo. The residue was purified by 
flash chromatography on silica gel (15:1 hexanes/EtOAc) to afford the title compound (2 
mg, 72%) as a colorless oil. [α]  +56.7 (c 0.43 CHCl3). IR (neat) 2953, 2920, 2852, 
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1700, 1684, 1684, 1644, 1435, 1379, 1209, 1144, 1095 cm-1. 1H NMR (500 MHz, 
CDCl3) δ 5.91 (dd, J = 3.5, 8.4 Hz, 1 H), 5.12 (br s, 1 H), 4.70 (br s, 1 H), 3.68 - 3.63 (m, 
2 H), 2.59 (td, J = 2.5, 15.1 Hz, 1 H), 2.50 (td, J = 2.4, 14.9 Hz, 1 H), 2.34 - 2.27 (m, 2 
H), 2.03 (td, J = 3.1, 14.4 Hz, 1 H), 1.97 (d, J = 10.3 Hz, 1 H), 1.96 - 1.93 (m, 1 H), 1.91 
(ddd, J = 3.6, 7.7, 12.1 Hz, 1 H), 1.84 (ddd, J = 2.8, 5.0, 7.5 Hz, 1 H), 1.59 (ddd, J = 2.0, 
3.6, 9.5 Hz, 1 H), 1.46 - 1.41 (m, 1 H), 1.29 - 1.22 (m, 2 H), 1.06 (s, 3 H), 1.03 (dd, J = 
1.6, 7.3 Hz, 1 H), 0.76 (d, J = 6.7 Hz, 3 H), 0.34 (s, 3 H), 0.13 (s, 3 H). 13C NMR (125 
MHz, CDCl3) δ 214.9, 144.4, 143.3, 119.2, 103.0, 65.4, 59.3, 47.1, 42.9, 36.8, 35.2, 34.0, 
30.9, 28.7, 28.2, 21.0, 20.5, 18.4, 12.1, 0.2, –2.4. HRMS(ES+) m/z 343.2106 [(M+H)+; 
calcd for C21H31O2Si: 343.2093]. 
 
Alcohol (+)-3.22: The following reaction was run in two equal size batches side by side. 
A solution of 9-BBN (0.5M/THF, 0.48 mL, 0.237 mmol) was added to the alkene (+)-3.4 
(neat, 42.8 mg, 0.118 mmol) at room temperature and the reaction mixture was stirred for 
1 h. The solution was cooled to 0 °C and a cold (0 °C) solution of aqueous NaOH 
(3.75 M, 0.31 mL, 1.18 mmol) was added dropwise. Then a cold (0 °C) solution of H2O2 
(35 wt% in H2O, 0.28 mL, 2.36 mmol) was carefully added dropwise. After stirring at 0 
°C for 10 min, the cold bath was removed and the reaction mixture was vigorously stirred 
at room temperature for 1 h. The reaction mixture was diluted with water (10 mL) and 
EtOAc (10 mL). The layers were separated and the aqueous layer was extracted with 
EtOAc (10 mL x 2). The combined organic layers were dried over MgSO4 and 
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concentrated in vacuo. The combined residue from the two batches was purified by 
medium pressure liquid chromatography on silica gel (1:1 hexanes/EtOAc) to provide 
alcohol (+)-3.22 (63.3 mg, 71%) as a colorless oil. [α]  +173 (c 0.45 CHCl3). IR (neat) 
3421, 2954, 2916, 2874, 1697, 1457, 1253, 1063 cm-1. 1H NMR (500 MHz, CDCl3) δ 
3.78 - 3.66 (m, 2 H), 3.63 - 3.53 (m, 2 H), 2.84 - 2.77 (m, 1 H), 2.52 - 2.40 (m, 2 H), 2.28 
(ddd, J = 4.2, 11.1, 13.7 Hz, 1 H), 2.07 (dd, J = 11.1, 14.1 Hz, 1 H), 1.96 - 1.85 (m, 2 H), 
1.85 - 1.78 (m, 1 H), 1.78 - 1.71 (m, 1 H), 1.64 - 1.55 (m, 2 H), 1.53 - 1.41 (m, 3 H), 1.40 
- 1.32 (m, 1 H), 1.26 (ddd, J = 5.4, 11.3, 18.2 Hz, 1 H), 1.20 (dd, J = 2.4, 5.7 Hz, 1 H), 
0.84 (s, 3 H), 0.70 (d, J = 6.7 Hz, 3 H), 0.38 (s, 3 H), 0.14 (s, 3 H). 13C NMR (125 MHz, 
CDCl3) δ 212.8, 209.4, 70.2, 65.6, 63.1, 49.6, 43.5, 43.4, 40.4, 34.7, 33.6, 33.1, 29.8, 
28.6, 26.5, 21.0, 19.0, 16.4, 12.2, 0.3, –1.7. HRMS(ES+) m/z 401.2124 [(M+Na)+; calcd 
for C21H34O4SiNa: 401.2124]. 
 
Silyl ether (+)-3.23: To a solution of alcohol (+)-3.22 (401 mg, 1.06 mmol) and 
imidazole (216 mg, 3.18 mmol) in DMF (10 mL) was added TBSCl (207 mg, 1.38 mmol) 
at 0 °C. The resulting solution was stirred at 0 °C for 1 h and allowed to warm to room 
temperature. The reaction mixture was quenched by the addition of water (10 mL) and 
diluted with EtOAc (20 mL). The layers were separated and the aqueous layer was 
extracted with EtOAc (20 mL x 2). The combined organic layers were dried over MgSO4 
and concentrated in vacuo. The residue was purified by flash chromatography on silica 
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gel (10:1 hexanes/EtOAc) to afford the title compound (490 mg, 94%) as a colorless oil. 
[α]  +115 (c 0.57 CHCl3). IR (neat) 2954, 2929, 2854, 1693, 1472, 1253, 1100 cm-1.  
1H NMR (500 MHz, CDCl3) δ 3.78 - 3.65 (m, 2 H), 3.61 (td, J = 5.2, 10.2 Hz, 1 H), 3.50 
(ddd, J = 4.9, 8.6, 10.0 Hz, 1 H), 2.84 - 2.72 (m, 1 H), 2.50 - 2.44 (m, 1 H), 2.42 (dd, J = 
6.7, 11.5 Hz, 1 H), 2.12 (dt, J = 4.4, 12.5 Hz, 1 H), 2.04 (dd, J = 10.9, 13.7 Hz, 1 H),  
1.92 - 1.86 (m, 2 H), 1.85 - 1.78 (m, 1 H), 1.76 (td, J = 2.2, 14.5 Hz, 1 H), 1.74 - 1.69 (m, 
1 H), 1.64 (dt, J = 4.4, 12.8 Hz, 1 H), 1.51 - 1.30 (m, 5 H), 1.22 - 1.14 (m, 1 H), 1.19 (dd, 
J = 2.2, 5.7 Hz, 1 H), 0.86 (s, 9 H), 0.82 (s, 3 H), 0.69 (d, J = 6.7 Hz, 3 H), 0.37 (s, 3 H), 
0.12 (s, 3 H), 0.02 (s, 3 H), 0.00 (s, 3 H). 13C NMR (125 MHz, CDCl3) δ 212.8, 208.9, 
70.1, 65.6, 63.4, 49.6, 43.6, 43.4, 40.4, 34.8, 33.6, 33.1, 29.8, 28.4, 27.0, 26.1, 21.0, 18.9, 
18.4, 16.4, 12.3, 0.4, –1.7, –5.19, –5.15. HRMS(ES+) m/z 493.3167 [(M+H)+; calcd for 
C27H49O4Si2: 493.3169]. 
 
Triflate (+)-3.24: To a solution of ketone (+)-3.23 (157.8 mg, 0.320 mmol) and PhN(Tf)2 
(171 mg, 0.480 mmol) in THF (3 mL) at –78 °C was added KHMDS (0.5 M/toluene, 
1.80 mL, 0.898 mmol) dropwise. The reaction mixture was stirred for 0.5 h and quenched 
by the rapid addition of pH 7 buffer (2 mL) at –78 °C. The resulting mixture was allowed 
to warm to room temperature. Water (5 mL) and EtOAc (5 mL) were added and the 
layers were separated. The aqueous layer was extracted with EtOAc (5 mL x 2). The 
combined organic layers were washed with saturated aqueous Na2CO3 (3 mL), dried over 
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MgSO4 and concentrated in vacuo. The residue was purified by flash chromatography on 
silica gel (12:1 hexanes/EtOAc) to afford the title compound (171.3 mg, 86%) as a 
colorless oil. [α]  +61.1 (c 1.20 CHCl3). IR (neat) 2954, 2932, 2894, 2857, 1711, 1636, 
1407, 1248, 1209, 1143, 1099 cm-1. 1H NMR (500 MHz, CDCl3) δ 6.02 (dd, J = 3.9, 10.4 
Hz, 1 H), 3.74 - 3.67 (m, 2 H), 3.63 (td, J = 4.7, 9.9 Hz, 1 H), 3.47 (dt, J = 4.6, 9.4 Hz, 1 
H), 2.44 (ddd, J = 6.7, 12.5, 17.8 Hz, 1 H), 2.17 (tdd, J = 3.0, 13.7, 19.6 Hz, 1 H), 2.07 - 
1.94 (m, 4 H), 1.93 - 1.85 (m, 1 H), 1.84 - 1.76 (m, 1 H), 1.75 - 1.71 (m, 1 H), 1.61 (ddd, 
J = 4.1, 8.8, 17.1 Hz, 1 H), 1.40 (ddd, J = 7.7, 10.7, 13.5 Hz, 1 H), 1.31 - 1.21 (m, 1 H), 
1.18 - 1.14 (m, 2 H), 1.12 (s, 3 H), 1.00 (dd, J = 2.2, 6.3 Hz, 1 H), 0.86 (s, 9 H), 0.70 (d, J 
= 6.7 Hz, 3 H), 0.34 (s, 3 H), 0.09 (s, 3 H), 0.01 (s, 3 H), –0.01 (s, 3 H). 13C NMR (125 
MHz, CDCl3) δ 209.6, 152.1, 123.8, 65.5, 62.9, 62.1, 48.9, 44.1, 40.4, 35.0, 34.0, 33.0, 
29.4, 27.9, 26.0, 21.1, 18.4, 18.3, 18.0, 12.4, 0.2, –2.0, –5.32, –5.27. HRMS(ES+) m/z 
625.2654 [(M+H)+; calcd for C28H48F3O6SSi2: 625.2662]. 
 
Dienone (+)-3.25: In a 10 mL pyrex reaction tube, LiCl (9.5 mg, 0.224 mmol) was 
thoroughly dried under vacuum using a heat gun, cooled under a stream of N2, then 
Pd(PPh3)4 (3.2 mg, 0.0028 mmol) was added. A solution of triflate (+)-3.24 (35.1 mg, 
0.0.056 mmol) in DMF (2 mL + 1 mL rinse) was added to this mixture via cannula. The 
resulting light yellow solution was vigorously stirred and saturated with CO for 20 
minutes, producing a deep yellow solution. Tetravinyltin (15 µL, 0.084 mmol) was 
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added, and the reaction tube was fitted with a CO balloon. The reaction mixture was 
heated to 90 °C for 10 minutes, and the precipitation of black Pd indicated completion of 
the reaction. After cooling to room temperature, the solution was diluted with EtOAc (5 
mL) and washed with water (4 mL x 3). The combined aqueous layers were extracted 
with EtOAc (5 mL x 2). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The residue was purified by medium pressure liquid 
chromatography on silica gel (6:1 hexanes/EtOAc) to afford the title compound (21.4 mg, 
72%) as a colorless oil. [α]  +107 (c 0.66 CHCl3). IR (neat) 2953, 2930, 2886, 2855, 
1702, 1673, 1653, 1610, 1253, 1099, 1068 cm-1. 1H NMR (500 MHz, CDCl3) δ 6.48 (dd, 
J = 10.3, 17.4 Hz, 1 H), 6.38 - 6.33 (m, 2 H), 5.91 (dd, J = 1.6, 10.3 Hz, 1 H), 3.76 - 3.65 
(m, 2 H), 3.44 (ddd, J = 4.8, 6.0, 10.3 Hz, 1 H), 3.30 (ddd, J = 5.5, 8.3, 9.9 Hz, 1 H), 2.46 
(ddd, J = 5.4, 6.5, 11.5 Hz, 1 H), 2.43 - 2.37 (m, 1 H), 2.25 (ddd, J = 4.0, 11.9, 14.9 Hz, 1 
H), 2.07 - 1.98 (m, 1 H), 1.97 - 1.93 (m, 2 H), 1.91 - 1.84 (m, 2 H), 1.76 - 1.66 (m, 3 H), 
1.36 (ddd, J = 6.9, 11.1, 13.3 Hz, 1 H), 1.22 - 1.12 (m, 1 H), 1.09 (dd, J = 2.6, 5.7 Hz, 2 
H), 1.05 (s, 3 H), 0.83 (s, 9 H), 0.69 (d, J = 6.7 Hz, 3 H), 0.35 (s, 3 H), 0.09 (s, 3 H), –
0.03 (s, 3 H), –0.04 (s, 3 H). 13C NMR (125 MHz, CDCl3) δ 212.7, 196.4, 144.3, 140.3, 
137.7, 131.5, 65.7, 63.1, 60.5, 49.6, 44.5, 40.6, 35.0, 33.8, 33.3, 28.2, 28.0, 26.1, 24.8, 
22.0, 21.2, 19.2, 18.4, 12.5, 0.4, –1.8, –5.2. HRMS(ES+) m/z 553.3145 [(M+Na)+; calcd 
for C30H50O4Si2Na: 553.3145]. 
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Enone (+)-3.26: To a solution of dienone (+)-3.25 (21.4 mg, 0.040 mmol) in CH2Cl2 (3 
mL) was added SnCl4 (1 M/CH2Cl2, 60 µL, 0.060 mmol) dropwise at room temperature. 
The reaction mixture was stirred for 0.5 h and quenched with saturated aqueous NH4Cl (3 
mL). The emulsion was vigorously stirred for 15 minutes and the layers were separated. 
The aqueous layer was extracted with CH2Cl2 (5 mL x 2) and the combined organic 
layers were dried over MgSO4 and concentrated in vacuo. The residue was purified by 
flash chromatography on silica gel (2:1 EtOAc/hexanes) to afford the title compound 
(13.6 mg, 82%) as a colorless oil. [α]  +119 (c 0.36 CHCl3). IR (neat) 3439, 2954, 
2922, 2878, 2856, 1695, 1618, 1443, 1378, 1280, 1253, 1129, 1099, 1065 cm-1. 1H NMR 
(500 MHz, CDCl3) δ 3.77 - 3.65 (m, 3 H), 3.63 - 3.55 (m, 1 H), 3.12 (t, J = 12.1 Hz, 1 H), 
2.72 (t, J = 14.5 Hz, 1 H), 2.61 (ddd, J = 1.6, 6.9, 19.0 Hz, 1 H), 2.55 (ddd, J = 3.4, 6.3, 
19.2 Hz, 1 H), 2.50 - 2.46 (m, 1 H), 2.45 (ddd, J = 2.2, 3.2, 6.5 Hz, 1 H), 2.37 (ddd, J = 
2.6, 6.5, 18.6 Hz, 1 H), 2.28 (br s, 1 H), 2.08 - 1.95 (m, 4 H), 1.94 - 1.85 (m, 2 H), 1.73 
(dt, J = 2.8, 5.0 Hz, 1 H), 1.64 (dt, J = 5.5, 12.5 Hz, 1 H), 1.49 - 1.40 (m, 1 H), 1.34 (ddd, 
J = 7.6, 11.4, 13.9 Hz, 1 H), 1.20 (tdd, J = 5.2, 7.3, 12.1 Hz, 1 H), 1.06 (dd, J = 2.6, 5.7 
Hz, 1 H), 0.85 (s, 3 H), 0.70 (d, J = 6.7 Hz, 3 H), 0.36 (s, 3 H), 0.11 (s, 3 H). 13C NMR 
(125 MHz, CDCl3) δ 211.9, 209.7, 181.3, 138.8, 65.6, 62.8, 59.3, 49.4, 44.0, 40.8, 36.2, 
34.9, 34.3, 33.1, 31.8, 29.1, 27.8, 26.7, 23.6, 20.7, 18.9, 12.5, 0.4, –1.7. HRMS(ES+) m/z 
417.2451 [(M+H)+; calcd for C24H37O4Si: 417.2461].  
 
€ 
D
20
O
CHO
O
O Si
 112 
Aldehyde (+)-3.27: To a solution of alcohol (+)-3.26 (8 mg, 0.019 mmol) in CH2Cl2 (2 
mL) was added Dess-Martin periodinane (12 mg, 0.029 mmol) at room temperature. The 
reaction mixture was stirred for 0.5 h, then saturated aqueous Na2S2O3 (1 mL) and 
saturated aqueous NaHCO3 (1 mL) were added. The turbid mixture was vigorously 
stirred for 15 minutes and the resulting clear layers were separated. The aqueous layer 
was extracted with CH2Cl2 (5 mL x 2) and combined organic layers were dried over 
MgSO4 and concentrated in vacuo. The residue was purified by flash chromatography on 
silica gel (2:1 hexanes/EtOAc) to afford the title compound (7.3 mg, 91%) as a colorless 
oil. [α]  +136 (c 0.24 CHCl3). IR (neat) 2953, 2916, 2852, 2722, 1722, 1693, 1618, 
1375, 1252, 1128, 1100, 1066 cm-1. 1H NMR (500 MHz, CDCl3) δ 9.71 (s, 1 H), 3.77 - 
3.64 (m, 2 H), 3.20 (ddd, J = 5.2, 7.7, 13.5 Hz, 1 H), 2.70 (t, J = 14.5 Hz, 1 H), 2.61 (ddd, 
J = 1.6, 6.7, 18.8 Hz, 1 H), 2.55 (dd, J = 5.2, 9.1 Hz, 1 H), 2.52 (dd, J = 5.0, 8.7 Hz, 1 H), 
2.45 (dddd, J = 1.0, 3.4, 7.7, 18.4 Hz, 1 H), 2.45 - 2.40 (m, 1 H), 2.37 (ddd, J = 2.6, 6.3, 
18.4 Hz, 1 H), 2.17 (td, J = 6.8, 18.5 Hz, 1 H), 2.07 - 2.01 (m, 3 H), 1.98 (ddd, J = 2.2, 
5.0, 15.5 Hz, 1 H), 1.88 (tt, J = 2.4, 14.2 Hz, 1 H), 1.74 (dt, J = 2.8, 5.4 Hz, 1 H), 1.41 - 
1.32 (m, 1 H), 1.27 - 1.24 (m, 1 H), 1.24 - 1.16 (m, 1 H), 1.05 (dd, J = 1.4, 5.7 Hz, 1 H), 
0.85 (s, 3 H), 0.64 (d, J = 6.7 Hz, 3 H), 0.37 (s, 3 H), 0.11 (s, 3 H). 13C NMR (125 MHz, 
CDCl3) δ 212.3, 208.8, 202.6, 180.7, 138.4, 65.7, 58.4, 49.4, 43.9, 41.0, 40.6, 36.0, 35.0, 
34.0, 32.8, 31.6, 27.8, 26.5, 20.6, 19.1, 18.9, 12.3, 0.4, –1.7. HRMS(ES+) m/z 415.2306 
[(M+H)+; calcd for C24H35O4Si: 415.2305]. 
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Aldehyde (+)-3.28: To a solution of aldehyde (+)-3.27 (13.4 mg, 0.0323 mmol) in 
benzene (3 mL) was added Bn2NH2O2CCF3 (2 mg, 0.0065 mmol) at room temperature. 
The reaction mixture was heated to 60 °C for 14 h and allowed to cool to room 
temperature. The reaction mixture was diluted with pH 5 citrate buffer (3 mL) and 
extracted with CH2Cl2 (5 mL x 3). The combined organic layers were dried over MgSO4 
and concentrated in vacuo. The residue was purified by flash chromatography on silica 
gel (4:1 hexanes/EtOAc) to afford the title compound (7.7 mg, 60%) as a light yellow oil. 
[α]  +74.9 (c 0.22 CHCl3). IR (neat) 2915, 2873, 2848, 2798, 1706, 1638, 1607, 1440, 
1381, 1346, 1253, 1226, 1101, 1064 cm-1. 1H NMR (500 MHz, C6D6) δ 9.83 (s, 1 H), 
3.66 (dd, J = 4.3, 11.8 Hz, 1 H), 3.57 (br s, 1 H), 3.46 (t, J = 11.7 Hz, 1 H), 3.13 - 3.02 
(m, 2 H), 2.44 (dddd, J = 6.7, 11.1, 13.3, 18.0 Hz, 1 H), 2.39 - 2.24 (m, 2 H), 2.14 - 2.11 
(m, 1 H), 2.07 - 1.98 (m, 1 H), 1.70 (dddd, J = 2.6, 4.2, 13.5, 15.5 Hz, 1 H), 1.64 - 1.57 
(m, 1 H), 1.55 (ddd, J = 2.4, 5.5, 8.3 Hz, 1 H), 1.47 (td, J = 3.5, 17.7 Hz, 1 H), 1.35 - 1.29 
(m, 2 H), 1.07 (dt, J = 3.3, 5.1 Hz, 1 H), 1.04 - 0.99 (m, 2 H), 0.67 (d, J = 6.7 Hz, 3 H), 
0.63 (s, 3 H), 0.14 (s, 3 H), 0.08 (s, 3 H). 13C NMR (125 MHz, C6D6) δ 212.6, 185.8, 
173.4, 154.9, 146.1, 129.6, 65.2, 57.1, 47.2, 42.9, 42.3, 42.0, 38.0, 35.7, 32.3, 28.4, 27.1, 
23.0, 22.6, 20.7, 18.3, 12.5, 0.8, –2.4. HRMS(ES+) m/z 397.2199 [(M+H)+; calcd for 
C24H33O3Si: 397.2199]. 
 
Ester (+)-3.29: To a solution of aldehyde (+)-3.28 (7.7 mg, 0.0194 mmol) in MeOH (2 
mL) was added NaCN (19 mg, 0.388 mmol) and AcOH (16 µL, 0.291 mmol) 
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sequentially at room temperature. The yellow reaction mixture was stirred for 0.5 h 
before MnO2 (84 mg, 0.970 mmol) was added in one portion. The resulting dark reaction 
mixture was vigorously stirred for 12 h and filtered through a pad of celite, which was 
washed with CH2Cl2 (20 mL). The volatiles were removed in vacuo and the residue was 
purified by flash chromatography on silica gel (2:1 hexanes/EtOAc) to afford the title 
compound (7 mg, 85%) as a colorless oil. [α]  +23.2 (c 0.13 CHCl3). IR (neat) 2944, 
2916, 2869, 2852, 1702, 1627, 1434, 1253, 1110, 1066 cm-1. 1H NMR (500 MHz, 
CDCl3) δ 3.71 (s, 3 H), 3.68 - 3.61 (m, 2 H), 3.08 - 2.99 (m, 1 H), 2.87 - 2.84 (m, 3 H), 
2.71 (m, 2 H), 2.46 - 2.37 (m, 1 H), 2.27 (ddd, J = 6.6, 12.8, 17.5 Hz, 1 H), 2.11 - 2.03 
(m, 1 H), 2.03 - 1.95 (m, 2 H), 1.86 (ddd, J = 2.1, 5.9, 8.4 Hz, 1 H), 1.71 (d, J = 8.3 Hz, 2 
H), 1.43 - 1.36 (m, 2 H), 1.08 (d, J = 8.3 Hz, 1 H), 0.89 (s, 3 H), 0.74 (d, J = 6.8 Hz, 3 H), 
0.33 (s, 3 H), 0.15 (s, 3 H). 13C NMR (125 MHz, CDCl3) δ 214.5, 170.2, 166.6, 153.3, 
145.2, 117.7, 65.3, 57.1, 51.2, 47.2, 43.8, 42.7, 42.2, 38.1, 35.3, 32.2, 28.2, 27.1, 25.5, 
23.1, 21.0, 18.2, 12.3, 0.8, –2.2. HRMS(ES+) m/z 427.2303 [(M+H)+; calcd for 
C25H35O4Si: 427.2305]. 
 
Ester (+)-3.31: To a solution of ester (+)-3.29 (1.4 mg, 3.3 µmol) in CH2Cl2 (0.3 mL) 
was added [(cod)(py)(PCy3)]IrPF6 (2.6 mg, 3.3 µmol) and the reaction mixture was 
placed in a Parr bomb. The Parr bomb was pressured to 400 psi of H2 and the reaction 
mixture was stirred at this pressure for 14 h. The solvent was removed in vacuo and the 
residue was purified by flash chromatography on silica gel (8:1 hexanes/EtOAc) to afford 
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the title compound (1.1 mg, 79%) as a colorless oil. [α]  +10.3 (c 0.08 CHCl3). IR 
(neat) 2922, 2857, 1736, 1703, 1638, 1461, 1440, 1251, 1163, 1100, 1070 cm-1.  1H 
NMR (500 MHz, CDCl3) δ 3.73 (s, 3 H), 3.71 - 3.66 (m, 1 H), 3.66 - 3.57 (m, 2 H), 2.65 
- 2.63 (m, 1 H), 2.62 (dd, J = 6.2, 13.5 Hz, 1 H), 2.50 (ddd, J = 2.8, 8.5, 12.0 Hz, 1 H), 
2.43 (dd, J = 9.2, 13.7 Hz, 1 H), 2.40 - 2.35 (m, 1 H), 2.33 - 2.25 (m, 1 H), 2.19 (td, J = 
5.6, 11.6 Hz, 1 H), 2.02 (dddd, J = 3.4, 7.3, 9.6, 14.7 Hz, 1 H), 1.95 (dd, J = 7.9, 12.0 Hz, 
1 H), 1.90 (dd, J = 6.4, 8.8 Hz, 1 H), 1.83 - 1.76 (m, 1 H), 1.74 - 1.68 (m, 2 H), 1.67 - 
1.63 (m, 1 H), 1.55 - 1.45 (m, 1 H), 1.35 (ddd, J = 7.9, 9.0, 15.6 Hz, 1 H), 1.02 (s, 3 H), 
0.92 (m, 2 H), 0.80 (d, J = 6.6 Hz, 3 H), 0.33 (s, 3 H), 0.24 (s, 3 H). 13C NMR (125 MHz, 
CDCl3) δ 216.6, 174.8, 152.9, 146.8, 65.3, 63.4, 51.9, 48.3, 46.5, 42.0, 39.8, 39.7, 39.2, 
36.8, 35.6, 33.3, 33.1, 32.5, 29.0, 28.1, 21.1, 18.7, 12.8, 1.9, –1.7. HRMS(ES+) m/z 
429.2453 [(M+H)+; calcd for C25H37O4Si: 429.2461].   
 
Alcohol (+)-3.36: To a solution of diketone (+)-3.4 (19.5 mg, 0.054 mmol) in THF (1 
mL) was added TBAF (1 M/THF, 0.11 mL, 0.108 mmol) at room temperature. The 
reaction mixture was stirred for 2 h and quenched by the addition of saturated aqueous 
Na2S2O3 (1 mL). Water (5 mL) and EtOAc (5 mL) were added and the layers were 
separated. The aqueous layer was extracted with EtOAc (5 mL) and the combined 
organic layers were dried over MgSO4 and concentrated in vacuo. The residue was 
purified by flash chromatography on silica gel (1:1 hexanes/EtOAc) to afford the title 
compound (14.9 mg, 91%) as a colorless oil. [α]  +43.4 (c 0.50 CHCl3). IR (neat) 3396, 
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3074, 2930, 2878, 1678, 1638, 1455, 1377, 1322, 1183, 1024 cm-1. 1H NMR (500 MHz, 
CDCl3) δ 6.14 (dtd, J = 4.8, 9.7, 17.2 Hz, 1 H), 5.24 (td, J = 1.8, 17.2 Hz, 1 H), 5.07 (td, J 
= 1.4, 10.1 Hz, 1 H), 3.73 (dd, J = 6.3, 10.5 Hz, 1 H), 3.60 (dd, J = 7.3, 10.5 Hz, 1 H), 
3.13 (ddd, J = 4.0, 10.3, 14.3 Hz, 1 H), 2.78 - 2.72 (m, 1 H), 2.56 (br s, 1 H), 2.37 (ddd, J 
= 3.8, 9.0, 14.4 Hz, 1 H), 2.16 (dd, J = 9.5, 13.1 Hz, 1 H), 2.02 - 1.94 (m, 2 H), 1.94 - 
1.91 (m, 1 H), 1.91 - 1.87 (m, 1 H), 1.87 - 1.83 (m, 1 H), 1.82 - 1.71 (m, 3 H), 1.62 - 1.51 
(m, 3 H), 1.21 (ddd, J = 4.8, 11.9, 13.9 Hz, 1 H), 0.99 (d, J = 6.9 Hz, 3 H), 0.74 (s, 3 H). 
13C NMR (125 MHz, CDCl3) δ 215.1, 139.3, 117.3, 70.5, 66.5, 65.8, 46.0, 45.8, 42.6, 
37.8, 35.8, 34.9, 33.9, 30.8, 28.5, 20.0, 19.7, 17.3, 14.4. HRMS(ES+) m/z 305.2154 
[(M+H)+; calcd for C19H29O3: 305.2038].   
 
Phenylsilane (+)-3.43: To a solution of siloxane (+)-3.24 (35 mg, 0.056 mmol) in Et2O 
(3 mL) was added PhLi (1.8 M/Bu2O, 0.15 mL, 0.28 mmol) dropwise at room 
temperature. The reaction mixture was stirred for 15 minutes and quenched by the 
addition of saturated aqueous NH4Cl (3 mL). The layers were separated and the aqueous 
layer was extracted with EtOAc (5 mL). The combined organic layers were dried over 
MgSO4 and concentrated in vacuo. The residue was purified by medium pressure liquid 
chromatography on silica gel (5:1 hexanes/EtOAc) to afford the title compound (28 mg, 
71%) as a colorless oil. [α]  +87.7 (c 0.70 CHCl3). IR (neat) 3407, 2953, 2932, 2890, 
2857, 1711, 1642, 1405, 1248, 1212, 1143, 1108 cm-1. 1H NMR (500 MHz, CDCl3) δ 
PhMe2Si
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7.55 (dd, J = 1.6, 7.5 Hz, 2 H), 7.41 - 7.32 (m, 3 H), 5.99 (dd, J = 4.3, 10.2 Hz, 1 H), 3.72 
- 3.65 (m, 2 H), 3.61 (td, J = 5.3, 10.1 Hz, 1 H), 3.45 (dt, J = 5.0, 9.3 Hz, 1 H), 2.13 - 
2.05 (m, 1 H), 2.03 - 1.93 (m, 1 H), 1.93 - 1.82 (m, 2 H), 1.80 - 1.73 (m, 2 H), 1.73 - 1.68 
(m, 3 H), 1.64 (dd, J = 11.2, 13.8 Hz, 1 H), 1.59 (dd, J = 3.0, 4.8 Hz, 1 H), 1.54 (ddd, J = 
4.1, 8.7, 17.0 Hz, 1 H), 1.31 - 1.22 (m, 3 H), 1.24 (d, J = 7.1 Hz, 3 H), 1.05 (s, 3 H), 0.86 
(s, 9 H), 0.54 (s, 3 H), 0.50 (s, 3 H), 0.01 (s, 6 H). 13C NMR (125 MHz, CDCl3) δ 213.7, 
152.3, 138.4, 134.2, 129.6, 128.1, 123.8, 64.7, 63.0, 62.0, 50.6, 46.1, 42.9, 38.9, 33.4, 
32.0, 29.0, 28.2, 28.1, 27.3, 26.1, 21.0, 18.4, 18.1, 14.0, –0.3, –1.3, –5.2, –5.3. 
HRMS(ES+) m/z 703.3141 [(M+H)+; calcd for C34H54F3O6SSi2: 703.3132]. 
 
Pthalimide (+)-3.44: To a solution of alcohol (+)-3.43 (18 mg, 0.025 mmol) in THF (3 
mL) was added PPh3 (14.6 mg, 0.056 mmol) and phthalimide (8.2 mg, 0.056 mmol). The 
resulting solution was cooled to 0 °C and DEAD (40 wt% in toluene, 21 µL, 0.070 mmol) 
was added dropwise. The reaction mixture was allowed to warm to room temperature and 
the volatiles were removed in vacuo. The residue was purified by flash chromatography 
on silica gel (8:1 hexanes/EtOAc) to afford the title compound (17.5 mg, 84%) as a 
colorless oil. [α]  +72.8 (c 0.52 CHCl3). IR (neat) 2953, 2932, 2890, 2857, 1773, 1715, 
1642, 1398, 1247, 1211, 1142 cm-1. 1H NMR (500 MHz, CDCl3) δ 7.86 (dd, J = 3.1, 5.4 
Hz, 2 H), 7.73 (dd, J = 3.1, 5.4 Hz, 2 H), 7.58 - 7.52 (m, 2 H), 7.31 - 7.26 (m, 3 H), 6.01 
(dd, J = 4.3, 10.2 Hz, 1 H), 3.96 (dd, J = 10.2, 13.2 Hz, 1 H), 3.68 - 3.59 (m, 1 H), 3.52 
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(dd, J = 2.1, 13.4 Hz, 1 H), 3.48 (dt, J = 5.0, 9.5 Hz, 1 H), 2.34 - 2.24 (m, 1 H), 2.03 - 
1.88 (m, 4 H), 1.77 (d, J = 11.1 Hz, 4 H), 1.66 - 1.55 (m, J = 3.2 Hz, 3 H), 1.37 - 1.25 (m, 
3 H), 1.10 (d, J = 6.9 Hz, 3 H), 1.08 (s, 3 H), 0.83 (s, 9 H), 0.51 (s, 3 H), 0.46 (s, 3 H), 
0.00 (s, 3 H), –0.02 (s, 3 H). 13C NMR (125 MHz, CDCl3) δ 212.0, 168.5, 152.3, 138.3, 
134.3, 134.0, 132.3, 129.5, 127.9, 123.8, 123.3, 63.1, 61.7, 50.6, 46.0, 40.5, 39.8, 38.9, 
33.3, 32.0, 29.1, 28.3, 28.2, 27.2, 26.0, 21.0, 18.4, 18.2, 14.3, –0.5, –1.4, –5.2, –5.3. 
HRMS(ES+) m/z 854.3161 [(M+Na)+; calcd for C42H56F3NO7SSi2Na: 854.3166]. 
 
Dienone (+)-3.45: In a 20 mL pyrex reaction tube, LiCl (3.3 mg, 0.079 mmol) was 
thoroughly dried under vacuum using a heat gun, cooled under a stream of N2, then 
Pd(PPh3)4 (1.1 mg, 0.001 mmol) was added. A solution of triflate (+)-3.44 (17 mg, 0.020 
mmol) in DMF (2 mL + 1 mL rinse) was added to this mixture via cannula. The resulting 
light yellow solution was vigorously stirred and saturated aqueous with CO for 20 
minutes, producing a deep yellow solution. Tetravinyltin (5 µL, 0.030 mmol) was added, 
and the reaction tube was fitted with a CO balloon. The reaction mixture was heated to 90 
°C for 10 minutes, and the precipitation of black Pd indicated completion of the reaction. 
After cooling to room temperature, the solution was diluted with EtOAc (10 mL) and 
washed with water (4 mL x 3). The aqueous layer was extracted with EtOAc (10 mL) and 
the combined organic layers were washed with brine, dried over MgSO4, and 
concentrated in vacuo. The residue was purified by medium pressure liquid 
chromatography on silica gel (3:1 hexanes/EtOAc) to afford the product (8.9 mg, 61%) as 
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a colorless oil. [α]  +110 (c 0.34 CHCl3). IR (neat) 2953, 2932, 2885, 2857, 1772, 1714, 
1671, 1648, 1613, 1398, 1255, 1098 cm-1. 1H NMR (500 MHz, CDCl3) δ 7.85 (dd, J = 
3.1, 5.3 Hz, 2 H), 7.72 (dd, J = 3.0, 5.5 Hz, 2 H), 7.58 - 7.52 (m, 2 H), 7.35 - 7.28 (m, 3 
H), 6.51 (dd, J = 10.4, 17.3 Hz, 1 H), 6.43 (dd, J = 4.4, 9.5 Hz, 1 H), 6.31 (dd, J = 1.4, 
17.2 Hz, 1 H), 5.86 (dd, J = 1.2, 10.5 Hz, 1 H), 3.98 (dd, J = 9.9, 13.5 Hz, 1 H), 3.51 (d, J 
= 12.3 Hz, 1 H), 3.46 - 3.40 (m, J = 5.6, 10.4 Hz, 1 H), 3.37 - 3.28 (m, J = 6.3, 7.7 Hz, 1 
H), 2.48 - 2.37 (m, 1 H), 2.30 - 2.20 (m, 2 H), 1.95 (dd, J = 4.4, 7.1 Hz, 1 H), 1.92 - 1.84 
(m, 2 H), 1.80 (dd, J = 10.7, 13.9 Hz, 2 H), 1.72 - 1.57 (m, 4 H), 1.16 (d, J = 6.7 Hz, 3 
H), 1.01 (s, 3 H), 0.98 - 0.95 (m, 1 H), 0.89 - 0.84 (m, 1 H), 0.80 (s, 9 H), 0.77 - 0.73 (m, 
1 H), 0.51 (s, 3 H), 0.45 (s, 3 H), –0.05 (s, 3 H), –0.07 (s, 3 H). 13C NMR (125 MHz, 
CDCl3) δ 215.2, 195.5, 168.6, 145.1, 141.6, 138.7, 137.1, 134.3, 133.9, 132.3, 130.8, 
129.3, 127.9, 123.3, 63.3, 60.2, 51.4, 46.3, 40.9, 39.9, 39.1, 32.8, 32.6, 29.0, 28.5, 27.8, 
26.1, 25.5, 22.2, 21.3, 18.4, 14.5, –0.4, –1.4, –5.21, –5.19. HRMS(ES+) m/z 738.4011 
[(M+H)+; calcd for C44H60NO5Si2: 738.4010]. 
 
Enone (+)-3.46: To a solution of dienone (+)-3.45 (5 mg, 0.007 mmol) in CH2Cl2 (1.5 
mL) was added SnCl4 (1 M/CH2Cl2, 33 µL, 0.033 mmol) dropwise at room temperature. 
The reaction mixture was stirred for 0.5 h and quenched with saturated aqueous NH4Cl (3 
mL). The emulsion was vigorously stirred for 15 minutes and the layers were separated. 
The aqueous layer was extracted with CH2Cl2 (5 mL x 2) and the combined organic 
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layers were dried over MgSO4 and concentrated in vacuo. The residue was purified by 
flash chromatography on silica gel (2:1 EtOAc/hexanes) to afford the title compound (3.4 
mg, 80%) as a colorless oil. [α]  +78.3 (c 0.17 CHCl3). IR (neat) 3420, 2949, 2928, 
2873, 1768, 1713, 1650, 1620, 1399, 1377, 1356, 1322, 1111 cm-1. 1H NMR (500 MHz, 
CDCl3) δ 7.85 (dd, J = 3.0, 5.4 Hz, 2 H), 7.72 (dd, J = 3.1, 5.4 Hz, 2 H), 7.58 - 7.51 (m, 2 
H), 7.33 - 7.27 (m, 3 H), 3.87 (dd, J = 8.7, 13.7 Hz, 1 H), 3.72 - 3.66 (m, 1 H), 3.63 - 3.59 
(m, 1 H), 3.62 (dd, J = 3.4, 13.5 Hz, 1 H), 3.09 (ddd, J = 2.4, 12.1, 14.1 Hz, 1 H), 2.53 
(m, 2 H), 2.49 (dd, J = 3.0, 6.7 Hz, 1 H), 2.45 (dd, J = 3.1, 6.8 Hz, 1 H), 2.42 (dd, J = 2.3, 
7.2 Hz, 1 H), 2.37 - 2.34 (m, 1 H), 2.34 - 2.29 (m, 1 H), 2.02 - 1.96 (m, 2 H), 1.92 (m, 2 
H), 1.85 - 1.77 (m, 3 H), 1.69 - 1.59 (m, 3 H), 1.36 - 1.28 (m, 2 H), 1.21 (d, J = 6.9 Hz, 3 
H), 0.80 (s, 3 H), 0.53 (s, 3 H), 0.46 (s, 3 H). 13C NMR (125 MHz, CDCl3) δ 214.9, 
209.4, 181.7, 168.7, 139.3, 138.5, 134.3, 134.0, 132.3, 129.5, 128.0, 123.3, 62.9, 58.9, 
51.2, 45.8, 41.2, 39.8, 39.2, 36.2, 33.0, 32.4, 31.3, 28.9, 28.3, 28.0, 26.5, 24.3, 20.7, 15.0, 
–0.3, –1.5. HRMS(ES+) m/z 624.3138 [(M+H)+; calcd for C38H46NO5Si: 624.3145]. 
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5-4: Experimental Procedures Relevant to Chapter 4 
 
Alcohol (+)-4.3: To a suspension of 4-iodoanisole (128 mg, 0.55 mmol) in Et2O (1.7 mL) 
at –78 °C was added t-BuLi (1.7M/pentane, 0.71 mL, 1.21 mmol) dropwise, at which 
point the suspension became a clear solution. The resulting solution was stirred at –78 °C 
for 20 min, then at room temperature for 45 min. In a separate flask, siloxane (+)-3.23  
(54.4 mg, 0.11 mmol) was dissolved in Et2O (1.1 mL), and the solution of 4-
methoxyphenyllithium was added dropwise over 10 min via cannula, at room 
temperature. The reaction was quenched by addition of saturated aqueous NH4Cl (5 mL) 
and diluted with EtOAc (6 mL). The layers were separated and the aqueous layer was 
extracted with EtOAc (10 mL). The combined organic layers were washed with brine (3 
mL), dried over MgSO4, and concentrated in vacuo. The residue was purified by medium 
pressure liquid chromatography on silica gel (4:1 hexanes/EtOAc) to afford the title 
compound (62.6 mg, 95%) as a colorless oil. [α]  +92.0 (c 1.45 CHCl3). IR (neat) 3442, 
2954, 2931, 2895, 2860, 1696, 1594, 1503, 1461, 1277, 1250, 1183, 1108 cm-1. 1H NMR 
(500 MHz, CDCl3) δ 7.49 (d, J = 8.7 Hz, 2 H), 6.90 (d, J = 8.7 Hz, 2 H), 3.82 (s, 3 H), 
3.69 (dd, J = 6.1, 10.7 Hz, 1 H), 3.62 (dd, J = 2.8, 10.5 Hz, 1 H), 3.56 (td, J = 5.4, 10.4 
Hz, 1 H), 3.45 (ddd, J = 5.2, 8.0, 10.0 Hz, 1 H), 2.66 (dd, J = 6.6, 17.5 Hz, 1 H), 2.36 
(ddd, J = 7.4, 11.4, 17.6 Hz, 1 H), 2.10 (ddd, J = 4.3, 11.9, 13.4 Hz, 1 H), 2.06 - 1.97 (m, 
1 H), 1.93 - 1.87 (m, 1 H), 1.87 - 1.82 (m, 1 H), 1.76 (t, J = 3.4 Hz, 2 H), 1.73 - 1.66 (m, 
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1 H), 1.66 - 1.55 (m, 2 H), 1.48 (ddd, J = 4.6, 11.8, 13.3 Hz, 1 H), 1.44 - 1.32 (m, 2 H), 
1.29 (d, J = 6.9 Hz, 3 H), 1.27 - 1.11 (m, 3 H), 0.98 (td, J = 5.9, 13.9 Hz, 1 H), 0.86 (s, 9 
H), 0.72 (s, 3 H), 0.52 (s, 3 H), 0.45 (s, 3 H), 0.01 (s, 3 H), 0.00 (s, 3 H). 13C NMR (125 
MHz, CDCl3) δ 217.4, 209.3, 160.8, 135.6, 129.4, 113.8, 69.6, 64.5, 63.4, 55.2, 51.5, 
45.0, 43.4, 42.4, 39.2, 32.2, 31.8, 29.7, 28.5, 28.0, 27.9, 26.1, 21.0, 18.4, 15.5, 13.7, –
0.20, –0.98, –5.14, –5.18. HRMS(ES+) m/z 623.3539 [(M+Na)+; calcd for C34H56-
O5Si2Na: 623.3533]. 
 
Pthalimide (+)-4.4: To a solution of alcohol (+)-4.3 (120.5 mg, 0.20 mmol) in THF (6 
mL) were added phthalimide (65 mg, 0.44 mmol) and PPh3 (116 mg, 0.44 mmol). The 
solution was cooled to 0 °C and DEAD (40 wt%/toluene, 0.17 mL, 0.56 mmol) was 
added dropwise. The resulting solution was allowed to warm to room temperature and stir 
for 0.5 h. The volatiles were removed in vacuo and the residue was purified by flash 
chromatography on silica gel (5:1 hexanes/EtOAc) to afford the title compound (144.7 
mg, 99%) as a colorless oil. [α]  +97.8 (c 1.24 CHCl3). IR (neat) 2953, 2936, 2895, 
2858, 1772, 1713, 1593, 1502, 1464, 1399, 1251, 1106 cm-1. 1H NMR (500 MHz, 
CDCl3) δ 7.85 (dd, J = 3.0, 5.4 Hz, 2 H), 7.72 (dd, J = 3.0, 5.4 Hz, 2 H), 7.48 (d, J = 8.5 
Hz, 2 H), 6.82 (d, J = 8.3 Hz, 2 H), 3.95 (dd, J = 10.1, 13.3 Hz, 1 H), 3.68 (s, 3 H), 3.57 
(td, J = 5.3, 10.3 Hz, 1 H), 3.51 - 3.43 (m, 2 H), 2.71 (dd, J = 6.5, 17.2 Hz, 1 H), 2.38 
(ddd, J = 7.5, 11.3, 18.4 Hz, 1 H), 2.29 - 2.19 (m, 1 H), 2.13 (ddd, J = 5.0, 11.3, 13.7 Hz, 
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1 H), 1.95 - 1.82 (m, 3 H), 1.82 - 1.70 (m, 2 H), 1.65 (dd, J = 10.9, 13.1 Hz, 1 H), 1.53 
(ddd, J = 5.4, 11.0, 13.7 Hz, 1 H), 1.46 (t, J = 14.1 Hz, 1 H), 1.39 (td, J = 6.7, 14.5 Hz, 1 
H), 1.34 - 1.21 (m, 3 H), 1.14 (d, J = 6.7 Hz, 3 H), 1.06 (td, J = 5.4, 12.9 Hz, 1 H), 0.82 
(s, 9 H), 0.75 (s, 3 H), 0.47 (s, 3 H), 0.42 (s, 3 H), –0.01 (s, 3 H), –0.03 (s, 3 H). 13C 
NMR (125 MHz, CDCl3) δ 215.3, 209.4, 168.5, 160.6, 135.7, 133.9, 132.2, 129.3, 123.2, 
113.6, 69.3, 63.4, 55.0, 51.3, 44.8, 43.3, 40.4, 39.4, 39.3, 32.2, 31.7, 29.8, 28.3, 27.9, 
27.8, 26.0, 21.0, 18.4, 15.5, 14.1, –0.5, –1.1, –5.2. HRMS(ES+) m/z 730.3943 [(M+H)+; 
calcd for C42H60NO6Si2: 730.3928]. 
 
Triflate (+)-4.5: To a solution of ketone (+)-4.4 (61 mg, 0.084 mmol) and PhN(Tf)2 (45 
mg, 0.125 mmol) in THF (3 mL) at –78 °C was added KHMDS (0.5M/toluene, 0.33 mL, 
0.167 mmol) dropwise. The light yellow solution was stirred at –78 °C for 0.5 h, 
quenched at this temperature by the dropwise addition of saturated aqueous NH4Cl (1.5 
mL), then allowed to warm to room temperature. Water (5 mL) and EtOAc (10 mL) were 
added and the layers were separated. The aqueous layer was extracted with EtOAc (10 
mL x 2), and the combined organic layers were dried over MgSO4 and concentrated in 
vacuo. The residue was purified by medium pressure liquid chromatography on silica gel 
(6:1 hexanes/EtOAc) to afford the title compound (52.8 mg, 73%) as a colorless oil. [α]  
+95.2 (c 0.56 CHCl3). IR (neat) 2953, 2929, 2893, 2854, 1773, 1716, 1595, 1399, 1211 
cm-1. 1H NMR (500 MHz, CDCl3) δ 7.86 (dd, J = 3.0, 5.4 Hz, 2 H), 7.73 (dd, J = 3.2, 5.5 
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Hz, 2 H), 7.47 (d, J = 8.7 Hz, 2 H), 6.83 (d, J = 8.5, 2 H), 6.02 (dd, J = 4.3, 10.2 Hz, 1 H), 
3.95 (dd, J = 10.3, 13.3 Hz, 1 H), 3.70 (s, 3 H), 3.63 (td, J = 5.3, 10.0 Hz, 1 H), 3.51 (dd, 
J = 2.2, 13.3 Hz, 1 H), 3.47 (ddd, J = 5.2, 8.7, 10.1 Hz, 1 H), 2.33 - 2.20 (m, 1 H), 2.05 - 
1.72 (m, 8 H), 1.66 - 1.50 (m, 3 H), 1.38 - 1.19 (m, 3 H), 1.09 (d, J = 7.1, 3 H), 1.08 (s, 3 
H), 0.83 (s, 9 H), 0.47 (s, 3 H), 0.43 (s, 3 H), 0.00 (s, 3 H), –0.02 (s, 3 H). 13C NMR (125 
MHz, CDCl3) δ 212.1, 168.6, 160.7, 152.3, 135.8, 134.0, 132.2, 129.0, 123.8, 123.3, 
113.7, 63.0, 61.7, 55.0, 50.6, 46.0, 40.5, 39.7, 38.9, 33.3, 32.1, 29.1, 28.4, 28.2, 27.1, 
26.0, 21.0, 18.4, 18.2, 14.3, –0.51, –1.14, –5.26, –5.30. HRMS(ES+) m/z 884.3281 
[(M+Na)+; calcd for C43H58F3NO8SSi2Na: 884.3272]. 
 
Dienone (+)-4.6: In a 20 mL pyrex reaction tube, LiCl (7.3 mg, 0.172 mmol) was 
thoroughly dried under vacuum using a heat gun, cooled under a stream of N2, then 
Pd(PPh3)4 (2.5 mg, 0.0021 mmol) was added. A solution of triflate (+)-4.5 (37 mg, 0.043 
mmol) in DMF (2 mL + 2 mL rinse) was added to this mixture via cannula. The resulting 
light yellow solution was vigorously stirred and saturated aqueous with CO for 20 
minutes, producing a deep yellow solution. Tetravinyltin (12 µL, 0.064 mmol) was 
added, and the reaction tube was fitted with a CO balloon. The reaction mixture was 
heated to 90 °C for 10 minutes, and the precipitation of black Pd indicated completion of 
the reaction. After cooling to room temperature, the solution was diluted with EtOAc (15 
mL) and washed with water (4 mL x 3). The aqueous layer was extracted with EtOAc (10 
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mL) and the combined organic layers were washed with brine, dried over MgSO4, and 
concentrated in vacuo. The residue was purified by medium pressure liquid 
chromatography on silica gel (3:1 hexanes/EtOAc) to afford the product (32.1 mg, 97%) 
as a colorless oil. [α]  +107 (c 0.97 CHCl3). IR (neat) 2953, 2932, 2891, 2856, 1772, 
1714, 1668, 1647, 1593, 1398, 1277, 1249, 1107 cm-1. 1H NMR (500 MHz, CDCl3) δ 
7.85 (dd, J = 3.1, 5.4 Hz, 2 H), 7.71 (dd, J = 3.0, 5.4 Hz, 2 H), 7.47 (d, J = 8.5 Hz, 2 H), 
6.82 (d, J = 8.5 Hz, 2 H), 6.51 (dd, J = 10.4, 17.3 Hz, 1 H), 6.44 (dd, J = 4.4, 9.5 Hz, 1 
H), 6.30 (dd, J = 1.5, 17.3 Hz, 1 H), 5.86 (dd, J = 1.5, 10.4 Hz, 1 H), 4.02 - 3.94 (m, 1 H), 
3.68 (s, 3 H), 3.50 (dd, J = 1.8, 13.5 Hz, 1 H), 3.42 (ddd, J = 4.9, 6.4, 10.5 Hz, 1 H), 3.31 
(ddd, J = 6.1, 7.9, 9.9 Hz, 1 H), 2.40 (dddd, J = 3.0, 7.5, 10.5, 14.0 Hz, 1 H), 2.30 - 2.18 
(m, 2 H), 1.97 - 1.73 (m, 6 H), 1.71 - 1.57 (m, 3 H), 1.31 - 1.18 (m, 2 H), 1.14 (d, J = 6.7 
Hz, 3 H), 1.01 (s, 3 H), 0.99 - 0.90 (m, 1 H), 0.79 (s, 9 H), 0.46 (s, 3 H), 0.41 (s, 3 H), -
0.05 (s, 3 H), –0.08 (s, 3 H). 13C NMR (125 MHz, CDCl3) δ 215.3, 195.5, 168.6, 160.6, 
145.0, 141.7, 137.0, 135.8, 133.9, 132.3, 130.8, 129.4, 123.2, 113.6, 63.2, 60.2, 55.0, 
51.4, 46.2, 40.9, 39.8, 39.1, 32.9, 32.5, 28.9, 28.5, 27.8, 26.0, 25.4, 22.2, 21.3, 18.4, 14.5, 
–0.4, –1.2, –5.24, –5.21. HRMS(ES+) m/z 768.4127 [(M+H)+; calcd for C45H62NO6Si2: 
768.4116].  
 
Silyl fluoride (+)-3.47: To a solution of enone (+)-4.6 (32.1 mg, 0.042 mmol) in CH2Cl2  
(3 mL) was added HBF4•OEt2 (57 µL, 0.42 mmol) dropwise at room temperature. The 
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resulting solution was stirred for 0.5 h and quenched by the dropwise addition of 
saturated aqueous NaHCO3 (2 mL). The reaction mixture was diluted with CH2Cl2 (8 
mL) and water (3 mL). The layers were separated and the aqueous layer was extracted 
with CH2Cl2 (10 mL x 2). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The residue was purified by medium pressure liquid 
chromatography (6:1 EtOAc/hexanes) to afford the title compound (19.5 mg, 82%) as a 
colorless oil. [α]  +115 (c 0.54 CHCl3). IR (neat) 3425, 2959, 2923, 2879, 1769, 1713, 
1616, 1400 cm-1. 1H NMR (500 MHz, CDCl3) δ 7.82 (dd, J = 3.1, 5.4 Hz, 2 H), 7.70 (dd, 
J = 3.1, 5.4 Hz, 2 H), 3.94 (dd, J = 8.7, 13.7 Hz, 1 H), 3.68 (ddd, J = 5.5, 10.7, 16.1 Hz, 1 
H), 3.65-3.61 (m, 1 H), 3.61 (dd, J = 3.0, 13.9 Hz, 1 H), 3.12 (dt, J = 2.0, 13.9 Hz, 1 H), 
2.68 - 2.55 (m, 3 H), 2.50 (dddd, J = 3.6, 6.5, 9.7, 13.1 Hz, 1 H), 2.44 (dd, J = 3.2, 6.9 
Hz, 1 H), 2.37 (ddd, J = 2.6, 6.3, 18.4 Hz, 1 H), 1.99-1.91 (m 5 H), 1.88-1.81 (m, 2 H), 
1.69 (ddd, J = 6.1, 12.1, 13.7 Hz, 1 H), 1.56 - 1.38 (m, 3 H), 1.35-1.27 (m, 2 H), 1.29 (d, 
J = 6.9 Hz, 3 H), 0.88 (s, 3 H), 0.37 (d, J = 7.5 Hz, 3 H), 0.34 (d, J = 9 Hz, 3 H). 13C 
NMR (125 MHz, CDCl3) δ 214.4, 209.3, 181.2, 168.7, 139.2, 134.0, 132.2, 123.3, 62.8, 
59.1, 50.3, 44.4, 41.2, 40.3, 39.5, 36.2, 33.6 (d), 32.6, 31.4, 28.9, 28.4, 28.3, 26.4, 24.2, 
20.7, 15.0, 0.78 (d), 0.06 (d). HRMS(ES+) m/z 548.2628 [(M–OH)+; calcd for 
C32H39FNO4Si: 548.2632]. 
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Diol (+)-3.48: To a solution of silyl fluoride (+)-3.47 (97 mg, 0.172 mmol) in DMF (6 
mL) was added KF (99 mg, 1.71 mmol), followed by m-CPBA (75 wt%, 392 mg, 1.71 
mmol). The reaction mixture was stirred at room temperature for 5 h, diluted with EtOAc 
(5 mL), and quenched by the addition of saturated aqueous Na2S2O3 (3 mL) and saturated 
aqueous NaHCO3 (3 mL). The suspension was vigorously stirred at room temperature for 
15 minutes, diluted with water (5 mL) and EtOAc (15 mL), and the layers were 
separated. The organic layer was washed with brine (4 mL) and the combined aqueous 
layers were extracted with EtOAc (10 mL x 2). The combined organic layers were dried 
over MgSO4 and concentrated in vacuo. The residue was purified by medium pressure 
liquid chromatography (EtOAc) to afford the title compound (64 mg, 74%) as a colorless 
oil. [α]  +60.0 (c 0.46 CHCl3). IR (neat) 3457, 2957, 2932, 2884, 1770, 1712, 1614, 
1443, 1400, 1377, 1357, 1049 cm-1. 1H NMR (500 MHz, CDCl3) δ 7.82 (dd, J = 3.1, 5.4 
Hz, 2 H), 7.70 (dd, J = 3.0, 5.5 Hz, 2 H), 4.03 (s, 1 H), 3.91 (d, J = 13.5 Hz, 1 H), 3.77 
(dd, J = 9.2, 13.8 Hz, 1 H), 3.68 (ddd, J = 5.4, 10.7, 15.9 Hz, 1 H), 3.61 (qd, J = 4.3, 10.3 
Hz, 1 H), 3.10 (dt, J = 2.5, 13.5 Hz, 1 H), 2.61 - 2.48 (m, 2 H), 2.44 (ddd, J = 3.4, 5.9, 
18.4 Hz, 1 H), 2.37 (ddd, J = 2.8, 6.1, 12.7 Hz, 2 H), 2.40 - 2.28 (m, 1 H), 2.21 - 2.08 (m, 
3 H), 2.07 - 1.97 (m, 2 H), 1.80 (td, J = 2.6, 14.1 Hz, 1 H), 1.76 - 1.68 (m, 2 H), 1.67 - 
1.61 (m, 2 H), 1.61 - 1.54 (m, 1 H), 1.41 (s, 1 H), 1.31 - 1.20 (m, 1 H), 1.13 (d, J = 6.9 
Hz, 3 H), 0.85 (s, 3 H). 13C NMR (125 MHz, CDCl3) δ 214.8, 209.4, 181.1, 169.0, 139.1, 
134.2, 132.1, 123.4, 62.8, 58.2, 55.4, 55.3, 41.0, 39.1, 37.3, 36.2, 32.2, 31.5, 28.9, 28.3, 
25.1, 24.4, 20.3, 15.3. HRMS(ES+) m/z 528.2355 [(M+Na)+; calcd for C30H35NO6Na: 
528.2362]. 
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Aldehyde (+)-4.7: To a solution of diol (+)-3.48 (3.2 mg, .0065 mmol) in CH2Cl2 (0.5 
mL) was added PhI(OAc)2 (2.7 mg, .0085 mmol) and TEMPO (one small crystal) 
sequentially at room temperature. The reaction mixture was stirred for 2 h, diluted with 
CH2Cl2 (3 mL), and quenched with saturated aqueous Na2S2O3 (3 mL). The layers were 
separated and the aqueous layer was extracted with CH2Cl2 (5 mL). The combined 
organic layers were dried over MgSO4 and concentrated in vacuo. The residue was 
purified by flash chromatography on silica gel (1:2 hexanes/EtOAc) to afford the title 
compound (3 mg, 92%) as a colorless oil. [α]  +39.6 (c 0.33 CHCl3). IR (neat) 3460, 
2957, 2928, 2857, 2726, 1772, 1712, 1617, 1400, 1377, 1360, 1246, 1048 cm-1. 1H NMR 
(500 MHz, CDCl3) δ 9.71 (s, 1 H), 7.84 (dd, J = 3.0, 5.4 Hz, 2 H), 7.71 (dd, J = 3.1, 5.4 
Hz, 2 H), 4.06 (d, J = 4.0 Hz, 1 H), 3.87 (d, J = 13.1 Hz, 1 H), 3.74 (dd, J = 9.8, 13.8 Hz, 
1 H), 3.17 (ddd, J = 5.8, 7.7, 14.0 Hz, 1 H), 2.58 - 2.54 (m, 2 H), 2.52 (dd, J = 5.7, 7.9 
Hz, 1 H), 2.45 (ddd, J = 3.4, 6.1, 18.6 Hz, 1 H), 2.38 (ddd, J = 2.8, 5.9, 18.4 Hz, 1 H), 
2.34 - 2.24 (m, 3 H), 2.21 - 2.16 (m, 1 H), 2.16 - 2.09 (m, 2 H), 2.09 - 2.02 (m, 2 H), 1.81 
(td, J = 2.2, 13.7 Hz, 1 H), 1.76 (br s, 1 H), 1.70 - 1.60 (m, 2 H), 1.28 - 1.23 (m, 1 H), 
1.09 (d, J = 6.9 Hz, 3 H), 0.87 (s, 3 H). 13C NMR (125 MHz, CDCl3) δ 215.3, 208.6, 
202.5, 180.6, 169.1, 138.8, 134.2, 132.3, 123.5, 57.4, 55.3, 55.1, 40.9, 40.8, 38.9, 37.1, 
36.1, 32.1, 31.4, 28.3, 25.3, 20.2, 19.9, 14.9. HRMS(ES+) m/z 526.2203 [(M+Na)+; calcd 
for C30H33NO6Na: 526.2206]. 
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Alcohol (+)-4.9: To a cooled (0 °C) solution of diol (+)-3.48 (46.9 mg, 0.092 mmol) in 
DMF (4 mL) was added imidazole (20 mg, 0.294 mmol) and TESCl (23 µL, 0.139 mmol) 
sequentially. After stirring at this temperature for 1.5 h, the reaction mixture was diluted 
with EtOAc (10 mL) and quenched with water (5 mL). The layers were separated and the 
organic layer was washed with brine (4 mL). The combined aqueous layers were 
extracted with EtOAc (10 mL x 2) and the combined organic layers were dried over 
MgSO4 and concentrated in vacuo. The residue was purified by medium pressure liquid 
chromatography (1:1 hexanes/EtOAc) to afford the product (46.9 mg, 83%) as a colorless 
oil. [α]  +51.1 (c 0.64 CHCl3). IR (neat) 3466, 2954, 2935, 2916, 2875, 1772, 1714, 
1616, 1443, 1399, 1377, 1357, 1091 cm-1. 1H NMR (500 MHz, CDCl3) δ 7.83 (dd, J = 
3.2, 5.4 Hz, 2 H), 7.71 (dd, J = 3.1, 5.4 Hz, 2 H), 4.00 (s, 1 H), 3.93 (d, J = 13.5 Hz, 1 H), 
3.79 (dd, J = 9.7, 12.9 Hz, 1 H), 3.67 (ddd, J = 4.4, 6.9, 10.1 Hz, 1 H), 3.53 (ddd, J = 6.5, 
8.1, 9.7 Hz, 1 H), 2.87 (ddd, J = 3.4, 11.9, 14.5 Hz, 2 H), 2.58 - 2.49 (m, 1 H), 2.49 - 2.40 
(m, 1 H), 2.38 (td, J = 3.7, 7.1 Hz, 1 H), 2.34 (dd, J = 2.8, 5.9 Hz, 1 H), 2.30 (dd, J = 2.6, 
6.1 Hz, 1 H), 2.20 - 2.10 (m, 2 H), 2.04 - 1.96 (m, 2 H), 1.81 - 1.70 (m, 3 H), 1.66 - 1.53 
(m, 2 H), 1.35 - 1.26 (m, J = 5.2 Hz, 1 H), 1.26 - 1.16 (m, 1 H), 1.09 (d, J = 6.9 Hz, 3 H), 
0.91 (t, J = 7.9 Hz, 9 H), 0.84 (s, 3 H), 0.55 (q, J = 7.9 Hz, 6 H). 13C NMR (125 MHz, 
CDCl3) δ 214.4, 208.4, 179.1, 169.0, 139.2, 134.1, 132.2, 123.4, 63.1, 58.0, 55.6, 55.3, 
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41.0, 39.1, 37.3, 36.0, 32.2, 31.3, 29.1, 28.2, 25.2, 24.0, 20.4, 15.3, 6.9, 4.5. HRMS(ES+) 
m/z 642.3210 [(M+Na)+; calcd for C36H49NO6SiNa: 642.3227].  
 
Enone (+)-4.10: To a solution of alcohol (+)-4.9 (13.5 mg, 0.021 mmol) in 1,2-
dichloroethane (1 mL) was added i-Pr2NEt (40 µL, 0.231), followed by MOMBr (17 µL, 
0.210 mmol) at room temperature, and the reaction mixture was heated to 80 °C for 4 h. 
The red solution was cooled to room temperature, diluted with CH2Cl2 (1 mL), and 
quenched by the dropwise addition of pH 7 buffer (1 mL). The biphasic mixture was 
vigorously stirred for 15 minutes, diluted with additional CH2Cl2 (4 mL) and pH 7 buffer 
(3 mL), and the layers were separated. The aqueous layer was extracted with CH2Cl2 (8 
mL x 2) and the combined organic layers were dried over MgSO4 and concentrated in 
vacuo. The residue was purified by flash chromatography on silica gel (2:1 
hexanes/EtOAc) to afford the title compound (11.6 mg, 88%) as a colorless oil. [α]  
+53.2 (c 0.48 CHCl3). IR (neat) 2953, 2935, 2911, 2880, 1774, 1715, 1618, 1398, 1095, 
1028 cm-1. 1H NMR (500 MHz, CDCl3) δ 7.83 (dd, J = 3.0, 5.4 Hz, 2 H), 7.70 (dd, J = 
3.1, 5.4 Hz, 2 H), 4.74 (d, J = 6.9 Hz, 1 H), 4.66 (d, J = 7.1 Hz, 1 H), 3.97 (dd, J = 11.0, 
13.0 Hz, 1 H), 3.92 (br s, 1 H), 3.54 (td, J = 7.3, 9.6 Hz, 1 H), 3.36 (s, 3 H), 2.90 (dt, J = 
3.2, 13.0 Hz, 1 H), 2.59 - 2.45 (m, 2 H), 2.41 (ddd, J = 3.4, 6.7, 18.0 Hz, 1 H), 2.34 (dd, J 
= 2.1, 5.8 Hz, 1 H), 2.32 - 2.26 (m, 2 H), 2.24 - 2.11 (m, 3 H), 2.04 - 1.93 (m, 2 H), 1.85 
(br. s., 1 H), 1.81 - 1.69 (m, 2 H), 1.68 - 1.63 (m, 1 H), 1.59 (td, J = 9.4, 13.4 Hz, 2 H), 
1.38 - 1.23 (m, 2 H), 1.13 (d, J = 6.9 Hz, 3 H), 0.90 (t, J = 8.0 Hz, 9 H), 0.86 (s, 3 H), 
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0.55 (q, J = 7.9 Hz, 6 H). 13C NMR (125 MHz, CDCl3) δ 214.5, 208.2, 179.2, 168.7, 
139.4, 133.9, 132.3, 123.3, 96.0, 63.1, 58.1, 56.3, 54.4, 52.5, 40.8, 38.8, 36.8, 36.0, 32.3, 
31.1, 29.1, 28.1, 25.9, 24.3, 20.3, 14.1, 6.9, 4.6. HRMS(ES+) m/z 664.3652 [(M+H)+; 
calcd for C38H54NO7Si: 664.3670]. 
 
Aldehyde (+)-4.11: To a solution of silyl ether (+)-4.10 (7.4 mg, 0.011 mmol) in 
DMSO/THF (0.6 mL/0.3 mL) was added IBX (10.8 mg, 0.039 mmol) in one portion at 
room temperature. The reaction mixture was stirred vigorously for 12 h, diluted with 
EtOAc (10 mL) and washed with H2O (3 mL x 3). The aqueous layer was extracted with 
EtOAc (10 mL x 2) and the combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash chromatography on silica gel 
(1:1 hexanes/EtOAc) to afford the title compound (5.7 mg, 95%) as a colorless oil. [α]  
+56.0 (c 0.39 CHCl3). IR (neat) 2933, 2827, 2726, 1771, 1714, 1469, 1441, 1400, 1377, 
1358, 1150, 1100, 1037 cm-1. 1H NMR (500 MHz, CDCl3) δ 9.72 (d, J = 0.6 Hz, 1 H), 
7.82 (dd, J = 3.0, 5.4 Hz, 2 H), 7.69 (dd, J = 3.0, 5.5 Hz, 2 H), 4.74 (d, J = 7.1 Hz, 1 H), 
4.64 (d, J = 7.1 Hz, 1 H), 3.97 (s, 1 H), 3.83 (dd, J = 10.4, 13.6 Hz, 1 H), 3.66 (dd, J = 
2.8, 13.7 Hz, 1 H), 3.36 (s, 3 H), 3.17 (td, J = 6.5, 13.5 Hz, 1 H), 2.61 - 2.51 (m, 3 H), 
2.43 (dd, J = 3.7, 6.0 Hz, 1 H), 2.42 - 2.38 (m, 1 H), 2.36 (td, J = 3.2, 6.1 Hz, 1 H), 2.25 - 
2.16 (m, 3 H), 2.16 - 2.10 (m, 1 H), 2.07 - 1.98 (m, 2 H), 1.90 - 1.85 (m, 1 H), 1.78 (tt, J 
= 2.4, 14.2 Hz, 1 H), 1.71 - 1.64 (m, 1 H), 1.64 - 1.57 (m, 2 H), 1.13 (d, J = 6.9 Hz, 3 H), 
0.87 (s, 3 H). 13C NMR (125 MHz, CDCl3) δ 215.5, 208.4, 202.5, 180.5, 168.8, 139.0, 
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133.9, 132.3, 123.3, 95.9, 78.3, 57.4, 56.3, 54.5, 52.2, 40.9, 40.5, 38.6, 36.4, 36.1, 32.1, 
31.1, 28.2, 26.0, 21.8, 20.2, 20.1, 13.8. HRMS(ES+) m/z 570.2472 [(M+Na)+; calcd for 
C32H37NO7Na: 570.2468]. 
 
Aldehyde (+)-4.12: To a solution of aldehyde (+)-4.11 (10 mg, 0.018 mmol) in benzene 
(3.5 mL) was added a solution of dibenzylammonium trifluoroacetate (7.1 mg, 0.023 
mmol) in CH2Cl2 (0.3 mL) at room temperature. The reaction mixture was heated to 50 
°C for 17 h. The resulting bright yellow solution was cooled to room temperature, diluted 
with pH 5.0 citrate buffer (5 mL), and extracted with CH2Cl2 (10 mL x 2). The combined 
organic layers were dried over MgSO4 and concentrated in vacuo. The residue was 
purified by preparative TLC (silica, 1:1 hexanes/EtOAc) to afford the product (5.3 mg) as 
a light yellow oil, along with recovered starting material (3 mg).   
The recovered starting material (3 mg, 0.0055 mmol) was dissolved in PhH (1.5 mL) and 
a solution of dibenzylammonium trifluoroacetate (2.2 mg, 0.0071 µmol) in CH2Cl2 (0.2 
mL) was added. The reaction mixture was heated to 50 °C for 21 hours. An identical 
workup and purification procedure provided a second batch of product (1.3 mg; total 6.6 
mg, 69%). [α]  +44.6 (c 0.15 CHCl3). IR (neat) 2925, 2851, 1771, 1714, 1662, 1637, 
1608, 1464, 1442, 1399, 1378, 1351, 1037 cm-1. 1H NMR (500 MHz, CDCl3) δ 9.70 (s, 1 
H), 7.82 (dd, J = 3.2, 5.4 Hz, 2 H), 7.69 (dd, J = 3.0, 5.4 Hz, 2 H), 4.79 (d, J = 7.1 Hz, 1 
H), 4.66 (d, J = 7.1 Hz, 1 H), 4.06 (dd, J = 9.7, 13.5 Hz, 1 H), 4.06 (br. s., 1 H), 3.62 (dd, 
J = 3.1, 13.6 Hz, 1 H), 3.38 (s, 3 H), 3.07 - 2.92 (m, 3 H), 2.81 - 2.75 (m, 1 H), 2.41 - 
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2.31 (m, 1 H), 2.28 (ddd, J = 3.3, 11.3, 14.0 Hz, 1 H), 2.17 (d, J = 3.6 Hz, 1 H), 2.14 (s, 1 
H), 2.11 - 2.02 (m, 1 H), 2.02 - 1.98 (m, 1 H), 1.98 - 1.88 (m, 2 H), 1.74 (ddd, J = 3.0, 
11.5, 14.3 Hz, 1 H), 1.59 (ddd, J = 6.1, 11.5, 13.3 Hz, 1 H), 1.55 (s, 3 H), 1.11 (d, J = 6.9 
Hz, 2 H), 0.90 (s, 3 H). 13C NMR (125 MHz, C6D6) δ 214.5, 185.4, 172.0, 168.2, 153.7, 
146.7, 133.1, 132.5, 129.7, 122.7, 95.7, 74.5, 57.3, 55.6, 53.2, 51.4, 43.2, 41.4, 40.3, 37.0, 
35.6, 31.8, 25.9, 24.2, 22.4, 21.9, 20.2, 13.5. HRMS(ES+) m/z 530.2548 [(M+H)+; calcd 
for C32H36NO6: 530.2543]. 
 
Ester (+)-4.14: To a solution of aldehyde (+)-4.12 (6.6 mg, 12 µmol) in MeOH (1.0 mL) 
were added NaCN (11.8 mg, 0.24 mmol) and AcOH (10 µL, 0.18 mmol) sequentially. 
The yellow reaction mixture was stirred for 0.5 h before MnO2 (73 mg, 0.84 mmol) was 
added in one portion. The resulting dark reaction mixture was vigorously stirred for 12 
hours and filtered through a pad of celite, which was washed with CH2Cl2 (20 mL). After 
removal of the solvent in vacuo, the residue was purified by flash chromatography on 
silica gel (2:1 hexanes/EtOAc) to afford the title compound (5.5 mg, 82%) as a colorless 
oil. [α]  +29.1 (c 0.15 CHCl3). IR (neat) 2926, 2850, 1772, 1714, 1664, 1628, 1465, 
1438, 1398, 1379, 1352, 1109, 1037 cm-1. 1H NMR (500 MHz, CDCl3) δ 7.82 (dd, J = 
3.1, 5.4 Hz, 2 H), 7.69 (dd, J = 3.1, 5.4 Hz, 2 H), 4.78 (d, J = 7.1 Hz, 1 H), 4.65 (d, J = 
7.1 Hz, 1 H), 4.08 (dd, J = 9.4, 13.7 Hz, 1 H), 4.06 (br. s., 1 H), 3.70 (s, 3 H), 3.61 (dd, J 
= 3.0, 13.7 Hz, 1 H), 3.37 (s, 3 H), 3.09 - 2.93 (m, 2 H), 2.83 (m, 2 H), 2.68 (d, J = 3.2 
Hz, 2 H), 2.36 - 2.27 (m, 1 H), 2.26 (ddd, J = 3.2, 11.2, 14.0 Hz, 1 H), 2.20 - 2.11 (m, 1 
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H), 2.11 - 2.00 (m, 2 H), 1.99 - 1.84 (m, 3 H), 1.73 (ddd, J = 3.4, 11.8, 15.0 Hz, 1 H), 
1.61 - 1.53 (m, 1 H), 1.10 (d, J = 7.1 Hz, 3 H), 0.91 (s, 3 H). 13C NMR (125 MHz, 
CDCl3) δ 216.2, 169.0, 168.6, 166.3, 152.2, 146.0, 133.8, 132.2, 123.1, 118.1, 96.0, 74.4, 
57.5, 56.2, 53.4, 51.4, 51.1, 45.1, 41.8, 40.4, 37.2, 35.4, 31.9, 26.0, 25.5, 24.4, 22.0, 20.7, 
13.4. HRMS(ES+) m/z 560.2651 [(M+H)+; calcd for C33H38NO7: 560.2648]. 
 
Ester (–)-4.15: To a solution of unsaturated ester (+)-4.14 (5.8 mg, 0.010 mmol) in 1,2-
dichloroethane (0.6 mL) was added [(cod)(py)(PCy3)]IrBArF (15 mg, 0.010 mmol). The 
reaction mixture was placed in a Parr bomb and the bomb was pressurized to 900 psi of 
H2. The reaction mixture was vigorously stirred at this pressure for 19 h. The volatiles 
were removed in vacuo and the residue was purified by flash chromatography on silica 
gel (4:1 hexanes/EtOAc) to afford the title compound (4.7 mg, 84%, 4:1 d.r.) as a 
colorless oil. The diastereomers were inseparable by flash chromatography but an 
analytically pure sample of the major diastereomer could be obtained by careful 
purification utilizing medium pressure liquid chromatography (4:1 hexanes/EtOAc).  
[α]  –64.5 (c 0.27 CHCl3). IR (neat) 2946, 2878, 2852, 1772, 1714, 1646, 1437, 1399, 
1355, 1320, 1167, 1097, 1039 cm-1. 1H NMR (500 MHz, CDCl3) δ 7.82 (dd, J = 3.0, 5.4 
Hz, 2 H), 7.69 (dd, J = 3.0, 5.5 Hz, 2 H), 4.85 (s, 2 H), 4.14 (d, J = 4.6 Hz, 1 H), 3.85 (dd, 
J = 7.1, 13.9 Hz, 1 H), 3.78 (dd, J = 6.5, 13.9 Hz, 1 H), 3.60 (s, 3 H), 3.42 (s, 3 H), 3.06 - 
2.98 (m, 1 H), 2.93 (ddd, J = 4.5, 9.1, 10.6 Hz, 1 H), 2.61 (dd, J = 7.1, 14.3 Hz, 1 H), 
2.55 - 2.45 (m, 1 H), 2.38 (dd, J = 4.6, 13.7 Hz, 1 H), 2.35 - 2.24 (m, 3 H), 2.19 - 2.09 
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(m, 3 H), 2.09 - 2.01 (m, 1 H), 1.90 (dt, J = 1.8, 6.3 Hz, 1 H), 1.67 - 1.57 (m, 3 H), 1.51 - 
1.42 (m, 2 H), 1.08 (s, 3 H), 1.06 (d, J = 7.3 Hz, 3 H). 13C NMR (125 MHz, CDCl3) δ 
215.3, 176.3, 168.7, 139.3, 135.5, 133.9, 132.4, 123.2, 97.0, 75.2, 61.4, 56.4, 54.8, 52.9, 
51.3, 49.8, 43.0, 42.5, 41.3, 38.6, 38.0, 34.1, 33.4, 27.5, 25.8, 24.0, 23.2, 22.5, 14.4. 
HRMS(ES+) m/z 584.2618 [(M+Na)+; calcd for C33H39NO7Na: 584.2624]. 
 
Imine (–)-4.16: To a solution of phthalimide (–)-4.15 (4.7 mg, 0.0083 mmol) in absolute 
EtOH (1 mL) was added hydrazine hydrate (13 µL, 0.415 mmol) and the reaction mixture 
was stirred at room temperature for 12 h. The volatiles were removed in vacuo and the 
residue was redissolved in EtOH (2 mL). Saturated aqueous NH4Cl (0.1 mL) was added 
and the resulting suspension was stirred at room temperature for 0.5 h. The reaction 
mixture was heated to 70 °C for 18 h, at which point LCMS analysis indicated complete 
consumption of the starting material. The reaction mixture was cooled to room 
temperature and partitioned between saturated aqueous Na2CO3 (5 mL) and CH2Cl2 (10 
mL). The aqueous layer was extracted with CH2Cl2 (10 mL) and the combined organic 
layers were dried over MgSO4 and concentrated in vacuo. The residue was purified by 
preparative TLC (1:1 hexanes/EtOAc) to afford the title compound (2.5 mg, 73% over 2 
steps) as a colorless oil. [α]  –101 (c 0.17 CHCl3). IR (neat) 2947, 2928, 2865, 1733, 
1644, 1436, 1371, 1318, 1192, 1167, 1099, 1048, 1019 cm-1. 1H NMR (500 MHz, 
CDCl3) δ 4.80 (d, J = 6.7 Hz, 1 H), 4.71 (d, J = 6.7 Hz, 1 H), 3.94 (dd, J = 7.1, 15.3 Hz, 1 
H), 3.83 (d, J = 4.6 Hz, 1 H), 3.64 (s, 3 H), 3.62 - 3.56 (m, 1 H), 3.44 (dd, J = 1.8, 15.3 
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Hz, 1 H), 3.41 (s, 3 H), 3.16 (dt, J = 4.8, 9.9 Hz, 1 H), 2.58 (dd, J = 5.0, 13.5 Hz, 1 H), 
2.55 - 2.47 (m, 1 H), 2.35 (dd, J = 9.1, 13.5 Hz, 1 H), 2.32 - 2.27 (m, 1 H), 2.21 - 2.11 
(m, 3 H), 2.05 (ddd, J = 1.8, 6.3, 8.5 Hz, 1 H), 2.02 - 1.96 (m, 1 H), 1.87 (td, J = 7.1, 11.9 
Hz, 1 H), 1.80 (app t, J = 5.4 Hz, 1 H), 1.47 (ddd, J = 6.9, 11.3, 13.4 Hz, 1 H), 1.34 (ddd, 
J = 2.6, 11.1, 13.5 Hz, 1 H), 1.29 - 1.21 (m, 3 H), 1.10 (s, 3 H), 0.93 (d, J = 7.1 Hz, 3 H). 
13C NMR (125 MHz, CDCl3) δ 185.4, 176.3, 141.7, 132.5, 96.6, 75.3, 67.7, 56.3, 56.0, 
54.5, 52.5, 51.1, 49.8, 42.6, 42.3, 39.7, 39.1, 37.4, 34.5, 27.5, 25.6, 24.4, 23.9, 22.1, 16.3. 
HRMS(ES+) m/z 414.2644 [(M+H)+; calcd for C25H36NO4: 414.2644]. 
Ph2BBr 
Bromodiphenylborane: The following procedure was slightly modified from a known 
protocol.1 A 20 mL sealed tube was charged with PhSiMe3 (4.1 mL, 24.0 mmol) and 
cooled to 0 °C. Boron tribromide (1.2 mL, 12.0 mmol) was added dropwise and the 
resulting mixture was allowed to warm to room temperature. The reaction mixture was 
heated to 180 °C for 18 h. The resulting black reaction mixture was cooled to room 
temperature and transferred to a 25 mL round bottomed flask via cannula. Trimethylsilyl 
bromide was distilled (bp 79 °C/760 torr) off, followed by a small amount of unreacted 
PhSiMe3 (bp 60 °C/0.1 torr). The remaining residue was distilled (bp 120-122 °C/0.1 
torr) to afford Ph2BBr (2.67 g, 91%) as a colorless liquid which rapidly becomes a yellow 
and eventually red liquid upon storage. 1H NMR (500 MHz, CDCl3) δ 8.00 (dd, J = 1.3, 
8.0 Hz, 2 H), 7.62 (tt, J = 1.2, 7.3 Hz, 1 H), 7.50 (t, J = 7.7 Hz, 2 H). 13C NMR (125 
MHz, CDCl3) δ 137.6, 133.2, 128.0.  
 137 
 
(–)-Calyciphylline N (1.15): To a solution of imine (–)-4.16 (2.5 mg, 0.006 mmol) in 
CH2Cl2 (1 mL) was added a freshly prepared solution of Ph2BBr (1 M/CH2Cl2, 30 µL, 
0.030 mmol) at –40 °C. The resulting light yellow solution was allowed to warm to room 
temperature and stirred for an additional 0.5 h. The reaction was quenched by the 
addition of saturated aqueous NaHCO3 (1 mL) and the emulsion was vigorously stirred at 
room temperature for 10 minutes. The reaction mixture was diluted with CH2Cl2 (5 mL) 
and saturated aqueous NaHCO3 (5 mL). The layers were separated and the aqueous layer 
was extracted with CH2Cl2 (8 mL x 2). The combined organic layers were dried over 
MgSO4 and concentrated in vacuo. The residue was purified by preparative TLC (100% 
EtOAc) to afford (–)-calyciphylline N (1.7 mg, 79%) as a colorless oil. [α]  –85.3 (c 
0.11 CHCl3). IR (neat) 3358, 2923, 2859, 1733, 1667, 1642, 1554, 1461, 1436, 1373, 
1318, 1192, 1168 cm-1. 1H NMR (500 MHz, CDCl3)2 δ 4.01 - 3.99 (m, 1 H), 3.93, (dd, J 
= 7.0, 15.4 Hz, 1 H), 3.59 (s, 3 H), 3.56 - 3.52 (m, 1 H), 3.43 (dd, J = 1.2, 15.5 Hz, 1 H), 
3.13 (ddd, J = 5.3, 9.3, 10.7 Hz, 1 H), 2.51 (dd, J = 5.2, 13.5 Hz, 1 H), 2.47 - 2.42 (m, 1 
H), 2.30 (dd, J = 9.2, 13.6 Hz, 1 H), 2.25 (dd, J = 9.1, 15.5 Hz, 1 H), 2.19 - 2.09 (m, 3 H), 
2.05 - 2.00 (m, 2 H), 1.89 - 1.85 (m, 1 H), 1.82 (dt, J = 7.3, 12.1 Hz, 1 H), 1.57 - 1.54 (m, 
1 H), 1.42 - 1.38 (m, 1 H), 1.26 (ddd, J = 2.2, 11.1, 13.3 Hz, 1 H), 1.21 (m, 1 H), 1.19 - 
1.15 (m, 1 H), 1.04 (s, 3 H), 0.97 (d, J = 7.1 Hz, 3 H). 13C NMR (125 MHz, CDCl3) δ 
185.3, 176.2, 141.4, 132.1, 68.0, 57.0, 54.4, 52.6, 51.9, 51.1, 42.7, 42.3, 39.5, 38.8, 37.0, 
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34.6, 27.4, 25.3, 23.4, 22.7, 21.5, 16.7. HRMS(ES+) m/z 370.2381 [(M+H)+; calcd for 
C23H32NO3: 370.2382]. 
5-5: References 
1. Haubold, W.; Herdtle, J; Gollinger, W; Einholz, W. J. Organomet. Chem. 1986, 315, 
1-8. 
2. This 1H NMR spectrum was referenced to CDCl3 at δ 7.21. 
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Appendix 1: Spectra Relevant to Chapter 2 
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Appendix 2: Spectra Relevant to Chapter 3 
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Appendix 4: X-Ray Crystallographic Data for Compound (–)-2.20 
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X-Ray Structure Determination of Compound (–)-2.20 
 
Compound (–)-2.20, C21H32SiO2, crystallizes in the orthorhombic space group P212121 
(systematic absences h00: h=odd, 0k0: k=odd, and 00l: l=odd) with a=6.3483(4)Å, b=8.5872(5)Å, 
c=35.965(2)Å, V=1960.6(2)Å3, Z=4, and dcalc=1.167 g/cm3 . X-ray intensity data were collected on 
a Bruker APEXII CCD area detector employing graphite-monochromated Mo-Kα radiation 
(λ=0.71073 Å) at a temperature of 143(1)K. Preliminary indexing was performed from a series of 
thirty-six 0.5° rotation frames with exposures of 5 seconds. A total of 1118 frames were collected 
with a crystal to detector distance of 38.276 mm, rotation widths of 0.5° and exposures of 5 
seconds:  
 
scan type 2θ ω φ χ frames 
φ 19.50 59.55 -11.29 -26.26 739 
ω -20.50 -18.67 -181.36 -31.86 73 
ω 17.00 -35.92 -175.56 82.07 110 
ω -15.50 -109.19 18.69 41.79 196 
 Rotation frames were integrated using SAINT, producing a listing of unaveraged F2 and 
σ(F2) values which were then passed to the SHELXTL program package for further processing 
and structure solution. A total of 19057 reflections were measured over the ranges 2.44 ≤ θ ≤ 
25.04°, -7 ≤ h ≤ 7, -10 ≤ k ≤ 10, -42 ≤ l ≤ 42 yielding 3465 unique reflections (Rint = 0.0282). The 
intensity data were corrected for Lorentz and polarization effects and for absorption using 
SADABS (minimum and maximum transmission 0.6705, 0.7452). 
The structure was solved by direct methods (SHELXS-97). Refinement was by full-matrix 
least squares based on F2 using SHELXL-97. All reflections were used during refinement. The 
OO Si
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weighting scheme used was w=1/[σ2(Fo2 )+ (0.0390P)2 + 0.5007P] where P = (Fo 2 + 2Fc2)/3. 
Non-hydrogen atoms were refined anisotropically and hydrogen atoms were refined using a riding 
model.  Refinement converged to R1=0.0303 and wR2=0.0768 for 3382 observed reflections for 
which F > 4σ(F) and R1=0.0312 and wR2=0.0777 and GOF =1.081 for all 3465 unique, non-zero 
reflections and 222 variables. The maximum Δ/σ in the final cycle of least squares was 0.000 and 
the two most prominent peaks in the final difference Fourier were +0.252 and -0.168 e/Å3. 
Table A4.1 lists cell information, data collection parameters, and refinement data. Final 
positional and equivalent isotropic thermal parameters are given in Tables A3.2 and A3.3.  
Anisotropic thermal parameters are in Table A3.4.  Tables A4.5 and A4.6 list bond distances and 
bond angles.  Figure 5.1 is an ORTEP representation of the molecule with 30% probability 
thermal ellipsoids displayed. 
 
 
Figure A4.1: ORTEP drawing of compound (–)-2.20 with 30% probability thermal ellipsoids. 
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Table A4.1:  Summary of Structure Determination of Compound (–)-2.20 
Empirical formula  C21H32SiO2 
Formula weight  344.56 
Temperature  143(1) K 
Wavelength  0.71073 Å 
Crystal system  orthorhombic 
Space group  P212121  
Cell constants:   
a  6.3483(4) Å 
b  8.5872(5) Å 
c  35.965(2) Å 
Volume 1960.6(2) Å3 
Z 4 
Density (calculated) 1.167 Mg/m3 
Absorption coefficient 0.130 mm-1 
F(000) 752 
Crystal size 0.38 x 0.35 x 0.12 mm3 
Theta range for data collection 2.44 to 25.04° 
Index ranges -7 ≤ h ≤ 7, -10 ≤ k ≤ 10, -42 ≤ l ≤ 42 
Reflections collected 19057 
Independent reflections 3465 [R(int) = 0.0282] 
Completeness to theta = 25.04° 99.2 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7452 and 0.6705 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3465 / 0 / 222 
Goodness-of-fit on F2 1.081 
Final R indices [I>2sigma(I)] R1 = 0.0303, wR2 = 0.0768 
R indices (all data) R1 = 0.0312, wR2 = 0.0777 
Absolute structure parameter 0.01(10) 
Largest diff. peak and hole 0.252 and -0.168 e.Å-3 
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Table A4.2: Refined Positional Parameters for Compound (–)-2.20 
 
  Atom x y z Ueq, Å2 
C1 0.2995(3) 0.7318(2) 0.07155(5) 0.0326(4) 
C2 0.2245(3) 0.57633(19) 0.05617(4) 0.0286(4) 
C3 0.3702(2) 0.43837(18) 0.06560(4) 0.0221(3) 
C4 0.3750(2) 0.40996(18) 0.10886(4) 0.0211(3) 
C5 0.7274(3) 0.6284(2) 0.14124(6) 0.0444(5) 
C6 0.3157(3) 0.6088(2) 0.18143(5) 0.0372(4) 
C7 0.1876(3) 0.5963(2) 0.01442(5) 0.0428(4) 
C8 0.2982(2) 0.28668(18) 0.04834(4) 0.0239(3) 
C9 0.4130(3) 0.16307(19) 0.05641(4) 0.0255(3) 
C10 0.5984(3) 0.19199(18) 0.08171(4) 0.0260(3) 
C11 0.5085(2) 0.26232(18) 0.11857(4) 0.0240(3) 
C12 0.6001(2) 0.46234(19) 0.05214(4) 0.0286(4) 
C13 0.7333(3) 0.3201(2) 0.06336(5) 0.0300(4) 
C14 0.7336(3) 0.0478(2) 0.08865(5) 0.0350(4) 
C15 0.3833(3) 0.14229(18) 0.14111(4) 0.0295(4) 
C16 0.3132(3) 0.2040(2) 0.17892(4) 0.0323(4) 
C17 0.2167(3) 0.08159(18) 0.20319(4) 0.0281(3) 
C18 0.0151(3) 0.0007(2) 0.19285(5) 0.0342(4) 
C19 -0.0363(3) -0.0997(2) 0.22704(5) 0.0385(4) 
C20 0.1516(3) -0.0815(2) 0.25247(5) 0.0383(4) 
C21 0.2910(3) 0.0325(2) 0.23559(5) 0.0353(4) 
O1 0.3298(2) 0.73512(13) 0.11042(3) 0.0381(3) 
O2 0.1764(3) -0.14927(19) 0.28200(4) 0.0620(5) 
Si1 0.44008(7) 0.59445(5) 0.134833(12) 0.02619(12) 
Ueq=1/3[U11(aa*)2+U22(bb*)2+U33(cc*)2+2U12aa*bb*cos γ+2U13aa*cc*cos β+2U23bb*cc*cosα] 
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Table A4.3: Positional Parameters for Hydrogens in Compound (–)-2.20 
 
  Atom x y z Uiso, Å2 
H1a 0.4314 0.7588 0.0595 0.043 
H1b 0.1972 0.8111 0.0650 0.043 
H2 0.0873 0.5545 0.0675 0.038 
H4 0.2299 0.3842 0.1158 0.028 
H5a 0.7945 0.6351 0.1174 0.067 
H5b 0.7873 0.5437 0.1551 0.067 
H5c 0.7486 0.7240 0.1546 0.067 
H6a 0.3397 0.7108 0.1915 0.056 
H6b 0.3761 0.5321 0.1977 0.056 
H6c 0.1669 0.5910 0.1792 0.056 
H7a 0.0968 0.6840 0.0103 0.064 
H7b 0.1228 0.5040 0.0046 0.064 
H7c 0.3199 0.6135 0.0022 0.064 
H8 0.1804 0.2809 0.0330 0.032 
H9 0.3817 0.0647 0.0471 0.034 
H11 0.6281 0.2960 0.1338 0.032 
H12a 0.6024 0.4748 0.0253 0.038 
H12b 0.6583 0.5558 0.0633 0.038 
H13a 0.8423 0.3528 0.0806 0.040 
H13b 0.8017 0.2779 0.0414 0.040 
H14a 0.6464 -0.0351 0.0979 0.053 
H14b 0.8404 0.0717 0.1067 0.053 
H14c 0.7989 0.0160 0.0658 0.053 
H15a 0.2600 0.1113 0.1270 0.039 
H15b 0.4698 0.0504 0.1448 0.039 
H16a 0.4340 0.2483 0.1916 0.043 
H16b 0.2115 0.2869 0.1751 0.043 
H18a 0.0342 -0.0636 0.1709 0.045 
H18b -0.0962 0.0755 0.1881 0.045 
H19a -0.1638 -0.0633 0.2391 0.051 
H19b -0.0551 -0.2078 0.2200 0.051 
H21 0.4164 0.0667 0.2462 0.047 
 
 346 
Table A4.4: Refined Thermal Parameters (U's) for Compound (–)-2.20 
 
  Atom U11 U22 U33 U23 U13 U12 
C1 0.0371(9) 0.0259(8) 0.0347(9) 0.0046(7) -0.0068(7) -0.0013(8) 
C2 0.0257(8) 0.0290(8) 0.0311(8) 0.0037(7) -0.0054(6) -0.0045(7) 
C3 0.0219(7) 0.0237(8) 0.0208(7) 0.0000(6) -0.0005(6) -0.0066(6) 
C4 0.0195(7) 0.0215(7) 0.0224(7) 0.0001(6) 0.0006(5) -0.0030(6) 
C5 0.0364(10) 0.0434(11) 0.0535(12) -0.0112(9) -0.0093(9) -0.0102(8) 
C6 0.0505(11) 0.0327(9) 0.0283(8) -0.0098(7) -0.0006(8) -0.0006(9) 
C7 0.0519(11) 0.0385(10) 0.0379(10) 0.0074(8) -0.0171(8) -0.0030(10) 
C8 0.0193(7) 0.0300(8) 0.0222(7) -0.0027(6) 0.0018(6) -0.0054(6) 
C9 0.0242(8) 0.0266(7) 0.0258(7) -0.0065(6) 0.0054(6) -0.0046(7) 
C10 0.0224(8) 0.0275(8) 0.0281(8) -0.0009(6) 0.0019(6) -0.0003(7) 
C11 0.0248(7) 0.0239(8) 0.0233(7) -0.0008(6) -0.0024(6) -0.0015(6) 
C12 0.0248(8) 0.0333(8) 0.0276(8) 0.0034(7) 0.0034(6) -0.0099(7) 
C13 0.0185(8) 0.0399(9) 0.0317(8) -0.0031(7) 0.0024(7) -0.0052(7) 
C14 0.0316(9) 0.0362(10) 0.0374(9) -0.0035(7) 0.0009(7) 0.0050(8) 
C15 0.0358(9) 0.0227(7) 0.0301(8) 0.0021(6) 0.0009(7) -0.0017(6) 
C16 0.0425(10) 0.0259(8) 0.0284(8) -0.0001(7) 0.0014(8) -0.0056(8) 
C17 0.0361(9) 0.0230(7) 0.0252(7) -0.0029(7) 0.0047(7) 0.0009(7) 
C18 0.0396(10) 0.0324(9) 0.0305(9) 0.0027(7) -0.0023(8) -0.0032(7) 
C19 0.0422(10) 0.0391(9) 0.0342(9) -0.0002(8) 0.0105(8) -0.0072(9) 
C20 0.0530(11) 0.0357(9) 0.0262(8) 0.0022(8) 0.0059(8) 0.0028(9) 
C21 0.0378(10) 0.0385(10) 0.0296(8) 0.0009(7) -0.0016(8) -0.0016(8) 
O1 0.0568(8) 0.0231(6) 0.0342(6) -0.0022(5) -0.0084(6) 0.0017(6) 
O2 0.0825(11) 0.0654(10) 0.0381(8) 0.0229(7) -0.0041(8) -0.0076(9) 
Si1 0.0293(2) 0.0228(2) 0.0264(2) -0.00349(18) -0.00369(18) -0.00263(19) 
The form of the anisotropic displacement parameter is: 
exp[-2π2(a*2U11h2+b*2U22k2+c*2U33l2+2b*c*U23kl+2a*c*U13hl+2a*b*U12hk)] 
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  Table A4.5: Bond Distances in Compound (–)-2.20, Å 
 
C1-O1  1.411(2) C1-C2  1.522(2) C2-C7  1.529(2) 
C2-C3  1.541(2) C3-C8  1.514(2) C3-C12  1.551(2) 
C3-C4  1.575(2) C4-C11  1.564(2) C4-Si1  1.8848(15) 
C5-Si1  1.8617(19) C6-Si1  1.8569(17) C8-C9  1.320(2) 
C9-C10  1.508(2) C10-C14  1.527(2) C10-C13  1.543(2) 
C10-C11  1.565(2) C11-C15  1.533(2) C12-C13  1.539(2) 
C15-C16  1.526(2) C16-C17  1.498(2) C17-C21  1.326(2) 
C17-C18  1.503(2) C18-C19  1.537(2) C19-C20  1.511(3) 
C20-O2  1.221(2) C20-C21  1.453(3) O1-Si1  1.6494(13) 
 
 
 
 
 
Table A4.6: Bond Angles in Compound (–)-2.20, ° 
 
O1-C1-C2 114.85(13) C1-C2-C7 107.85(14) C1-C2-C3 113.99(13) 
C7-C2-C3 113.23(14) C8-C3-C2 112.95(12) C8-C3-C12 105.69(12) 
C2-C3-C12 113.20(13) C8-C3-C4 106.12(12) C2-C3-C4 110.39(12) 
C12-C3-C4 108.08(12) C11-C4-C3 110.88(12) C11-C4-Si1 116.87(10) 
C3-C4-Si1 111.32(10) C9-C8-C3 115.79(13) C8-C9-C10 115.54(14) 
C9-C10-C14 113.80(14) C9-C10-C13 107.02(13) C14-C10-
C13 
109.66(13) 
C9-C10-C11 106.86(12) C14-C10-
C11 
112.30(13) C13-C10-
C11 
106.84(12) 
C15-C11-
C10 
112.18(12) C15-C11-C4 112.46(12) C10-C11-C4 108.75(12) 
C13-C12-C3 109.26(12) C12-C13-
C10 
111.90(13) C16-C15-
C11 
112.89(13) 
C17-C16-
C15 
113.27(13) C21-C17-
C16 
126.15(16) C21-C17-
C18 
111.94(15) 
C16-C17-
C18 
121.90(14) C17-C18-
C19 
104.01(14) C20-C19-
C18 
105.00(15) 
O2-C20-C21 127.32(19) O2-C20-C19 125.37(19) C21-C20-
C19 
107.30(14) 
C17-C21-
C20 
111.40(16) C1-O1-Si1 124.78(11) O1-Si1-C6 104.55(8) 
O1-Si1-C5 111.53(9) C6-Si1-C5 107.13(9) O1-Si1-C4 105.00(6) 
C6-Si1-C4 114.20(7) C5-Si1-C4 114.07(8)   
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X-ray Structure Determination of Compound (+)-3.4 
 
 
Compound (+)-3.4, C21H32SiO3, crystallizes in the orthorhombic space group P212121 
(systematic absences h00:  h=odd, 0k0:  k=odd, and 00l:  l=odd) with a=9.5916(4)Å, 
b=11.3171(5)Å, c=18.2254(8)Å, V=1978.35(15)Å3, Z=4, and dcalc=1.211 g/cm3 . X-ray intensity 
data were collected on a Bruker APEXII CCD area detector employing graphite-monochromated 
Mo-Kα radiation (λ=0.71073 Å) at a temperature of 143(1)K. Preliminary indexing was performed 
from a series of thirty-six 0.5° rotation frames with exposures of 5 seconds. A total of 1729 frames 
were collected with a crystal to detector distance of 37.596 mm, rotation widths of 0.5° and 
exposures of 5 seconds:  
 
scan type 2θ ω φ χ frames 
φ -15.50 258.48 -311.30 19.46 658 
φ -15.50 -10.67 -119.39 -77.44 173 
ω 4.50 -102.77 -128.06 52.47 159 
φ 19.50 -32.21 -344.03 36.30 739 
 Rotation frames were integrated using SAINT, producing a listing of unaveraged F2 and 
σ(F2) values which were then passed to the SHELXTL program package for further processing 
and structure solution. A total of 30835 reflections were measured over the ranges 2.12 ≤ θ ≤ 
25.14°, -11 ≤ h ≤ 11, -13 ≤ k ≤ 13, -21 ≤ l ≤ 21 yielding 3543 unique reflections (Rint = 0.0314). 
The intensity data were corrected for Lorentz and polarization effects and for absorption using 
SADABS (minimum and maximum transmission 0.6911, 0.7452). 
The structure was solved by direct methods (SHELXS-97). Refinement was by full-matrix 
least squares based on F2 using SHELXL-97. All reflections were used during refinement. The 
weighting scheme used was w=1/[σ2(Fo2 )+ (0.0435P)2 + 0.3812P] where P = (Fo 2 + 2Fc2)/3. 
O Si
O
O
!
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Non-hydrogen atoms were refined anisotropically and hydrogen atoms were refined using a riding 
model.  Refinement converged to R1=0.0278 and wR2=0.0756 for 3429 observed reflections for 
which F > 4σ(F) and R1=0.0288 and wR2=0.0762 and GOF =1.051 for all 3543 unique, non-zero 
reflections and 231 variables. The maximum Δ/σ in the final cycle of least squares was 0.000 and 
the two most prominent peaks in the final difference Fourier were +0.218 and -0.133 e/Å3. 
Table A4.1 lists cell information, data collection parameters, and refinement data. Final 
positional and equivalent isotropic thermal parameters are given in Tables A4.2 and A4.3.  
Anisotropic thermal parameters are in Table A5.4. Tables A5.5 and A5.6 list bond distances and 
bond angles.  Figure A5.1 is an ORTEP representation of the molecule with 30% probability 
thermal ellipsoids displayed. 
 
 
Figure A5.1: ORTEP drawing of Compound (+)-3.4 with 30% probability thermal ellipsoids. 
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Table A5.1:  Summary of Structure Determination of Compound (+)-3.4 
Empirical formula  C21H32SiO3 
Formula weight  360.56 
Temperature  143(1) K 
Wavelength  0.71073 Å 
Crystal system  orthorhombic 
Space group  P212121 
Cell constants:   
a  9.5916(4) Å 
b  11.3171(5) Å 
c  18.2254(8) Å 
Volume 1978.35(15) Å3 
Z 4 
Density (calculated) 1.211 Mg/m3 
Absorption coefficient 0.135 mm-1 
F(000) 784 
Crystal size 0.42 x 0.28 x 0.18 mm3 
Theta range for data collection 2.12 to 25.14° 
Index ranges -11 ≤ h ≤ 11, -13 ≤ k ≤ 13, -21 ≤ l ≤ 21 
Reflections collected 30835 
Independent reflections 3543 [R(int) = 0.0314] 
Completeness to theta = 25.14° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7452 and 0.6911 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3543 / 0 / 231 
Goodness-of-fit on F2 1.051 
Final R indices [I>2sigma(I)] R1 = 0.0278, wR2 = 0.0756 
R indices (all data) R1 = 0.0288, wR2 = 0.0762 
Absolute structure parameter 0.11(10) 
Largest diff. peak and hole 0.218 and -0.133 e.Å-3 
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Table A5.2: Refined Positional Parameters for Compound (+)-3.4 
 
  Atom x y z Ueq, Å2 
C1 0.52044(17) 0.51978(15) 0.34842(8) 0.0321(4) 
C2 0.44319(16) 0.47741(13) 0.28039(8) 0.0278(3) 
C3 0.51306(14) 0.51550(11) 0.20786(7) 0.0212(3) 
C4 0.66587(14) 0.46686(12) 0.20245(8) 0.0214(3) 
C5 0.73211(14) 0.49650(13) 0.12653(7) 0.0225(3) 
C6 0.63209(16) 0.57570(12) 0.08098(8) 0.0235(3) 
C7 0.48988(14) 0.50994(13) 0.06767(7) 0.0235(3) 
C8 0.44794(15) 0.45484(12) 0.14121(8) 0.0235(3) 
C9 0.50556(16) 0.41801(14) 0.00527(8) 0.0295(3) 
C10 0.5845(2) 0.30378(15) 0.01287(10) 0.0433(4) 
C11 0.68466(19) 0.28435(14) 0.07633(9) 0.0337(4) 
C12 0.78824(17) 0.38415(13) 0.08891(8) 0.0297(3) 
C13 0.51603(15) 0.65061(12) 0.19759(8) 0.0237(3) 
C14 0.60392(16) 0.68472(12) 0.13007(8) 0.0244(3) 
C15 0.85136(19) 0.64960(15) 0.28861(10) 0.0397(4) 
C16 0.91047(18) 0.38613(16) 0.29630(10) 0.0398(4) 
C17 0.29055(16) 0.51761(16) 0.28545(9) 0.0378(4) 
C18 0.70002(18) 0.61694(14) 0.00951(8) 0.0324(4) 
C19 0.37065(16) 0.59626(14) 0.04413(9) 0.0303(3) 
C20 0.22989(18) 0.54066(16) 0.03892(10) 0.0413(4) 
C21 0.1215(2) 0.5740(2) 0.07503(13) 0.0565(5) 
O1 0.66066(12) 0.47773(11) 0.35393(6) 0.0388(3) 
O2 0.37674(12) 0.36660(9) 0.14433(6) 0.0340(3) 
O3 0.45467(14) 0.43917(12) -0.05448(6) 0.0430(3) 
Si1 0.77234(4) 0.49960(4) 0.28640(2) 0.02731(11) 
Ueq=1/3[U11(aa*)2+U22(bb*)2+U33(cc*)2+2U12aa*bb*cos γ+2U13aa*cc*cos β+2U23bb*cc*cosα] 
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Table A5.3: Positional Parameters for Hydrogens in Compound (+)-3.4 
 
  Atom x y z Uiso, Å2 
H1a 0.5217 0.6055 0.3484 0.043 
H1b 0.4693 0.4944 0.3915 0.043 
H2 0.4434 0.3908 0.2815 0.037 
H4 0.6554 0.3807 0.2023 0.028 
H5 0.8140 0.5454 0.1371 0.030 
H10a 0.6373 0.2929 -0.0320 0.058 
H10b 0.5161 0.2408 0.0148 0.058 
H11a 0.7363 0.2120 0.0675 0.045 
H11b 0.6307 0.2733 0.1208 0.045 
H12a 0.8268 0.4067 0.0417 0.040 
H12b 0.8644 0.3536 0.1184 0.040 
H13a 0.5551 0.6873 0.2411 0.031 
H13b 0.4216 0.6797 0.1914 0.031 
H14a 0.6919 0.7181 0.1461 0.032 
H14b 0.5550 0.7444 0.1019 0.032 
H15a 0.7791 0.7077 0.2936 0.060 
H15b 0.9017 0.6632 0.2439 0.060 
H15c 0.9141 0.6553 0.3295 0.060 
H16a 0.9582 0.3974 0.3421 0.060 
H16b 0.9757 0.3934 0.2566 0.060 
H16c 0.8691 0.3089 0.2954 0.060 
H17a 0.2492 0.4861 0.3292 0.057 
H17b 0.2402 0.4896 0.2434 0.057 
H17c 0.2868 0.6023 0.2869 0.057 
H18a 0.7851 0.6580 0.0204 0.049 
H18b 0.6376 0.6690 -0.0160 0.049 
H18c 0.7201 0.5497 -0.0208 0.049 
H19a 0.3663 0.6606 0.0792 0.040 
H19b 0.3942 0.6299 -0.0032 0.040 
H20 0.2197 0.4770 0.0071 0.055 
H21a 0.1276 0.6373 0.1074 0.075 
H21b 0.0372 0.5347 0.0688 0.075 
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Table A5.4: Refined Thermal Parameters (U's) for Compound (+)-3.4 
 
  Atom U11 U22 U33 U23 U13 U12 
C1 0.0382(8) 0.0362(9) 0.0217(7) 0.0025(6) 0.0087(6) 0.0059(7) 
C2 0.0340(8) 0.0229(7) 0.0265(7) 0.0009(6) 0.0102(6) -0.0007(6) 
C3 0.0239(6) 0.0174(6) 0.0222(7) 0.0008(6) 0.0041(5) -0.0005(5) 
C4 0.0252(7) 0.0167(6) 0.0223(7) -0.0003(5) 0.0040(6) 0.0022(5) 
C5 0.0245(6) 0.0224(6) 0.0207(7) -0.0023(6) 0.0039(5) -0.0029(6) 
C6 0.0294(7) 0.0211(7) 0.0201(7) 0.0004(6) 0.0032(6) -0.0033(6) 
C7 0.0272(7) 0.0208(7) 0.0225(7) -0.0008(6) -0.0002(5) -0.0013(6) 
C8 0.0224(7) 0.0193(6) 0.0287(8) 0.0004(6) 0.0026(6) 0.0001(6) 
C9 0.0281(8) 0.0312(8) 0.0291(8) -0.0056(7) 0.0019(6) -0.0070(6) 
C10 0.0588(12) 0.0317(9) 0.0395(9) -0.0137(7) -0.0061(8) 0.0014(8) 
C11 0.0456(9) 0.0227(7) 0.0327(8) -0.0080(6) 0.0035(7) 0.0053(7) 
C12 0.0317(8) 0.0308(8) 0.0268(7) -0.0037(6) 0.0076(7) 0.0051(7) 
C13 0.0292(7) 0.0184(7) 0.0233(7) -0.0014(5) 0.0023(6) 0.0016(6) 
C14 0.0310(8) 0.0173(6) 0.0249(7) 0.0015(6) 0.0010(6) -0.0034(6) 
C15 0.0440(10) 0.0392(9) 0.0360(9) -0.0077(8) -0.0101(8) -0.0002(8) 
C16 0.0371(9) 0.0417(9) 0.0406(9) 0.0005(8) -0.0058(8) 0.0126(7) 
C17 0.0313(8) 0.0458(10) 0.0363(9) -0.0043(8) 0.0116(7) -0.0040(7) 
C18 0.0421(9) 0.0311(8) 0.0241(7) 0.0039(6) 0.0054(7) -0.0079(7) 
C19 0.0327(8) 0.0287(7) 0.0295(8) 0.0009(7) -0.0041(7) 0.0030(7) 
C20 0.0345(8) 0.0366(9) 0.0527(11) -0.0084(8) -0.0116(8) 0.0026(7) 
C21 0.0378(10) 0.0553(12) 0.0763(15) -0.0072(11) 0.0053(10) -0.0020(9) 
O1 0.0406(6) 0.0545(8) 0.0213(5) 0.0070(5) 0.0022(5) 0.0138(6) 
O2 0.0373(6) 0.0269(5) 0.0378(6) -0.0004(5) 0.0040(5) -0.0121(5) 
O3 0.0476(7) 0.0547(8) 0.0266(6) -0.0075(5) -0.0052(6) 0.0021(6) 
Si1 0.0307(2) 0.0299(2) 0.0213(2) -0.00067(17) -0.00138(15) 0.00650(18) 
The form of the anisotropic displacement parameter is: 
exp[-2π2(a*2U11h2+b*2U22k2+c*2U33l2+2b*c*U23kl+2a*c*U13hl+2a*b*U12hk)] 
 355 
  Table A5.5: Bond Distances in Compound (+)-3.4, Å 
 
C1-O1  1.430(2) C1-C2  1.522(2) C2-C17  1.536(2) 
C2-C3  1.5436(18) C3-C8  1.5288(19) C3-C13  1.5407(19) 
C3-C4  1.5687(18) C4-C5  1.5591(18) C4-Si1  1.8765(15) 
C5-C12  1.5417(19) C5-C6  1.553(2) C6-C18  1.529(2) 
C6-C14  1.5479(19) C6-C7  1.573(2) C7-C8  1.5319(19) 
C7-C9  1.549(2) C7-C19  1.564(2) C8-O2  1.2110(18) 
C9-O3  1.217(2) C9-C10  1.505(2) C10-C11  1.519(2) 
C11-C12  1.522(2) C13-C14  1.5409(19) C15-Si1  1.8595(18) 
C16-Si1  1.8538(16) C19-C20  1.493(2) C20-C21  1.287(3) 
O1-Si1  1.6502(12)     
 
 
 
 
Table A5.6: Bond Angles in Compound (+)-3.4, ° 
 
O1-C1-C2 114.22(12) C1-C2-C17 108.78(12) C1-C2-C3 113.47(12) 
C17-C2-C3 112.49(12) C8-C3-C13 110.90(11) C8-C3-C2 112.19(11) 
C13-C3-C2 112.90(11) C8-C3-C4 100.04(10) C13-C3-C4 108.86(11) 
C2-C3-C4 111.19(11) C5-C4-C3 111.16(11) C5-C4-Si1 117.35(9) 
C3-C4-Si1 112.83(9) C12-C5-C6 116.99(12) C12-C5-C4 111.08(12) 
C6-C5-C4 110.29(11) C18-C6-C14 108.87(12) C18-C6-C5 111.60(13) 
C14-C6-C5 105.00(11) C18-C6-C7 112.50(12) C14-C6-C7 108.36(12) 
C5-C6-C7 110.18(11) C8-C7-C9 113.24(12) C8-C7-C19 107.59(12) 
C9-C7-C19 106.81(12) C8-C7-C6 106.59(11) C9-C7-C6 110.30(11) 
C19-C7-C6 112.39(12) O2-C8-C3 124.29(13) O2-C8-C7 121.66(13) 
C3-C8-C7 113.89(11) O3-C9-C10 116.96(14) O3-C9-C7 119.07(14) 
C10-C9-C7 123.94(13) C9-C10-C11 120.84(13) C10-C11-
C12 
114.83(14) 
C11-C12-C5 116.82(13) C3-C13-C14 110.84(11) C13-C14-C6 110.95(11) 
C20-C19-C7 114.55(13) C21-C20-
C19 
125.07(17) C1-O1-Si1 120.54(9) 
O1-Si1-C16 106.70(7) O1-Si1-C15 112.67(8) C16-Si1-C15 109.81(9) 
O1-Si1-C4 103.02(6) C16-Si1-C4 109.36(7) C15-Si1-C4 114.82(7) 
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